Combination therapy using molecules that bind to TCR

Abstract

Provided herein are methods of treating a disease or condition in a subject, or combination therapies using agents that bind to the T cell receptor alpha variable region (TCR alpha V) and / or the T cell receptor beta variable region (TCR beta V).

Description

[0001] Related Applications

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 498,671, filed April 27, 2023, the entire contents of which are hereby incorporated by reference. BACKGROUND

[0003] Currently available molecules designed to redirect T cells to promote tumor cell lysis for cancer immunotherapy generally target the CD3 epsilon (CD3e) subunit of the T cell receptor (TCR). However, this approach has limitations. Previous studies have shown that, for example, low doses of anti-CD3e monoclonal antibodies (mAbs) can cause T cell dysfunction and exert an immunosuppressive effect. In addition, anti-CD3e mAbs bind to all T cells and, thus, activate a large number of T cells. Such non-physiological massive activation of T cells by these anti-CD3e mAbs can cause the production of proinflammatory cytokines such as IFN-g, IL-1-b, IL-6, IL-10, and TNF-a, leading to a “cytokine storm” known as cytokine release syndrome (CRS), which is also associated with neurotoxicity (NT). Thus, there is a need for improved T cell receptor binding molecules for redirecting T cells for cancer immunotherapy. SUMMARY

[0004] In one aspect, provided herein, among other things, is a method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a first agent comprising a first binder that binds to a first target molecule, and administering to the subject a second agent comprising a second binder that binds to a second target molecule, thereby treating the disease or condition in the subject;

[0005] wherein administration of the first agent is followed by administration of the second agent;

[0006] wherein the first target molecule and the second target molecule are independently selected from the group consisting of a T cell receptor alpha variable region (TCRaV) and a T cell receptor beta variable region (TCRpV); and wherein the first target molecule and the second target molecule are different.

[0007] In some embodiments, the first agent and the second agent are not administered to the subject at the same time.

[0008] In some embodiments, administering the first agent comprises administering to the subject a therapeutically effective amount of the first agent.

[0009] In some embodiments, administering the second agent comprises administering to the subject a therapeutically effective amount of the second agent.

[0010] In some embodiments, the method can be more effective in treating the disease or condition in the subject compared to a method in which the first agent is administered to the subject but the second agent is not administered.

[0011] In some embodiments, the method can be more effective in treating the disease or condition in the subject compared to a method in which the second agent is administered to the subject but the first agent is not administered.

[0012] In some embodiments, the method can be more effective in treating the disease or condition in the subject compared to a method in which the first agent is administered to the subject at a first administration and subsequently the first agent is administered to the subject at a second administration.

[0013] In some embodiments, the method can be more effective in treating the disease or condition in the subject compared to a method in which the second agent is administered to the subject at a first administration and subsequently the second agent is administered to the subject at a second administration.

[0014] In some embodiments, the method can be more effective in treating the disease or condition in the subject compared to a method in which the second agent is administered to the subject at a first administration and subsequently the first agent is administered to the subject at a second administration.

[0015] In some embodiments, the administration of the first agent comprises one or more doses.

[0016] In some embodiments, the administration of the first agent comprises two or more doses.

[0017] In some embodiments, the administration of the first agent comprises one dose per week.

[0018] In some embodiments, the administration of the first agent comprises two or more doses per week.

[0019] In some embodiments, the first agent is administered to the subject once every two weeks.

[0020] In some embodiments, the first agent is administered to the subject once every three weeks.

[0021] In some embodiments, the first agent is administered to the subject once a week for at least 1 week, 2 weeks, 3 weeks, or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months, or at least 1 year, 2 years, or 3 years.

[0022] In some embodiments, the administration of the first agent comprises one or more doses.

[0023] In some embodiments, the first agent is administered to the subject once every two weeks for at least 1 week, 2 weeks, 3 weeks, or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months, or at least 1 year, 2 years, or 3 years.

[0024] In some embodiments, the first agent is administered to the subject once every three weeks for at least 1 week, 2 weeks, 3 weeks, or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months, or at least 1 year, 2 years, or 3 years.

[0025] In some embodiments, the administration of the second agent comprises one or more doses.

[0026] In some embodiments, the administration of the second agent comprises two or more doses.

[0027] In some embodiments, the administration of the second agent comprises one dose per week.

[0028] In some embodiments, the administration of the second agent comprises two or more doses per week.

[0029] In some embodiments, the second agent is administered to the subject once every two weeks.

[0030] In some embodiments, the second agent is administered to the subject once every three weeks.

[0031] In some embodiments, the second agent is administered to the subject once a week for at least 1 week, 2 weeks, 3 weeks, or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months, or at least 1 year, 2 years, or 3 years.

[0032] In some embodiments, the administration of the second agent comprises two or more doses per week for at least 1 week, 2 weeks, 3 weeks, or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months, or at least 1 year, 2 years, or 3 years.

[0033] In some embodiments, the second agent is administered to the subject once every two weeks for at least 1 week, 2 weeks, 3 weeks, or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months, or at least 1 year, 2 years, or 3 years.

[0034] In some embodiments, the second agent is administered to the subject once every three weeks for at least 1 week, 2 weeks, 3 weeks, or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months, or at least 1 year, 2 years, or 3 years.

[0035] In some embodiments, the administration of the first agent and the administration of the second agent are separated by one week.

[0036] In some embodiments, the administration of the first agent and the administration of the second agent are separated by two or more weeks.

[0037] In some embodiments, the administration of the first agent and the administration of the second agent are separated by 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.

[0038] In some embodiments, the administration of the first agent and the administration of the second agent are repeated two or more times.

[0039] In some embodiments, the first agent and the second agent are administered to the subject according to a dosing regimen, wherein the dosing regimen comprises administering the first agent once a week for two weeks, followed by administering the second agent once a week for two weeks, wherein the second agent is administered to the subject one week after the last administration of the first agent.

[0040] In some embodiments, the dosing regimen is repeated two or more times.

[0041] In some embodiments, the dosing regimen is repeated at one week intervals.

[0042] In some embodiments, the dosing regimen is repeated at 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months intervals.

[0043] In some embodiments, the first agent and the second agent are administered to the subject in the same amount.

[0044] In some embodiments, the first agent and the second agent are administered to the subject in different amounts.

[0045] In some embodiments, the administration of the first agent comprises two or more doses, and each dose comprises the same amount of the first agent.

[0046] In some embodiments, the administration of the first agent comprises two or more doses, and each dose comprises a different amount of the first agent.

[0047] In some embodiments, the administration of the second agent comprises two or more doses, and each dose comprises the same amount of the second agent.

[0048] In some embodiments, the administration of the second agent comprises two or more doses, and each dose comprises a different amount of the second agent.

[0049] In some embodiments, the first agent is administered to a subject at a dose of about 0.001 mg / kg to about 10 mg / kg.

[0050] In some embodiments, the second agent is administered to the subject at a dose of about 0.001 mg / kg to about 10 mg / kg.

[0051] In some embodiments, the first agent is administered to the subject at a dose of about 0.3 mg / kg or about 1 mg / kg.

[0052] In some embodiments, the second agent is administered to the subject at a dose of about 0.3 mg / kg or about 1 mg / kg.

[0053] In some embodiments, the first target molecule is a first TCR bV and the second target molecule is a second TCR bV, wherein the first TCR bV and the second TCR bV are different.

[0054] In some embodiments, the first target molecule is a first TCR aV and the second target molecule is a second TCR aV, wherein the first TCR aV and the second TCR aV are different.

[0055] In some embodiments, the first target molecule is a TCR bV and the second target molecule is a TCR aV.

[0056] In some embodiments, the first target molecule is TCRaV and the second target molecule is TCRbV.

[0057] In some embodiments, the first target molecule is human TCRbV6.

[0058] In some embodiments, the first target molecule is human TCRbV10.

[0059] In some embodiments, the second target molecule is human TCRbV15.

[0060] In some embodiments, the second target molecule is human TCRbV27.

[0061] In some embodiments, the second target molecule is human TCRbV5.

[0062] In some embodiments, the first target molecule is human TCRbV6 and the second target molecule is human TCRbV5.

[0063] In some embodiments, the first target molecule is human TCRbV6 and the second target molecule is human TCRbV15.

[0064] In some embodiments, the first target molecule is human TCRbV6 and the second target molecule is human TCRbV27.

[0065] In some embodiments, the first target molecule is human TCRbV10 and the second target molecule is human TCRbV5.

[0066] In some embodiments, the first target molecule is human TCRbV10 and the second target molecule is human TCRbV15.

[0067] In some embodiments, the first target molecule is human TCRbV10 and the second target molecule is human TCRbV27.

[0068] In some embodiments, the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20, or human TRBV28.

[0069] In some embodiments, the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28.

[0070] In some embodiments, the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30.

[0071] In some embodiments, the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30.

[0072] In some embodiments, the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV15, human TRBV27, human TRBV19, human TRBV20, or human TRBV28.

[0073] In some embodiments, the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV15, human TRBV27, human TRBV19, human TRBV20-1, or human TRBV28.

[0074] In some embodiments, the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30.

[0075] In some embodiments, the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30.

[0076] In some embodiments, the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20, or human TRBV28, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV15, human TRBV27, human TRBV19, human TRBV20, or human TRBV28, wherein the first target molecule and the second target molecule are different.

[0077] In some embodiments, the first target molecule and the second target molecule:

[0078] These are human TRBV5 and human TRBV5; these are human TRBV5 and human TRBV6; these are human TRBV5 and human TRBV10; these are human TRBV5 and human TRBV7; these are human TRBV5 and human TRBV19; these are human TRBV5 and human TRBV20; these are human TRBV5 and human TRBV28; these are human TRBV6 and human TRBV5; these are human TRBV6 and human TRBV6; these are human TRBV6 and human TRBV10; these are human TRBV6 and human TRBV7; these are human TRBV6 and human TRBV15; these are human TRBV6 and human TRBV27; these are human TRBV6 and human TRBV... BV19; refers to human TRBV6 and human TRBV20; refers to human TRBV6 and human TRBV28; refers to human TRBV10 and human TRBV5; refers to human TRBV10 and human TRBV10; refers to human TRBV10 and human TRBV6; refers to human TRBV10 and human TRBV7; refers to human TRBV10 and human TRBV15; refers to human TRBV10 and human TRBV27; refers to human TRBV10 and human TRBV19; refers to human TRBV10 and human TRBV20; refers to human TRBV10 and human TRBV28; refers to human TRBV7 and human TRBV5; refers to human TRBV7 and human TRBV 6; respectively human TRBV7 and human TRBV10; respectively human TRBV7 and human TRBV7; respectively human TRBV7 and human TRBV19; respectively human TRBV7 and human TRBV20; respectively human TRBV7 and human TRBV28; respectively human TRBV19 and human TRBV5; respectively human TRBV19 and human TRBV6; respectively human TRBV19 and human TRBV10; respectively human TRBV19 and human TRBV7; respectively human TRBV19 and human TRBV19; respectively human TRBV19 and human TRBV20; respectively human TRBV19 and human TRBV28; respectively human TRBV20 and human TRBV5; respectively It is human TRBV20 and human TRBV6; it is human TRBV20 and human TRBV10; it is human TRBV20 and human TRBV7; it is human TRBV20 and human TRBV19; it is human TRBV20 and human TRBV20; it is human TRBV20 and human TRBV28; it is human TRBV28 and human TRBV5; it is human TRBV28 and human TRBV6; it is human TRBV28 and human TRBV10; it is human TRBV28 and human TRBV7; it is human TRBV28 and human TRBV19; it is human TRBV28 and human TRBV20; or it is human TRBV28 and human TRBV28.

[0079] In some embodiments, the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV15, human TRBV27, human TRBV19, human TRBV20-1, or human TRBV28, wherein the first target molecule and the second target molecule are different.

[0080] In some embodiments, the first target molecule and the second target molecule:

[0081] These are human TRBV5-1 and human TRBV6-5; these are human TRBV5-1 and human TRBV10-1; these are human TRBV5-1 and human TRBV10-2; these are human TRBV5-1 and human TRBV10-3; these are human TRBV5-1 and human TRBV7-2; these are human TRBV5-1 and human TRBV7-3; these are human TRBV5-1 and human TRBV19; these are human TRBV5-1 and human TRBV20-1; these are human TRBV5-1 and human TRBV28; these are human TRBV6-5 and human TRBV5-1; these are human TRBV6-5 and human TRBV7-2; these are human TRBV6-5 and... Human TRBV7-3; Human TRBV6-5 and Human TRBV15; Human TRBV6-5 and Human TRBV27; Human TRBV6-5 and Human TRBV19; Human TRBV6-5 and Human TRBV20-1; Human TRBV6-5 and Human TRBV28; Human TRBV10-1 and Human TRBV5-1; Human TRBV10-1 and Human TRBV7-2; Human TRBV10-1 and Human TRBV7-3; Human TRBV10-1 and Human TRBV15; Human TRBV10-1 and Human TRBV27; Human TRBV10-1 and Human TRBV19; Human TR BV10-1 and human TRBV20-1; respectively human TRBV10-1 and human TRBV28; respectively human TRBV10-2 and human TRBV5-1; respectively human TRBV10-2 and human TRBV7-2; respectively human TRBV10-2 and human TRBV7-3; respectively human TRBV10-2 and human TRBV15; respectively human TRBV10-2 and human TRBV27; respectively human TRBV10-2 and human TRBV19; respectively human TRBV10-2 and human TRBV20-1; respectively human TRBV10-2 and human TRBV28; respectively human TRBV10-3 and human TRBV5-1; respectively human TRBV10-3 and Human TRBV7-2; Human TRBV10-3 and Human TRBV7-3; Human TRBV10-3 and Human TRBV15; Human TRBV10-3 and Human TRBV27; Human TRBV10-3 and Human TRBV19; Human TRBV10-3 and Human TRBV20-1; Human TRBV10-3 and Human TRBV28; Human TRBV7-2 and Human TRBV5-1; Human TRBV7-2 and Human TRBV6-5; Human TRBV7-2 and Human TRBV10-1; Human TRBV7-2 and Human TRBV10-2; Human TRBV7-2 and Human TRBV10-3;These are human TRBV7-2 and human TRBV7-3; these are human TRBV7-2 and human TRBV19; these are human TRBV7-2 and human TRBV20-1; these are human TRBV7-2 and human TRBV28; these are human TRBV7-3 and human TRBV5-1; these are human TRBV7-3 and human TRBV6-5; these are human TRBV7-3 and human TRBV10-1; these are human TRBV7-3 and human TRBV10-2; these are human TRBV7-3 and human TRBV10-3; these are human TRBV7-3 and human TRBV7- 2; These are human TRBV7-3 and human TRBV19; These are human TRBV7-3 and human TRBV20-1; These are human TRBV7-3 and human TRBV28; These are human TRBV19 and human TRBV5-1; These are human TRBV19 and human TRBV6-5; These are human TRBV19 and human TRBV10-1; These are human TRBV19 and human TRBV10-2; These are human TRBV19 and human TRBV10-3; These are human TRBV19 and human TRBV7-2; These are human TRBV19 and human TRBV7-3; These are... Human TRBV19 and human TRBV20-1; human TRBV19 and human TRBV28; human TRBV20-1 and human TRBV5-1; human TRBV20-1 and human TRBV6-5; human TRBV20-1 and human TRBV10-1; human TRBV20-1 and human TRBV10-2; human TRBV20-1 and human TRBV10-3; human TRBV20-1 and human TRBV7-2; human TRBV20-1 and human TRBV7-3; human TRBV20-1 and human TRBV7-3. BV19; refers to human TRBV20-1 and human TRBV28; refers to human TRBV28 and human TRBV5-1; refers to human TRBV28 and human TRBV6-5; refers to human TRBV28 and human TRBV10-1; refers to human TRBV28 and human TRBV10-2; refers to human TRBV28 and human TRBV10-3; refers to human TRBV28 and human TRBV7-2; refers to human TRBV28 and human TRBV7-3; refers to human TRBV28 and human TRBV19; or refers to human TRBV28 and human TRBV20-1.

[0082] In some embodiments, the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30, wherein the first target molecule and the second target molecule are different.

[0083] In some embodiments, the first target molecule and the second target molecule:

[0084] They are human TRAV12 and human TRAV12, respectively.

[0085] They are human TRAV12 and human TRAV13, respectively.

[0086] They are human TRAV12 and human TRAV19, respectively.

[0087] They are human TRAV12 and human TRAV21, respectively.

[0088] These are human TRAV12 and human TRAV30, respectively.

[0089] They are human TRAV13 and human TRAV12, respectively.

[0090] They are human TRAV13 and human TRAV13, respectively.

[0091] They are human TRAV13 and human TRAV19, respectively.

[0092] They are human TRAV13 and human TRAV21, respectively.

[0093] They are TRAV13 and TRAV30, respectively.

[0094] They are human TRAV19 and human TRAV12, respectively.

[0095] They are human TRAV19 and human TRAV13, respectively.

[0096] They are human TRAV19 and human TRAV19, respectively.

[0097] They are human TRAV19 and human TRAV21, respectively.

[0098] They are human TRAV19 and human TRAV30, respectively.

[0099] They are human TRAV21 and human TRAV12, respectively.

[0100] They are human TRAV21 and human TRAV13, respectively.

[0101] They are human TRAV21 and human TRAV19, respectively.

[0102] They are human TRAV21 and human TRAV21, respectively.

[0103] They are human TRAV21 and human TRAV30, respectively.

[0104] These are TRAV30 and TRAV12 for humans, respectively.

[0105] They are TRAV30 and TRAV13 for humans, respectively.

[0106] These are TRAV30 and TRAV19 for humans, respectively.

[0107] These are TRAV30 and TRAV21 for humans, respectively; or

[0108] They are TRAV30 and TRAV30 respectively.

[0109] In some embodiments, the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30, wherein the first target molecule and the second target molecule are different.

[0110] In some embodiments, the first target molecule and the second target molecule:

[0111] These are human TRAV12-2 and human TRAV13-1, respectively.

[0112] These are human TRAV12-2 and human TRAV19, respectively.

[0113] These are human TRAV12-2 and human TRAV21, respectively.

[0114] These are human TRAV12-2 and human TRAV30, respectively.

[0115] They are human TRAV13-1 and human TRAV12-2, respectively.

[0116] These are human TRAV13-1 and human TRAV19, respectively.

[0117] These are human TRAV13-1 and human TRAV21, respectively.

[0118] These are human TRAV13-1 and human TRAV30, respectively.

[0119] They are human TRAV19 and human TRAV12-2, respectively.

[0120] They are human TRAV19 and human TRAV13-1, respectively.

[0121] They are human TRAV19 and human TRAV21, respectively.

[0122] They are human TRAV19 and human TRAV30, respectively.

[0123] These are human TRAV21 and human TRAV12-2, respectively.

[0124] These are human TRAV21 and human TRAV13-1, respectively.

[0125] They are human TRAV21 and human TRAV19, respectively.

[0126] They are human TRAV21 and human TRAV30, respectively.

[0127] These are human TRAV30 and human TRAV12-2, respectively.

[0128] These are human TRAV30 and human TRAV13-1, respectively.

[0129] These are TRAV30 and TRAV19 for individuals, respectively; or

[0130] They are TRAV30 and TRAV21, respectively.

[0131] In some embodiments, the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

[0132] In some embodiments, the first target molecule and the second target molecule:

[0133] These are human TRBV5 and human TRAV12; these are human TRBV5 and human TRAV13; these are human TRBV5 and human TRAV19; these are human TRBV5 and human TRAV21; these are human TRBV5 and human TRAV30; these are human TRBV6 and human TRAV12; these are human TRBV6 and human TRAV13; these are human TRBV6 and human TRAV19; these are human TRBV6 and human TRAV21; these are human TRBV6 and human TRAV30; these are human TRBV10 and human TRAV12; these are human TRBV10 and human TRAV13; these are human TRBV10 and human TRAV19; these are human TRBV10 and human TRAV21; these are human TRBV10 and human TRAV30; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV13 ...2; these are human TRBV7 and human TRAV13; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV13; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV13; these are V19; are human TRBV7 and human TRAV21; are human TRBV7 and human TRAV30; are human TRBV19 and human TRAV12; are human TRBV19 and human TRAV13; are human TRBV19 and human TRAV19; are human TRBV19 and human TRAV21; are human TRBV19 and human TRAV30; are human TRBV20 and human TRAV12; are human TRBV20 and human TRAV13; are human TRBV20 and human TRAV19; are human TRBV20 and human TRAV21; are human TRBV20 and human TRAV30; are human TRBV28 and human TRAV12; are human TRBV28 and human TRAV13; are human TRBV28 and human TRAV19; are human TRBV28 and human TRAV21; or are human TRBV28 and human TRAV30.

[0134] In some embodiments, the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

[0135] In some embodiments, the first target molecule and the second target molecule:

[0136] These are human TRBV5 and human TRAV12-2; these are human TRBV5 and human TRAV13-1; these are human TRBV5 and human TRAV19; these are human TRBV5 and human TRAV21; these are human TRBV5 and human TRAV30; these are human TRBV6 and human TRAV12-2; these are human TRBV6 and human TRAV13-1; these are human TRBV6 and human TRAV19; these are human TRBV6 and human TRAV21. These are human TRBV6 and human TRAV30; these are human TRBV10 and human TRAV12-2; these are human TRBV10 and human TRAV13-1; these are human TRBV10 and human TRAV19; these are human TRBV10 and human TRAV21; these are human TRBV10 and human TRAV30; these are human TRBV7 and human TRAV12-2; these are human TRBV7 and human TRAV13-1; these are human TRBV7 and human TRAV12-2; these are human TRBV7 and human TRAV13-1; these are human TRBV7 and human TRAV12-2. RAV19; These are human TRBV7 and human TRAV21; These are human TRBV7 and human TRAV30; These are human TRBV19 and human TRAV12-2; These are human TRBV19 and human TRAV13-1; These are human TRBV19 and human TRAV19; These are human TRBV19 and human TRAV21; These are human TRBV19 and human TRAV30; These are human TRBV20 and human TRAV12-2; These are human TRBV 20 and human TRAV13-1; human TRBV20 and human TRAV19; human TRBV20 and human TRAV21; human TRBV20 and human TRAV30; human TRBV28 and human TRAV12-2; human TRBV28 and human TRAV13-1; human TRBV28 and human TRAV19; human TRBV28 and human TRAV21; or human TRBV28 and human TRAV30.

[0137] In some embodiments, the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30.

[0138] In some embodiments, the first target molecule and the second target molecule:

[0139] These are human TRBV5-1 and human TRAV12; these are human TRBV5-1 and human TRAV13; these are human TRBV5-1 and human TRAV19; these are human TRBV5-1 and human TRAV21; these are human TRBV5-1 and human TRAV30; these are human TRBV6-5 and human TRAV12; these are human TRBV6-5 and human TRAV13; these are human TRBV6-5 and human TRAV19; these are human TRBV6-5 and human TRAV21; these are human TRBV6-5 and human TRAV30; these are human TRBV10-1 and human TRAV12; these are human TRBV10-1 and human TRAV13; these are human T RBV10-1 and human TRAV19; respectively human TRBV10-1 and human TRAV21; respectively human TRBV10-1 and human TRAV30; respectively human TRBV10-2 and human TRAV12; respectively human TRBV10-2 and human TRAV13; respectively human TRBV10-2 and human TRAV19; respectively human TRBV10-2 and human TRAV21; respectively human TRBV10-2 and human TRAV30; respectively human TRBV10-3 and human TRAV12; respectively human TRBV10-3 and human TRAV13; respectively human TRBV10-3 and human TRAV19; respectively human TRBV10-3 and human TRAV21; divided They are human TRBV10-3 and human TRAV30; they are human TRBV7-2 and human TRAV12; they are human TRBV7-2 and human TRAV13; they are human TRBV7-2 and human TRAV19; they are human TRBV7-2 and human TRAV21; they are human TRBV7-2 and human TRAV30; they are human TRBV7-3 and human TRAV12; they are human TRBV7-3 and human TRAV13; they are human TRBV7-3 and human TRAV19; they are human TRBV7-3 and human TRAV21; they are human TRBV7-3 and human TRAV30; they are human TRBV19 and human TRAV12; they are human TRBV1 9 and TRAV13; TRBV19 and TRAV19; TRBV19 and TRAV21; TRBV19 and TRAV30; TRBV20-1 and TRAV12; TRBV20-1 and TRAV13; TRBV20-1 and TRAV19; TRBV20-1 and TRAV21; TRBV20-1 and TRAV30; TRBV28 and TRAV12; TRBV28 and TRAV13; TRBV28 and TRAV19; TRBV28 and TRAV21.Or they may be human TRBV28 and human TRAV30, respectively.

[0140] In some embodiments, the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30.

[0141] In some embodiments, the first target molecule and the second target molecule:

[0142] These are human TRBV5-1 and human TRAV12-2; these are human TRBV5-1 and human TRAV13-1; these are human TRBV5-1 and human TRAV19; these are human TRBV5-1 and human TRAV21; these are human TRBV5-1 and human TRAV30; these are human TRBV6-5 and human TRAV12-2; these are human TRBV6-5 and human TRAV13-1; these are human TRBV6-5 and human TRAV19; these are human TRBV6-5 and human TRAV21; these are human TRBV6-5 and human TRAV30; these are human TRBV10-1 and human TRAV12-2; these are human TRBV10-1 and human TRAV12-2. V13-1; These are human TRBV10-1 and human TRAV19; These are human TRBV10-1 and human TRAV21; These are human TRBV10-1 and human TRAV30; These are human TRBV10-2 and human TRAV12-2; These are human TRBV10-2 and human TRAV13-1; These are human TRBV10-2 and human TRAV19; These are human TRBV10-2 and human TRAV21; These are human TRBV10-2 and human TRAV30; These are human TRBV10-3 and human TRAV12-2; These are human TRBV10-3 and human TRAV13-1; These are human TRBV10-3 and human TRAV19; These are... Human TRBV10-3 and human TRAV21; respectively human TRBV10-3 and human TRAV30; respectively human TRBV7-2 and human TRAV12-2; respectively human TRBV7-2 and human TRAV13-1; respectively human TRBV7-2 and human TRAV19; respectively human TRBV7-2 and human TRAV21; respectively human TRBV7-2 and human TRAV30; respectively human TRBV7-3 and human TRAV12-2; respectively human TRBV7-3 and human TRAV13-1; respectively human TRBV7-3 and human TRAV19; respectively human TRBV7-3 and human TRAV21; respectively human TRBV7-3 and human TRAV30; They are human TRBV19 and human TRAV12-2; they are human TRBV19 and human TRAV13-1; they are human TRBV19 and human TRAV19; they are human TRBV19 and human TRAV21; they are human TRBV19 and human TRAV30; they are human TRBV20-1 and human TRAV12-2; they are human TRBV20-1 and human TRAV13-1; they are human TRBV20-1 and human TRAV19; they are human TRBV20-1 and human TRAV21; they are human TRBV20-1 and human TRAV30; they are human TRBV28 and human TRAV12-2; they are human TRBV28 and human TRAV13-1.These are human TRBV28 and human TRAV19; these are human TRBV28 and human TRAV21; or these are human TRBV28 and human TRAV30.

[0143] In some embodiments, the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20, or human TRBV28.

[0144] In some embodiments, the first target molecule and the second target molecule:

[0145] These are human TRAV12 and human TRBV5; these are human TRAV12 and human TRBV6; these are human TRAV12 and human TRBV10; these are human TRAV12 and human TRBV7; these are human TRAV12 and human TRBV19; these are human TRAV12 and human TRBV20; these are human TRAV12 and human TRBV28; these are human TRAV13 and human TRBV5; these are human TRAV13 and human TRBV6; these are human TRAV13 and human TRBV10; these are human TRAV13 and human TRBV7; these are human TRAV13 and human TRBV19; these are human TRAV13 and human TRBV20; these are human TRAV13 and human TRBV28; these are human TRAV19 and human TRBV5; these are human TRAV19 and human TRBV6; these are human TRAV19 and human TRBV10; these are human TRAV19 And human TRBV7; respectively human TRAV19 and human TRBV19; respectively human TRAV19 and human TRBV20; respectively human TRAV19 and human TRBV28; respectively human TRAV21 and human TRBV5; respectively human TRAV21 and human TRBV6; respectively human TRAV21 and human TRBV10; respectively human TRAV21 and human TRBV7; respectively human TRAV21 and human TRBV19; respectively human TRAV21 and human TRBV20; respectively human TRAV21 and human TRBV28; respectively human TRAV30 and human TRBV5; respectively human TRAV30 and human TRBV6; respectively human TRAV30 and human TRBV10; respectively human TRAV30 and human TRBV7; respectively human TRAV30 and human TRBV19; respectively human TRAV30 and human TRBV20; or respectively human TRAV30 and human TRBV28.

[0146] In some embodiments, the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20, or human TRBV28.

[0147] In some embodiments, the first target molecule and the second target molecule:

[0148] These are human TRAV12-2 and human TRBV5; these are human TRAV12-2 and human TRBV6; these are human TRAV12-2 and human TRBV10; these are human TRAV12-2 and human TRBV7; these are human TRAV12-2 and human TRBV19; these are human TRAV12-2 and human TRBV20; these are human TRAV12-2 and human TRBV28; these are human TRAV13-1 and human TRBV5; these are human T... RAV13-1 and human TRBV6; respectively human TRAV13-1 and human TRBV10; respectively human TRAV13-1 and human TRBV7; respectively human TRAV13-1 and human TRBV19; respectively human TRAV13-1 and human TRBV20; respectively human TRAV13-1 and human TRBV28; respectively human TRAV19 and human TRBV5; respectively human TRAV19 and human TRBV6; respectively human TRAV19 and human TRBV6 V10; refers to human TRAV19 and human TRBV7; refers to human TRAV19 and human TRBV19; refers to human TRAV19 and human TRBV20; refers to human TRAV19 and human TRBV28; refers to human TRAV21 and human TRBV5; refers to human TRAV21 and human TRBV6; refers to human TRAV21 and human TRBV10; refers to human TRAV21 and human TRBV7; refers to human TRAV21 and human TRBV19 ; are human TRAV21 and human TRBV20 respectively; are human TRAV21 and human TRBV28 respectively; are human TRAV30 and human TRBV5 respectively; are human TRAV30 and human TRBV6 respectively; are human TRAV30 and human TRBV10 respectively; are human TRAV30 and human TRBV7 respectively; are human TRAV30 and human TRBV19 respectively; are human TRAV30 and human TRBV20 respectively; or are human TRAV30 and human TRBV28 respectively.

[0149] In some embodiments, the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28.

[0150] In some embodiments, the first target molecule and the second target molecule:

[0151] These are human TRAV12 and human TRBV5-1; these are human TRAV12 and human TRBV6-5; these are human TRAV12 and human TRBV10-1; these are human TRAV12 and human TRBV10-2; these are human TRAV12 and human TRBV10-3; these are human TRAV12 and human TRBV7-2; these are human TRAV12 and human TRBV7-3; these are human TRAV12 and human TRBV19; these are human TRAV12 and human TRBV20-1; these are human TRAV12 and human TRBV28; these are human TRAV13 and human TRBV5-1; these are human TRAV13 and human TRBV6-5; these are human T RAV13 and human TRBV10-1; respectively human TRAV13 and human TRBV10-2; respectively human TRAV13 and human TRBV10-3; respectively human TRAV13 and human TRBV7-2; respectively human TRAV13 and human TRBV7-3; respectively human TRAV13 and human TRBV19; respectively human TRAV13 and human TRBV20-1; respectively human TRAV13 and human TRBV28; respectively human TRAV19 and human TRBV5-1; respectively human TRAV19 and human TRBV6-5; respectively human TRAV19 and human TRBV10-1; respectively human TRAV19 and human TRBV10-2; respectively human TRAV1 9 and human TRBV10-3; respectively human TRAV19 and human TRBV7-2; respectively human TRAV19 and human TRBV7-3; respectively human TRAV19 and human TRBV19; respectively human TRAV19 and human TRBV20-1; respectively human TRAV19 and human TRBV28; respectively human TRAV21 and human TRBV5-1; respectively human TRAV21 and human TRBV6-5; respectively human TRAV21 and human TRBV10-1; respectively human TRAV21 and human TRBV10-2; respectively human TRAV21 and human TRBV10-3; respectively human TRAV21 and human TRBV7-2; respectively human TRAV21 and human TR BV7-3; These are human TRAV21 and human TRBV19; These are human TRAV21 and human TRBV20-1; These are human TRAV21 and human TRBV28; These are human TRAV30 and human TRBV5-1; These are human TRAV30 and human TRBV6-5; These are human TRAV30 and human TRBV10-1; These are human TRAV30 and human TRBV10-2; These are human TRAV30 and human TRBV10-3; These are human TRAV30 and human TRBV7-2; These are human TRAV30 and human TRBV7-3; These are human TRAV30 and human TRBV19; These are human TRAV30 and human TRBV20-1;Or they may be human TRAV30 and human TRBV28, respectively.

[0152] In some embodiments, the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28.

[0153] In some embodiments, the first target molecule and the second target molecule:

[0154] These are human TRAV12-2 and human TRBV5-1; these are human TRAV12-2 and human TRBV6-5; these are human TRAV12-2 and human TRBV10-1; these are human TRAV12-2 and human TRBV10-2; these are human TRAV12-2 and human TRBV10-3; these are human TRAV12-2 and human TRBV7-2; these are human TRAV12-2 and human TRBV7-3; these are human TRAV12-2 and human TRBV19; these are human TRAV12-2 and human TRBV20-1; these are human TRAV12-2 and human TRBV28; these are human TRAV13-1 and human TRBV5-1; these are... Human TRAV13-1 and human TRBV6-5; respectively human TRAV13-1 and human TRBV10-1; respectively human TRAV13-1 and human TRBV10-2; respectively human TRAV13-1 and human TRBV10-3; respectively human TRAV13-1 and human TRBV7-2; respectively human TRAV13-1 and human TRBV7-3; respectively human TRAV13-1 and human TRBV19; respectively human TRAV13-1 and human TRBV20-1; respectively human TRAV13-1 and human TRBV28; respectively human TRAV19 and human TRBV5-1; respectively human TRAV19 and human TRBV6-5; respectively human TRAV19 and... Human TRBV10-1; Human TRAV19 and Human TRBV10-2; Human TRAV19 and Human TRBV10-3; Human TRAV19 and Human TRBV7-2; Human TRAV19 and Human TRBV7-3; Human TRAV19 and Human TRBV19; Human TRAV19 and Human TRBV20-1; Human TRAV19 and Human TRBV28; Human TRAV21 and Human TRBV5-1; Human TRAV21 and Human TRBV6-5; Human TRAV21 and Human TRBV10-1; Human TRAV21 and Human TRBV10-2; Human TRAV21 and Human TRBV10-2 V10-3; These are human TRAV21 and human TRBV7-2; These are human TRAV21 and human TRBV7-3; These are human TRAV21 and human TRBV19; These are human TRAV21 and human TRBV20-1; These are human TRAV21 and human TRBV28; These are human TRAV30 and human TRBV5-1; These are human TRAV30 and human TRBV6-5; These are human TRAV30 and human TRBV10-1; These are human TRAV30 and human TRBV10-2; These are human TRAV30 and human TRBV10-3; These are human TRAV30 and human TRBV7-2; These are human TRAV30 and human TRBV7-3;These are human TRAV30 and human TRBV19; these are human TRAV30 and human TRBV20-1; or these are human TRAV30 and human TRBV28.

[0155] In some embodiments, the first target molecule is human TCRβV27, and the second target molecule is human TCRβV6.

[0156] In some embodiments, the first conjugate comprises a whole antibody or its antigen-binding fragment, a bivalent antibody, a bispecific antibody, or a biparatopic antibody.

[0157] In some embodiments, the second conjugate comprises a whole antibody or its antigen-binding fragment, a bivalent antibody, a bispecific antibody, or a biparatopic antibody.

[0158] In some embodiments, the antigen-binding fragment is Fab, F(ab')2, Fv, single-chain Fv (scFv), single-domain antibody, double antibody, single-domain antibody, or camel antibody.

[0159] In some embodiments, the first conjugate includes a heavy chain variable region (VH), the VH including a heavy chain complementarity determination region 3 (HC CDR3), the HC CDR3 including a sequence of SEQ ID NO: 3343, SEQ ID NO: 3323, SEQ ID NO: 3353, SEQ ID NO: 1187, SEQ ID NO: 3373, SEQ ID NO: 3383, SEQ ID NO: 3393, SEQ ID NO: 3403 or SEQ ID NO: 3413.

[0160] In some embodiments, the first conjugate comprises a VH, the VH comprising a heavy chain complementarity determination region 1 (HCCDR1), the HCCDR1 comprising a sequence of SEQ ID NO: 3341, SEQ ID NO: 3321, SEQ ID NO: 3351, SEQ ID NO: 1190, SEQ ID NO: 3371, SEQ ID NO: 3381, SEQ ID NO: 3391, SEQ ID NO: 3401, SEQ ID NO: 3411, SEQ ID NO: 3421 or SEQ ID NO: 3702.

[0161] In some embodiments, the first conjugate comprises a VH, the VH comprising a heavy chain complementarity determination region 2 (HCCDR2), the HCCDR2 comprising a sequence of SEQ ID NO: 3342, SEQ ID NO: 3322, SEQ ID NO: 3352, SEQ ID NO: 1186, SEQ ID NO: 3372, SEQ ID NO: 3382, SEQ ID NO: 3392, SEQ ID NO: 3402, or SEQ ID NO: 3412.

[0162] In some embodiments, the first combination comprises VH, the VH comprising:

[0163] (i) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3341, HC CDR2 contains the sequence of SEQ ID NO: 3342 and HC CDR3 contains the sequence of SEQ ID NO: 3343;

[0164] (ii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3321, HC CDR2 contains the sequence of SEQ ID NO: 3322 and HC CDR3 contains the sequence of SEQ ID NO: 3323;

[0165] (iii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3351, HC CDR2 contains the sequence of SEQ ID NO: 3352 and HC CDR3 contains the sequence of SEQ ID NO: 3353;

[0166] (iv) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 1190, HC CDR2 contains the sequence of SEQ ID NO: 1186 and HC CDR3 contains the sequence of SEQ ID NO: 1187;

[0167] (v) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3371, HC CDR2 contains the sequence of SEQ ID NO: 3372 and HC CDR3 contains the sequence of SEQ ID NO: 3373;

[0168] (vi) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3381, HC CDR2 contains the sequence of SEQ ID NO: 3382 and HC CDR3 contains the sequence of SEQ ID NO: 3383;

[0169] (vii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3391, HC CDR2 contains the sequence of SEQ ID NO: 3392 and HC CDR3 contains the sequence of SEQ ID NO: 3393;

[0170] (viii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3401, HC CDR2 contains the sequence of SEQ ID NO: 3402 and HC CDR3 contains the sequence of SEQ ID NO: 3403;

[0171] (ix) HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; or

[0172] (x) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3411, HC CDR2 contains the sequence of SEQ ID NO: 3412 and HC CDR3 contains the sequence of SEQ ID NO: 3413.

[0173] In some embodiments, the first conjugate includes a light chain variable region (VL), the VL including a light chain complementarity determination region 3 (LC CDR3), the LC CDR3 including a sequence of SEQ ID NO: 3346, SEQ ID NO: 3326, SEQ ID NO: 3356, SEQ ID NO: 1193, SEQ ID NO: 3376, SEQ ID NO: 3386, SEQ ID NO: 3396, SEQ ID NO: 3406 or SEQ ID NO: 3416.

[0174] In some embodiments, the first conjugate comprises a VL, the VL comprising a light chain complementarity determination region 1 (LCCDR1), the LCCDR1 comprising a sequence of SEQ ID NO: 3344, SEQ ID NO: 3324, SEQ ID NO: 3354, SEQ ID NO: 1191, SEQ ID NO: 3374, SEQ ID NO: 3384, SEQ ID NO: 3394, SEQ ID NO: 3404, or SEQ ID NO: 3414.

[0175] In some embodiments, the first conjugate comprises a VL, the VL comprising a light chain complementarity determination region 2 (LCCDR2), the LCCDR2 comprising a sequence of SEQ ID NO: 3345, SEQ ID NO: 3325, SEQ ID NO: 3355, SEQ ID NO: 1192, SEQ ID NO: 3375, SEQ ID NO: 3395, SEQ ID NO: 3405, SEQ ID NO: 3415 or SEQ ID NO: 3443.

[0176] In some embodiments, the first combination comprises VL, the VL comprising:

[0177] (i) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3344, LC CDR2 contains the sequence of SEQ ID NO: 3345 and LC CDR3 contains the sequence of SEQ ID NO: 3346;

[0178] (ii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3324, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3326;

[0179] (iii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3355, and LC CDR3 contains the sequence of SEQ ID NO: 3356;

[0180] (iv) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 1191, LC CDR2 contains the sequence of SEQ ID NO: 1192 and LC CDR3 contains the sequence of SEQ ID NO: 1193;

[0181] (v) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3374, LC CDR2 contains the sequence of SEQ ID NO: 3375, and LC CDR3 contains the sequence of SEQ ID NO: 3376;

[0182] (vi) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3384, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3386;

[0183] (vii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3394, LC CDR2 contains the sequence of SEQ ID NO: 3395 and LC CDR3 contains the sequence of SEQ ID NO: 3396;

[0184] (viii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3404, LC CDR2 contains the sequence of SEQ ID NO: 3405 and LC CDR3 contains the sequence of SEQ ID NO: 3406;

[0185] (ix) LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3414, LC CDR2 contains the sequence of SEQ ID NO: 3415, and LC CDR3 contains the sequence of SEQ ID NO: 3416; or

[0186] (x) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3443 and LC CDR3 contains the sequence of SEQ ID NO: 3356.

[0187] In some embodiments, the first combination comprises:

[0188] (i) VH, which comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3341, HC CDR2 comprises the sequence of SEQ ID NO: 3342, and HC CDR3 comprises the sequence of SEQ ID NO: 3343; and VL, which comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3344, LC CDR2 comprises the sequence of SEQ ID NO: 3345, and LC CDR3 comprises the sequence of SEQ ID NO: 3346;

[0189] (ii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3321, HC CDR2 comprises the sequence of SEQ ID NO: 3322, and HC CDR3 comprises the sequence of SEQ ID NO: 3323; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3324, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3326;

[0190] (iii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, LC CDR2 comprises the sequence of SEQ ID NO: 3355, and LC CDR3 comprises the sequence of SEQ ID NO: 3356;

[0191] (iv) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 1190, HC CDR2 comprises the sequence of SEQ ID NO: 1186, and HC CDR3 comprises the sequence of SEQ ID NO: 1187; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 1191, LC CDR2 comprises the sequence of SEQ ID NO: 1192, and LC CDR3 comprises the sequence of SEQ ID NO: 1193;

[0192] (v) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3371, HC CDR2 comprises the sequence of SEQ ID NO: 3372, and HC CDR3 comprises the sequence of SEQ ID NO: 3373; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3374, LC CDR2 comprises the sequence of SEQ ID NO: 3375, and LC CDR3 comprises the sequence of SEQ ID NO: 3376;

[0193] (vi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3381, HC CDR2 comprises the sequence of SEQ ID NO:3382, and HC CDR3 comprises the sequence of SEQ ID NO:3383; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3384, LC CDR2 comprises the sequence of SEQ ID NO:3325, and LC CDR3 comprises the sequence of SEQ ID NO:3386;

[0194] (vii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3391, HC CDR2 comprises the sequence of SEQ ID NO:3392, and HC CDR3 comprises the sequence of SEQ ID NO:3393; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3394, LC CDR2 comprises the sequence of SEQ ID NO:3395, and LC CDR3 comprises the sequence of SEQ ID NO:3396;

[0195] (viii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3401, HC CDR2 comprises the sequence of SEQ ID NO:3402, and HC CDR3 comprises the sequence of SEQ ID NO:3403; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3404, LC CDR2 comprises the sequence of SEQ ID NO:3405, and LC CDR3 comprises the sequence of SEQ ID NO:3406;

[0196] (ix) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3411, HC CDR2 comprises the sequence of SEQ ID NO: 3412, and HC CDR3 comprises the sequence of SEQ ID NO: 3413; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3414, LC CDR2 comprises the sequence of SEQ ID NO: 3415, and LC CDR3 comprises the sequence of SEQ ID NO: 3416;

[0197] (x) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises the sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, wherein LC CDR2 comprises the sequence of SEQ ID NO: 3355, and wherein LC CDR3 comprises the sequence of SEQ ID NO: 3356; or

[0198] (xi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises a sequence of 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3443, and wherein LC CDR3 comprises a sequence of SEQ ID NO: 3356.

[0199] In some embodiments, the first combination comprises a VH, the VH comprising a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

[0200] In some embodiments, the first combination comprises VH, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

[0201] In some embodiments, the first combination comprises a VL, the VL comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

[0202] In some embodiments, the first combination comprises a VL, the VL comprising any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

[0203] In some embodiments, the first combination comprises:

[0204] (i) VH, wherein VH comprises a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and

[0205] (ii) VL, which comprises sequences having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

[0206] In some embodiments, the first combination comprises:

[0207] (i) VH, wherein VH comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and

[0208] (ii) VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

[0209] In some embodiments, the first combination comprises:

[0210] (i) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3445, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3446;

[0211] (ii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3448, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3449;

[0212] (iii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3450, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3451;

[0213] (iv) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1349;

[0214] (v) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1196, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1195;

[0215] (vi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3455, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3456;

[0216] (vii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3457, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3458;

[0217] (viii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3463, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3464;

[0218] (ix) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3465, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3466;

[0219] (x) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3470, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3471;

[0220] (xi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3475; or

[0221] (xii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3476.

[0222] In some embodiments, the first combination comprises:

[0223] (i) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3445 and VL contains the sequence of SEQ ID NO: 3446;

[0224] (ii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3448 and VL comprises the sequence of SEQ ID NO: 3449;

[0225] (iii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3450 and VL comprises the sequence of SEQ ID NO: 3451;

[0226] (iv) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346 and VL comprises the sequence of SEQ ID NO: 1349;

[0227] (v) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1196 and VL contains the sequence of SEQ ID NO: 1195;

[0228] (vi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3455 and VL comprises the sequence of SEQ ID NO: 3456;

[0229] (vii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3457 and VL contains the sequence of SEQ ID NO: 3458;

[0230] (viii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3463 and VL comprises the sequence of SEQ ID NO: 3464;

[0231] (ix) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3465 and VL contains the sequence of SEQ ID NO: 3466;

[0232] (x) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3470 and VL contains the sequence of SEQ ID NO: 3471;

[0233] (xi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346, and VL comprises the sequence of SEQ ID NO: 3475; or

[0234] (xii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1346 and VL contains the sequence of SEQ ID NO: 3476.

[0235] In some embodiments, the second conjugate includes a heavy chain variable region (VH), the VH including a heavy chain complementarity determination region 3 (HC CDR3), the HC CDR3 including the sequence of SEQ ID NO: 3343, SEQ ID NO: 3323, SEQ ID NO: 3353, SEQ ID NO: 1187, SEQ ID NO: 3373, SEQ ID NO: 3383, SEQ ID NO: 3393, SEQ ID NO: 3403 or SEQ ID NO: 3413.

[0236] In some embodiments, the second conjugate comprises a VH, the VH comprising a heavy chain complementarity-determining region 1 (HCCDR1), the HCCDR1 comprising a sequence of SEQ ID NO: 3341, SEQ ID NO: 3321, SEQ ID NO: 3351, SEQ ID NO: 1190, SEQ ID NO: 3371, SEQ ID NO: 3381, SEQ ID NO: 3391, SEQ ID NO: 3401, SEQ ID NO: 3411, SEQ ID NO: 3421, or SEQ ID NO: 3702.

[0237] In some embodiments, the second conjugate comprises a VH, the VH comprising a heavy chain complementarity determination region 2 (HCCDR2), the HCCDR2 comprising a sequence of SEQ ID NO: 3342, SEQ ID NO: 3322, SEQ ID NO: 3352, SEQ ID NO: 1186, SEQ ID NO: 3372, SEQ ID NO: 3382, SEQ ID NO: 3392, SEQ ID NO: 3402, or SEQ ID NO: 3412.

[0238] In some embodiments, the second combination comprises VH, the VH comprising:

[0239] (i) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3341, HC CDR2 contains the sequence of SEQ ID NO: 3342 and HC CDR3 contains the sequence of SEQ ID NO: 3343;

[0240] (ii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3321, HC CDR2 contains the sequence of SEQ ID NO: 3322 and HC CDR3 contains the sequence of SEQ ID NO: 3323;

[0241] (iii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3351, HC CDR2 contains the sequence of SEQ ID NO: 3352 and HC CDR3 contains the sequence of SEQ ID NO: 3353;

[0242] (vi) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 1190, HC CDR2 contains the sequence of SEQ ID NO: 1186 and HC CDR3 contains the sequence of SEQ ID NO: 1187;

[0243] (v) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3371, HC CDR2 contains the sequence of SEQ ID NO: 3372 and HC CDR3 contains the sequence of SEQ ID NO: 3373;

[0244] (vi) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3381, HC CDR2 contains the sequence of SEQ ID NO: 3382 and HC CDR3 contains the sequence of SEQ ID NO: 3383;

[0245] (vii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3391, HC CDR2 contains the sequence of SEQ ID NO: 3392 and HC CDR3 contains the sequence of SEQ ID NO: 3393;

[0246] (viii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3401, HC CDR2 contains the sequence of SEQ ID NO: 3402 and HC CDR3 contains the sequence of SEQ ID NO: 3403;

[0247] (ix) HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; or

[0248] (x) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3411, HC CDR2 contains the sequence of SEQ ID NO: 3412 and HC CDR3 contains the sequence of SEQ ID NO: 3413.

[0249] In some embodiments, the second conjugate includes a light chain variable region (VL), the VL including a light chain complementarity determination region 3 (LC CDR3), the LC CDR3 including a sequence of SEQ ID NO: 3346, SEQ ID NO: 3326, SEQ ID NO: 3356, SEQ ID NO: 1193, SEQ ID NO: 3376, SEQ ID NO: 3386, SEQ ID NO: 3396, SEQ ID NO: 3406 or SEQ ID NO: 3416.

[0250] In some embodiments, the second conjugate comprises a VL, the VL comprising a light chain complementarity determination region 1 (LCCDR1), the LCCDR1 comprising a sequence of SEQ ID NO: 3344, SEQ ID NO: 3324, SEQ ID NO: 3354, SEQ ID NO: 1191, SEQ ID NO: 3374, SEQ ID NO: 3384, SEQ ID NO: 3394, SEQ ID NO: 3404, or SEQ ID NO: 3414.

[0251] In some embodiments, the second conjugate comprises a VL, the VL comprising a light chain complementarity determination region 2 (LCCDR2), the LCCDR2 comprising a sequence of SEQ ID NO: 3345, SEQ ID NO: 3325, SEQ ID NO: 3355, SEQ ID NO: 1192, SEQ ID NO: 3375, SEQ ID NO: 3395, SEQ ID NO: 3405, SEQ ID NO: 3415 or SEQ ID NO: 3443.

[0252] In some embodiments, the second combination comprises VL, the VL comprising:

[0253] (i) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3344, LC CDR2 contains the sequence of SEQ ID NO: 3345 and LC CDR3 contains the sequence of SEQ ID NO: 3346;

[0254] (ii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3324, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3326;

[0255] (iii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3355, and LC CDR3 contains the sequence of SEQ ID NO: 3356;

[0256] (iv) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 1191, LC CDR2 contains the sequence of SEQ ID NO: 1192 and LC CDR3 contains the sequence of SEQ ID NO: 1193;

[0257] (v) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3374, LC CDR2 contains the sequence of SEQ ID NO: 3375, and LC CDR3 contains the sequence of SEQ ID NO: 3376;

[0258] (vi) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3384, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3386;

[0259] (vii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3394, LC CDR2 contains the sequence of SEQ ID NO: 3395 and LC CDR3 contains the sequence of SEQ ID NO: 3396;

[0260] (viii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3404, LC CDR2 contains the sequence of SEQ ID NO: 3405 and LC CDR3 contains the sequence of SEQ ID NO: 3406;

[0261] (ix) LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3414, LC CDR2 contains the sequence of SEQ ID NO: 3415, and LC CDR3 contains the sequence of SEQ ID NO: 3416; or

[0262] (x) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3443 and LC CDR3 contains the sequence of SEQ ID NO: 3356.

[0263] In some embodiments, the second combination comprises:

[0264] (i) VH, which comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3341, HC CDR2 comprises the sequence of SEQ ID NO: 3342, and HC CDR3 comprises the sequence of SEQ ID NO: 3343; and VL, which comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3344, LC CDR2 comprises the sequence of SEQ ID NO: 3345, and LC CDR3 comprises the sequence of SEQ ID NO: 3346;

[0265] (ii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3321, HC CDR2 comprises the sequence of SEQ ID NO: 3322, and HC CDR3 comprises the sequence of SEQ ID NO: 3323; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3324, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3326;

[0266] (iii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, LC CDR2 comprises the sequence of SEQ ID NO: 3355, and LC CDR3 comprises the sequence of SEQ ID NO: 3356;

[0267] (iv) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 1190, HC CDR2 comprises the sequence of SEQ ID NO: 1186, and HC CDR3 comprises the sequence of SEQ ID NO: 1187; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 1191, LC CDR2 comprises the sequence of SEQ ID NO: 1192, and LC CDR3 comprises the sequence of SEQ ID NO: 1193;

[0268] (v) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3371, HC CDR2 comprises the sequence of SEQ ID NO: 3372, and HC CDR3 comprises the sequence of SEQ ID NO: 3373; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3374, LC CDR2 comprises the sequence of SEQ ID NO: 3375, and LC CDR3 comprises the sequence of SEQ ID NO: 3376;

[0269] (vi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3381, HC CDR2 comprises the sequence of SEQ ID NO:3382, and HC CDR3 comprises the sequence of SEQ ID NO:3383; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3384, LC CDR2 comprises the sequence of SEQ ID NO:3325, and LC CDR3 comprises the sequence of SEQ ID NO:3386;

[0270] (vii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3391, HC CDR2 comprises the sequence of SEQ ID NO:3392, and HC CDR3 comprises the sequence of SEQ ID NO:3393; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3394, LC CDR2 comprises the sequence of SEQ ID NO:3395, and LC CDR3 comprises the sequence of SEQ ID NO:3396;

[0271] (viii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3401, HC CDR2 comprises the sequence of SEQ ID NO:3402, and HC CDR3 comprises the sequence of SEQ ID NO:3403; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3404, LC CDR2 comprises the sequence of SEQ ID NO:3405, and LC CDR3 comprises the sequence of SEQ ID NO:3406;

[0272] (ix) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3411, HC CDR2 comprises the sequence of SEQ ID NO: 3412, and HC CDR3 comprises the sequence of SEQ ID NO: 3413; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3414, LC CDR2 comprises the sequence of SEQ ID NO: 3415, and LC CDR3 comprises the sequence of SEQ ID NO: 3416;

[0273] (x) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises the sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, wherein LC CDR2 comprises the sequence of SEQ ID NO: 3355, and wherein LC CDR3 comprises the sequence of SEQ ID NO: 3356; or

[0274] (xi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises a sequence of 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3443, and wherein LC CDR3 comprises a sequence of SEQ ID NO: 3356.

[0275] In some embodiments, the second combination comprises a VH, the VH comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

[0276] In some embodiments, the second combination comprises VH, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

[0277] In some embodiments, the second combination comprises a VL, the VL comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

[0278] In some embodiments, the second combination comprises VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

[0279] In some embodiments, the second combination comprises:

[0280] (i) VH, wherein VH comprises a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and

[0281] (ii) VL, which comprises sequences having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

[0282] In some embodiments, the second combination comprises:

[0283] (i) VH, wherein VH comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and

[0284] (ii) VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

[0285] In some embodiments, the second combination comprises:

[0286] (i) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3445, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3446;

[0287] (ii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3448, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3449;

[0288] (iii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3450, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3451;

[0289] (iv) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1349;

[0290] (v) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1196, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1195;

[0291] (vi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3455, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3456;

[0292] (vii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3457, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3458;

[0293] (viii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3463, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3464;

[0294] (ix) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3465, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3466;

[0295] (x) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3470, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3471;

[0296] (xi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3475; or

[0297] (xii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3476.

[0298] In some embodiments, the second combination comprises:

[0299] (i) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3445 and VL contains the sequence of SEQ ID NO: 3446;

[0300] (ii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3448 and VL comprises the sequence of SEQ ID NO: 3449;

[0301] (iii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3450 and VL comprises the sequence of SEQ ID NO: 3451;

[0302] (iv) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346 and VL comprises the sequence of SEQ ID NO: 1349;

[0303] (v) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1196 and VL contains the sequence of SEQ ID NO: 1195;

[0304] (vi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3455 and VL comprises the sequence of SEQ ID NO: 3456;

[0305] (vii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3457 and VL contains the sequence of SEQ ID NO: 3458;

[0306] (viii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3463 and VL comprises the sequence of SEQ ID NO: 3464;

[0307] (ix) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3465 and VL contains the sequence of SEQ ID NO: 3466;

[0308] (x) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3470 and VL contains the sequence of SEQ ID NO: 3471;

[0309] (xi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346, and VL comprises the sequence of SEQ ID NO: 3475; or

[0310] (xii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1346 and VL contains the sequence of SEQ ID NO: 3476.

[0311] In some embodiments, the first and second conjugates bind to different TCRβV regions.

[0312] In some embodiments, the first and second conjugates bind to different TCRβVs belonging to different subfamilies.

[0313] In some embodiments, the first and second conjugates bind to different members of the same TCRβV subfamily.

[0314] In some embodiments, the first conjugate comprises one or more heavy chain constant regions selected from the group consisting of: IgG1 heavy chain constant region or fragments thereof, IgG2 heavy chain constant region or fragments thereof, IgG3 heavy chain constant region or fragments thereof, IgGA1 heavy chain constant region or fragments thereof, IgGA2 heavy chain constant region or fragments thereof, IgG4 heavy chain constant region or fragments thereof, IgJ heavy chain constant region or fragments thereof, IgM heavy chain constant region or fragments thereof, IgD heavy chain constant region or fragments thereof, and IgE heavy chain constant region or fragments thereof.

[0315] In some embodiments, the first combination comprises a κ light chain constant region or a fragment thereof, a λ light chain constant region or a fragment thereof, or a combination thereof.

[0316] In some embodiments, the second conjugate comprises one or more heavy chain constant regions selected from the group consisting of: IgG1 heavy chain constant region or fragment thereof, IgG2 heavy chain constant region or fragment thereof, IgG3 heavy chain constant region or fragment thereof, IgGA1 heavy chain constant region or fragment thereof, IgGA2 heavy chain constant region or fragment thereof, IgG4 heavy chain constant region or fragment thereof, IgJ heavy chain constant region or fragment thereof, IgM heavy chain constant region or fragment thereof, IgD heavy chain constant region or fragment thereof, and IgE heavy chain constant region or fragment thereof.

[0317] In some embodiments, the second combination comprises a κ light chain constant region or a fragment thereof, a λ light chain constant region or a fragment thereof, or a combination thereof.

[0318] In some embodiments, the first agent is a multifunctional molecule.

[0319] In some embodiments, the first agent is a multispecific molecule.

[0320] In some embodiments, the second agent is a multifunctional molecule.

[0321] In some embodiments, the second agent is a multispecific molecule.

[0322] In some embodiments, the first agent, the second agent, or a combination thereof comprises at least two discontinuous polypeptide chains;

[0323] The first polypeptide chain of the at least two discontinuous polypeptide chains contains a first Fc region, and the second polypeptide chain of the at least two discontinuous polypeptide chains contains a second Fc region; and

[0324] The first Fc region and the second Fc region contain the Fc interface with the pestle and mortar.

[0325] In some embodiments, the first Fc region, the second Fc region, or a combination thereof may contain the Asn297Ala mutation, the Leu234Ala / Leu235Ala mutation, or a combination thereof.

[0326] In some embodiments, the first agent is a multispecific molecule, which further comprises one or more of a tumor-targeting portion, a cytokine molecule, a matrix-modifying portion, or an immune cell conjugate.

[0327] In some embodiments, the second agent is a multispecific molecule, which further comprises one or more of a tumor-targeting portion, a cytokine molecule, a matrix-modifying portion, or an immune cell conjugate.

[0328] In some embodiments, the first agent comprises the following configuration:

[0329] A-, B-[dimerization module]-C, -D,

[0330] in:

[0331] (a) The dimerization module includes a first immunoglobulin chain constant region and a second immunoglobulin chain constant region;

[0332] (b) A and C are connected to the first immunoglobulin chain constant region; and B and D are connected to the second immunoglobulin chain constant region;

[0333] (c) A, B, C, and D independently (i) are absent; (ii) are the first conjugate; (iii) are the tumor-targeting portion; (iv) are the cytokine molecule; (v) are the matrix-modifying portion; or (vi) are the immune cell conjugate; and

[0334] At least one, two, or three of A, B, C, and D contain the first combination.

[0335] In some embodiments, the second agent comprises the following configuration:

[0336] A-, B-[dimerization module]-C, -D,

[0337] in:

[0338] (a) The dimerization module includes a first immunoglobulin chain constant region and a second immunoglobulin chain constant region;

[0339] (b) A and C are connected to the first immunoglobulin chain constant region; and B and D are connected to the second immunoglobulin chain constant region;

[0340] (c) A, B, C, and D independently (i) are absent; (ii) are the second conjugate; (iii) are the tumor-targeting portion; (iv) are the cytokine molecule; (v) are the matrix-modifying portion; or (vi) are the immune cell conjugate; and

[0341] At least one, two, or three of A, B, C, and D contain the second combination.

[0342] In some embodiments, the first immunoglobulin chain constant region includes a first fragment crystallizable region (Fc region), and the second first immunoglobulin chain constant region includes a second fragment crystallizable region (Fc region).

[0343] In some embodiments, dimerization of the first Fc region and the second Fc region is enhanced by providing an Fc interface between the first Fc region and the second Fc region and one or more of the paired cavity protrusions, electrostatic interactions, or chain exchanges, such that the ratio of heteropolymers to homopolymers formed is greater relative to the unengineered interface.

[0344] In some embodiments, the immune cell conjugate is selected from the group consisting of: T cell conjugate, NK cell conjugate, B cell conjugate, dendritic cell conjugate, macrophage conjugate, and any combination thereof.

[0345] In some embodiments, the cytokine molecules are selected from the group consisting of: interleukin-2 (IL-2) or a functional variant thereof, interleukin-7 (IL-7) or a functional variant thereof, interleukin-12 (IL-12) or a functional variant thereof, interleukin-15 (IL-15) or a functional variant thereof, interleukin-18 (IL-18) or a functional variant thereof, interleukin-21 (IL-21) or a functional variant thereof, interferon-γ or a functional variant thereof, and any combination thereof.

[0346] In some embodiments, the cytokine molecule comprises interleukin-2 (IL-2) or a functional variant thereof.

[0347] In some embodiments, the interleukin-2 (IL-2) or a functional variant thereof comprises the sequence of SEQ ID NO: 2270 or SEQ ID NO: 2191.

[0348] In some embodiments, the cytokine molecule comprises interleukin-15 (IL-15) or a functional variant thereof.

[0349] In some embodiments, the interleukin-15 (IL-15) or a functional variant thereof comprises the sequence of SEQ ID NO: 2170.

[0350] In some embodiments, the cytokine molecule further comprises an IL15Rα dimerization domain covalently linked to interleukin-15 (IL-15) or a functional variant thereof.

[0351] In some embodiments, the IL15Rα dimerization domain comprises the IL-15 receptor α sushi domain or a functional variant thereof.

[0352] In some embodiments, the IL15Rα dimerization domain comprises the sequence of SEQ ID NO: 3472.

[0353] In some embodiments, the interleukin-15 (IL-15) or a functional variant thereof is covalently linked to the IL15Rα dimerization domain via a connector.

[0354] In some embodiments, the interleukin-15 (IL-15) or a functional variant thereof is covalently linked to the IL15Rα dimerization domain via a connector comprising the sequence of SEQ ID NO: 3473.

[0355] In some embodiments, the cytokine molecule comprises the sequence of SEQ ID NO: 3474.

[0356] In some embodiments, the matrix modification portion is selected from the group consisting of hyaluronidase, collagenase, chondroitinase, and matrix metalloproteinase.

[0357] In some embodiments, the tumor-targeting portion binds to a cancer antigen.

[0358] In some embodiments, the tumor-targeting portion binds to a cancer antigen.

[0359] In some embodiments, the cancer antigen is present on hematologic malignancies, solid tumors, metastatic cancers, soft tissue tumors, metastatic lesions, or combinations thereof.

[0360] In some embodiments, the cancer antigen is a tumor antigen, matrix antigen, or blood antigen.

[0361] In some embodiments, the cancer antigen is selected from the group consisting of: BCMA, CD19, CD20, CD22, FcRH5, PDL1, CD47, ganglioside 2 (GD2), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron kinase, c-Met, immature laminin receptor, TAG-72, BING-4, calcium-activated chloride channel 2, cyclin-B1, 9D7, Ep-CAM, EphA3, Her2 / neu, telomerase, SAP-1, susceptin, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, Gp100 / pmel17, tyrosinase, MC1R, β-catenin, BRCA1 / 2 CDK4, CML66, fibronectin, p53, Ras, TGF-β receptor, AFP, ETA, MAGE, CA-125, BAGE, GAGE, CDC27, α-actin-4, TRP1 / gp75, TRP2, gangliosides, WT1, epidermal growth factor receptor (EGFR), MART-2, MUC1, MUC2, MUM1, MUM2, MUM3, NA88-1, NPM, OA1, OGT, RCC, RU11, RU12, SAGE, TRG, TSTA, folate receptor α, L1-CAM, CAIX, gpA33, GD3, GM2, VEGFR, integrin, carbohydrates, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, TGF-β, hyaluronic acid, collagen, tendinin C and tendinin W.

[0362] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0363] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3445, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0364] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0365] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3446, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0366] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0367] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3448, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0368] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0369] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3449, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0370] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0371] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0372] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0373] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0374] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0375] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0376] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0377] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0378] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0379] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[0380] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0381] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0382] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0383] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1196, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0384] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0385] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1195, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0386] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0387] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3455, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0388] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0389] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3456, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0390] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0391] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3457, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460.

[0392] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[0393] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3458, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[0394] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0395] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3463, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460.

[0396] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[0397] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3464, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[0398] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0399] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3465, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3467, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3468.

[0400] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3469, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[0401] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3466, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[0402] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0403] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3470, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0404] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0405] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3471, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0406] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0407] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[0408] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[0409] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0410] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0411] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[0412] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[0413] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3475, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0414] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0415] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[0416] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[0417] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3476, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0418] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0419] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3445, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0420] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0421] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3446, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0422] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0423] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3448, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0424] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0425] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3449, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0426] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0427] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0428] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0429] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0430] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0431] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0432] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0433] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0434] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0435] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[0436] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0437] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0438] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0439] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1196, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0440] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0441] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1195, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0442] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0443] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3455, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0444] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0445] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3456, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0446] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0447] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3457, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460.

[0448] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[0449] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3458, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[0450] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0451] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3463, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460.

[0452] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[0453] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3464, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[0454] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0455] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3465, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3467, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3468.

[0456] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3469, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[0457] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3466, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[0458] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0459] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3470, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[0460] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[0461] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3471, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0462] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0463] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[0464] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[0465] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0466] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0467] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[0468] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[0469] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3475, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0470] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0471] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[0472] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[0473] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3476, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[0474] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0475] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3338;

[0476] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0477] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3339.

[0478] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0479] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3318;

[0480] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0481] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3319.

[0482] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0483] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328;

[0484] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0485] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

[0486] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0487] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328;

[0488] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3350 or the sequence of SEQ ID NO: 3500; and

[0489] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

[0490] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0491] (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0492] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0493] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3349.

[0494] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0495] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3358;

[0496] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0497] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3359.

[0498] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0499] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3368;

[0500] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0501] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3369.

[0502] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0503] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3378;

[0504] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3380; and

[0505] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3379.

[0506] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0507] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3388;

[0508] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3390; and

[0509] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3389.

[0510] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0511] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3398;

[0512] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3400; and

[0513] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3399.

[0514] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0515] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3408;

[0516] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0517] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3409.

[0518] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0519] (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0520] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and

[0521] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3349.

[0522] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0523] (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0524] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and

[0525] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3428.

[0526] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0527] (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0528] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and

[0529] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3437.

[0530] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0531] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3338;

[0532] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0533] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3339.

[0534] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0535] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3318;

[0536] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0537] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3319.

[0538] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0539] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3328;

[0540] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0541] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3329.

[0542] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0543] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3328;

[0544] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3350 or the sequence of SEQ ID NO: 3500; and

[0545] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3329.

[0546] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0547] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0548] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0549] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3349.

[0550] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0551] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3358;

[0552] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0553] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3359.

[0554] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0555] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3368;

[0556] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0557] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3369.

[0558] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0559] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3378;

[0560] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3380; and

[0561] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3379.

[0562] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0563] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3388;

[0564] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3390; and

[0565] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3389.

[0566] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0567] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3398;

[0568] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3400; and

[0569] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3399.

[0570] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0571] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3408;

[0572] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0573] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3409.

[0574] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0575] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0576] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and

[0577] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3349.

[0578] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0579] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0580] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and

[0581] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3428.

[0582] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0583] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0584] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and

[0585] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3437.

[0586] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0587] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3338;

[0588] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0589] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3339.

[0590] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0591] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3318;

[0592] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0593] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3319.

[0594] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0595] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328;

[0596] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0597] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

[0598] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0599] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328;

[0600] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3350 or the sequence of SEQ ID NO: 3500; and

[0601] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

[0602] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0603] (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0604] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0605] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3349.

[0606] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0607] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3358;

[0608] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0609] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3359.

[0610] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0611] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3368;

[0612] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0613] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3369.

[0614] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0615] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3378;

[0616] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3380; and

[0617] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3379.

[0618] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0619] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3388;

[0620] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3390; and

[0621] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3389.

[0622] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0623] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3398;

[0624] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3400; and

[0625] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3399.

[0626] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0627] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3408;

[0628] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0629] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3409.

[0630] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0631] (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0632] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and

[0633] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3349.

[0634] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0635] (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0636] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and

[0637] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3428.

[0638] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0639] (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0640] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and

[0641] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3437.

[0642] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0643] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3338;

[0644] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0645] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3339.

[0646] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0647] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3318;

[0648] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0649] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3319.

[0650] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0651] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3328;

[0652] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0653] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3329.

[0654] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0655] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3328;

[0656] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3350 or the sequence of SEQ ID NO: 3500; and

[0657] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3329.

[0658] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0659] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0660] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0661] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3349.

[0662] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0663] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3358;

[0664] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0665] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3359.

[0666] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0667] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3368;

[0668] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0669] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3369.

[0670] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0671] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3378;

[0672] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3380; and

[0673] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3379.

[0674] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0675] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3388;

[0676] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3390; and

[0677] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3389.

[0678] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0679] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3398;

[0680] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3400; and

[0681] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3399.

[0682] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0683] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3408;

[0684] (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[0685] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3409.

[0686] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0687] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0688] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and

[0689] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3349.

[0690] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0691] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0692] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and

[0693] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3428.

[0694] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[0695] (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[0696] (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and

[0697] (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3437.

[0698] In some embodiments, the disease or symptom is cancer.

[0699] In some embodiments, the cancer is a solid tumor.

[0700] In some embodiments, the solid tumor is melanoma, pancreatic cancer, breast cancer, colorectal cancer, lung cancer, skin cancer, ovarian cancer, or liver cancer.

[0701] In some embodiments, the solid tumor is selected from the group consisting of: high mutation burden (TMB-H), microsatellite instability / DNA mismatch repair (MSI-H / dMMR), virus-associated tumors, metastatic triple-negative breast cancer (mTNBC), recurrent and refractory epithelial ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), K-Ras wild-type CRC, K-Ras mutant CRC, and primary stage IV or recurrent non-small cell lung cancer (NSCLC).

[0702] In some embodiments, the virus-associated tumor includes Merkel cell carcinoma, cervical cancer, oropharyngeal cancer, anal cancer, penile cancer, vaginal cancer, or vulvar cancer.

[0703] In some embodiments, the cancer is a blood cancer.

[0704] In some embodiments, the blood cancer is a B-cell or T-cell malignancy.

[0705] In some embodiments, the B-cell or T-cell malignancy is Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma, or acute lymphoblastic leukemia.

[0706] In some embodiments, the non-Hodgkin's lymphoma is B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, or hairy cell leukemia.

[0707] In some embodiments, the application includes applying a first pharmaceutical composition comprising the first agent and a second pharmaceutical composition comprising the second agent, wherein the first pharmaceutical composition and the second pharmaceutical composition independently further comprise pharmaceutically acceptable excipients, carriers, or diluents.

[0708] On the other hand, this article provides in particular a combination therapy for treating a disease or symptom in a subject in need, the combination therapy comprising administering to the subject a first agent comprising a first conjugate binding to a first target molecule, and administering to the subject a second agent comprising a second conjugate binding to a second target molecule, thereby treating the subject's disease or symptom;

[0709] The second drug is applied after the first drug is applied.

[0710] The first target molecule and the second target molecule are independently selected from the group consisting of the T cell receptor α variable region (TCRαV) and the T cell receptor β variable region (TCRβV); and

[0711] The first target molecule and the second target molecule are different.

[0712] In some embodiments, the first agent and the second agent are not administered to the subject simultaneously.

[0713] In some embodiments, administering the first agent comprises administering a therapeutically effective amount of the first agent to the subject.

[0714] In some embodiments, administering the second agent comprises administering a therapeutically effective amount of the second agent to the subject.

[0715] In some embodiments, the combination therapy may treat the subject’s disease or condition more effectively than the method of administering the first agent to the subject but not the second agent.

[0716] In some embodiments, the combination therapy may treat the subject’s disease or condition more effectively than the method of administering the second agent to the subject but not the first agent.

[0717] In some embodiments, the combination therapy may treat the subject’s disease or condition more effectively than a method of administering the first agent to the subject in a first administration and then administering the first agent to the subject in a second administration.

[0718] In some embodiments, the combination therapy may treat the subject’s disease or condition more effectively than a method of administering the second agent to the subject in a first administration and then administering the second agent to the subject in a second administration.

[0719] In some embodiments, the combination therapy may treat the subject’s disease or condition more effectively than the method of administering the second agent to the subject in a first administration and then administering the first agent to the subject in a second administration.

[0720] In some embodiments, the administration of the first agent comprises one or more doses.

[0721] In some embodiments, the administration of the first agent comprises two or more doses.

[0722] In some embodiments, the administration of the first agent comprises one dose per week.

[0723] In some embodiments, the administration of the first agent comprises two or more doses per week.

[0724] In some embodiments, the first agent is administered to the subject once every two weeks.

[0725] In some embodiments, the first agent is administered to the subject once every three weeks.

[0726] In some embodiments, the first agent is administered to the subject once a week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

[0727] In some embodiments, the administration of the first agent comprises two or more doses per week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

[0728] In some embodiments, the first agent is administered to the subject every two weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

[0729] In some embodiments, the first agent is administered to the subject once every three weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

[0730] In some embodiments, the administration of the second agent comprises one or more doses.

[0731] In some embodiments, the administration of the second agent comprises two or more doses.

[0732] In some embodiments, the administration of the second agent comprises a weekly dose.

[0733] In some embodiments, the administration of the second agent comprises two or more doses per week.

[0734] In some embodiments, the second agent is administered to the subject once every two weeks.

[0735] In some embodiments, the second agent is administered to the subject once every three weeks.

[0736] In some embodiments, the second agent is administered to the subject once a week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

[0737] In some embodiments, the administration of the second agent comprises two or more doses per week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

[0738] In some embodiments, the second agent is administered to the subject every two weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

[0739] In some embodiments, the second agent is administered to the subject once every three weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

[0740] In some embodiments, the administration of the first agent and the administration of the second agent are spaced one week apart.

[0741] In some embodiments, the administration of the first agent and the administration of the second agent are spaced two weeks or more apart.

[0742] In some embodiments, the interval between the application of the first agent and the application of the second agent is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.

[0743] In some embodiments, the administration of the first and second agents is repeated two or more times.

[0744] In some embodiments, the first and second agents are administered to the subject according to a dosing regimen, wherein the dosing regimen comprises administering the first agent once weekly for two weeks, followed by administering the second agent once weekly for two weeks, wherein the second agent is administered to the subject one week after the last administration of the first agent.

[0745] In some embodiments, the dosing regimen is repeated two or more times.

[0746] In some embodiments, the dosing regimen is repeated at weekly intervals.

[0747] In some embodiments, the dosing regimen is repeated at intervals of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.

[0748] In some embodiments, the first and second agents are administered to the subject in the same amount.

[0749] In some embodiments, the first and second agents are administered to the subject in different amounts.

[0750] In some embodiments, the administration of the first agent comprises two or more doses, and each dose comprises the same amount of the first agent.

[0751] In some embodiments, the administration of the first agent comprises two or more doses, and each dose comprises a different amount of the first agent.

[0752] In some embodiments, the administration of the second agent comprises two or more doses, and each dose comprises the same amount of the second agent.

[0753] In some embodiments, the administration of the second agent comprises two or more doses, and each dose comprises a different amount of the second agent.

[0754] In some embodiments, the first agent is administered to the subject at a dose of about 0.001 mg / kg to about 10 mg / kg.

[0755] In some embodiments, the second agent is administered to the subject at a dose of about 0.001 mg / kg to about 10 mg / kg.

[0756] In some embodiments, the first agent is administered to the subject at a dose of about 0.3 mg / kg or about 1 mg / kg.

[0757] In some embodiments, the second agent is administered to the subject at a dose of about 0.3 mg / kg or about 1 mg / kg.

[0758] In some embodiments, the first target molecule is a first TCRβV and the second target molecule is a second TCRβV, wherein the first TCRβV and the second TCRβV are different.

[0759] In some embodiments, the first target molecule is a first TCRαV and the second target molecule is a second TCRαV, wherein the first TCRαV and the second TCRαV are different.

[0760] In some embodiments, the first target molecule is TCRβV, and the second target molecule is TCRαV.

[0761] In some embodiments, the first target molecule is TCRαV and the second target molecule is TCRβV.

[0762] In some embodiments, the first target molecule is human TCRβV6.

[0763] In some embodiments, the first target molecule is human TCRβV10.

[0764] In some embodiments, the second target molecule is human TCRβV15.

[0765] In some embodiments, the second target molecule is human TCRβV27.

[0766] In some embodiments, the second target molecule is human TCRβV5.

[0767] In some embodiments, the first target molecule is human TCRβV6, and the second target molecule is human TCRβV5.

[0768] In some embodiments, the first target molecule is human TCRβV6, and the second target molecule is human TCRβV15.

[0769] In some embodiments, the first target molecule is human TCRβV6, and the second target molecule is human TCRβV27.

[0770] In some embodiments, the first target molecule is human TCRβV10, and the second target molecule is human TCRβV5.

[0771] In some embodiments, the first target molecule is human TCRβV10, and the second target molecule is human TCRβV15.

[0772] In some embodiments, the first target molecule is human TCRβV10, and the second target molecule is human TCRβV27.

[0773] In some embodiments, the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20, or human TRBV28.

[0774] In some embodiments, the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28.

[0775] In some embodiments, the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30.

[0776] In some embodiments, the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30.

[0777] In some embodiments, the second target molecule is human TRBV5, human TRBV15, human TRBV27, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20, or human TRBV28.

[0778] In some embodiments, the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV15, human TRBV27, human TRBV19, human TRBV20-1, or human TRBV28.

[0779] In some embodiments, the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30.

[0780] In some embodiments, the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30.

[0781] In some embodiments, the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20, or human TRBV28, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV15, human TRBV27, human TRBV19, human TRBV20, or human TRBV28, wherein the first target molecule and the second target molecule are different.

[0782] In some embodiments, the first target molecule and the second target molecule:

[0783] These are human TRBV5 and human TRBV5; these are human TRBV5 and human TRBV6; these are human TRBV5 and human TRBV10; these are human TRBV5 and human TRBV7; these are human TRBV5 and human TRBV19; these are human TRBV5 and human TRBV20; these are human TRBV5 and human TRBV28; these are human TRBV6 and human TRBV5; these are human TRBV6 and human TRBV6; these are human TRBV6 and human TRBV10; these are human TRBV6 and human TRBV7; these are human TRBV6 and human TRBV15; these are human TRBV6 and human TRBV27; these are human TRBV6 and human TRBV... BV19; refers to human TRBV6 and human TRBV20; refers to human TRBV6 and human TRBV28; refers to human TRBV10 and human TRBV5; refers to human TRBV10 and human TRBV6; refers to human TRBV10 and human TRBV10; refers to human TRBV10 and human TRBV7; refers to human TRBV10 and human TRBV15; refers to human TRBV10 and human TRBV27; refers to human TRBV10 and human TRBV19; refers to human TRBV10 and human TRBV20; refers to human TRBV10 and human TRBV28; refers to human TRBV7 and human TRBV5; refers to human TRBV7 and human TRBV 6; respectively human TRBV7 and human TRBV10; respectively human TRBV7 and human TRBV7; respectively human TRBV7 and human TRBV19; respectively human TRBV7 and human TRBV20; respectively human TRBV7 and human TRBV28; respectively human TRBV19 and human TRBV5; respectively human TRBV19 and human TRBV6; respectively human TRBV19 and human TRBV10; respectively human TRBV19 and human TRBV7; respectively human TRBV19 and human TRBV19; respectively human TRBV19 and human TRBV20; respectively human TRBV19 and human TRBV28; respectively human TRBV20 and human TRBV5; respectively It is human TRBV20 and human TRBV6; it is human TRBV20 and human TRBV10; it is human TRBV20 and human TRBV7; it is human TRBV20 and human TRBV19; it is human TRBV20 and human TRBV20; it is human TRBV20 and human TRBV28; it is human TRBV28 and human TRBV5; it is human TRBV28 and human TRBV6; it is human TRBV28 and human TRBV10; it is human TRBV28 and human TRBV7; it is human TRBV28 and human TRBV19; it is human TRBV28 and human TRBV20; or it is human TRBV28 and human TRBV28.

[0784] In some embodiments, the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV15, human TRBV27, human TRBV19, human TRBV20-1, or human TRBV28, wherein the first target molecule and the second target molecule are different.

[0785] In some embodiments, the first target molecule and the second target molecule:

[0786] These are human TRBV5-1 and human TRBV6-5; these are human TRBV5-1 and human TRBV10-1; these are human TRBV5-1 and human TRBV10-2; these are human TRBV5-1 and human TRBV10-3; these are human TRBV5-1 and human TRBV7-2; these are human TRBV5-1 and human TRBV7-3; these are human TRBV5-1 and human TRBV19; these are human TRBV5-1 and human TRBV20-1; these are human TRBV5-1 and human TRBV28; these are human TRBV6-5 and human TRBV5-1; these are human TRBV6-5 and human TRBV7-2; these are human TRBV6-5 and... Human TRBV7-3; Human TRBV6-5 and Human TRBV15; Human TRBV6-5 and Human TRBV27; Human TRBV6-5 and Human TRBV19; Human TRBV6-5 and Human TRBV20-1; Human TRBV6-5 and Human TRBV28; Human TRBV10-1 and Human TRBV5-1; Human TRBV10-1 and Human TRBV7-2; Human TRBV10-1 and Human TRBV7-3; Human TRBV10-1 and Human TRBV15; Human TRBV10-1 and Human TRBV27; Human TRBV10-1 and Human TRBV19; Human TR BV10-1 and human TRBV20-1; respectively human TRBV10-1 and human TRBV28; respectively human TRBV10-2 and human TRBV5-1; respectively human TRBV10-2 and human TRBV7-2; respectively human TRBV10-2 and human TRBV7-3; respectively human TRBV10-2 and human TRBV15; respectively human TRBV10-2 and human TRBV27; respectively human TRBV10-2 and human TRBV19; respectively human TRBV10-2 and human TRBV20-1; respectively human TRBV10-2 and human TRBV28; respectively human TRBV10-3 and human TRBV5-1; respectively human TRBV10-3 and Human TRBV7-2; Human TRBV10-3 and Human TRBV7-3; Human TRBV10-3 and Human TRBV15; Human TRBV10-3 and Human TRBV27; Human TRBV10-3 and Human TRBV19; Human TRBV10-3 and Human TRBV20-1; Human TRBV10-3 and Human TRBV28; Human TRBV7-2 and Human TRBV5-1; Human TRBV7-2 and Human TRBV6-5; Human TRBV7-2 and Human TRBV10-1; Human TRBV7-2 and Human TRBV10-2; Human TRBV7-2 and Human TRBV10-3;These are human TRBV7-2 and human TRBV7-3; these are human TRBV7-2 and human TRBV19; these are human TRBV7-2 and human TRBV20-1; these are human TRBV7-2 and human TRBV28; these are human TRBV7-3 and human TRBV5-1; these are human TRBV7-3 and human TRBV6-5; these are human TRBV7-3 and human TRBV10-1; these are human TRBV7-3 and human TRBV10-2; these are human TRBV7-3 and human TRBV10-3; these are human TRBV7-3 and human TRBV7- 2; These are human TRBV7-3 and human TRBV19; These are human TRBV7-3 and human TRBV20-1; These are human TRBV7-3 and human TRBV28; These are human TRBV19 and human TRBV5-1; These are human TRBV19 and human TRBV6-5; These are human TRBV19 and human TRBV10-1; These are human TRBV19 and human TRBV10-2; These are human TRBV19 and human TRBV10-3; These are human TRBV19 and human TRBV7-2; These are human TRBV19 and human TRBV7-3; These are... Human TRBV19 and human TRBV20-1; human TRBV19 and human TRBV28; human TRBV20-1 and human TRBV5-1; human TRBV20-1 and human TRBV6-5; human TRBV20-1 and human TRBV10-1; human TRBV20-1 and human TRBV10-2; human TRBV20-1 and human TRBV10-3; human TRBV20-1 and human TRBV7-2; human TRBV20-1 and human TRBV7-3; human TRBV20-1 and human TRBV7-3. BV19; refers to human TRBV20-1 and human TRBV28; refers to human TRBV28 and human TRBV5-1; refers to human TRBV28 and human TRBV6-5; refers to human TRBV28 and human TRBV10-1; refers to human TRBV28 and human TRBV10-2; refers to human TRBV28 and human TRBV10-3; refers to human TRBV28 and human TRBV7-2; refers to human TRBV28 and human TRBV7-3; refers to human TRBV28 and human TRBV19; or refers to human TRBV28 and human TRBV20-1.

[0787] In some embodiments, the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30, wherein the first target molecule and the second target molecule are different.

[0788] In some embodiments, the first target molecule and the second target molecule:

[0789] They are human TRAV12 and human TRAV12, respectively.

[0790] They are human TRAV12 and human TRAV13, respectively.

[0791] They are human TRAV12 and human TRAV19, respectively.

[0792] They are human TRAV12 and human TRAV21, respectively.

[0793] These are human TRAV12 and human TRAV30, respectively.

[0794] They are human TRAV13 and human TRAV12, respectively.

[0795] They are human TRAV13 and human TRAV13, respectively.

[0796] They are human TRAV13 and human TRAV19, respectively.

[0797] They are human TRAV13 and human TRAV21, respectively.

[0798] They are TRAV13 and TRAV30, respectively.

[0799] They are human TRAV19 and human TRAV12, respectively.

[0800] They are human TRAV19 and human TRAV13, respectively.

[0801] They are human TRAV19 and human TRAV19, respectively.

[0802] They are human TRAV19 and human TRAV21, respectively.

[0803] They are human TRAV19 and human TRAV30, respectively.

[0804] They are human TRAV21 and human TRAV12, respectively.

[0805] They are human TRAV21 and human TRAV13, respectively.

[0806] They are human TRAV21 and human TRAV19, respectively.

[0807] They are human TRAV21 and human TRAV21, respectively.

[0808] They are human TRAV21 and human TRAV30, respectively.

[0809] These are TRAV30 and TRAV12 for humans, respectively.

[0810] They are TRAV30 and TRAV13 for humans, respectively.

[0811] These are TRAV30 and TRAV19 for humans, respectively.

[0812] These are TRAV30 and TRAV21 for humans, respectively; or

[0813] They are TRAV30 and TRAV30 respectively.

[0814] In some embodiments, the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30, wherein the first target molecule and the second target molecule are different.

[0815] In some embodiments, the first target molecule and the second target molecule:

[0816] These are human TRAV12-2 and human TRAV13-1, respectively.

[0817] These are human TRAV12-2 and human TRAV19, respectively.

[0818] These are human TRAV12-2 and human TRAV21, respectively.

[0819] These are human TRAV12-2 and human TRAV30, respectively.

[0820] They are human TRAV13-1 and human TRAV12-2, respectively.

[0821] These are human TRAV13-1 and human TRAV19, respectively.

[0822] These are human TRAV13-1 and human TRAV21, respectively.

[0823] These are human TRAV13-1 and human TRAV30, respectively.

[0824] They are human TRAV19 and human TRAV12-2, respectively.

[0825] They are human TRAV19 and human TRAV13-1, respectively.

[0826] They are human TRAV19 and human TRAV21, respectively.

[0827] They are human TRAV19 and human TRAV30, respectively.

[0828] These are human TRAV21 and human TRAV12-2, respectively.

[0829] These are human TRAV21 and human TRAV13-1, respectively.

[0830] They are human TRAV21 and human TRAV19, respectively.

[0831] They are human TRAV21 and human TRAV30, respectively.

[0832] These are human TRAV30 and human TRAV12-2, respectively.

[0833] These are human TRAV30 and human TRAV13-1, respectively.

[0834] These are TRAV30 and TRAV19 for individuals, respectively; or

[0835] They are TRAV30 and TRAV21, respectively.

[0836] In some embodiments, the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

[0837] In some embodiments, the first target molecule and the second target molecule:

[0838] These are human TRBV5 and human TRAV12; these are human TRBV5 and human TRAV13; these are human TRBV5 and human TRAV19; these are human TRBV5 and human TRAV21; these are human TRBV5 and human TRAV30; these are human TRBV6 and human TRAV12; these are human TRBV6 and human TRAV13; these are human TRBV6 and human TRAV19; these are human TRBV6 and human TRAV21; these are human TRBV6 and human TRAV30; these are human TRBV10 and human TRAV12; these are human TRBV10 and human TRAV13; these are human TRBV10 and human TRAV19; these are human TRBV10 and human TRAV21; these are human TRBV10 and human TRAV30; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV13 ...2; these are human TRBV7 and human TRAV13; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV13; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV12; these are human TRBV7 and human TRAV13; these are V19; are human TRBV7 and human TRAV21; are human TRBV7 and human TRAV30; are human TRBV19 and human TRAV12; are human TRBV19 and human TRAV13; are human TRBV19 and human TRAV19; are human TRBV19 and human TRAV21; are human TRBV19 and human TRAV30; are human TRBV20 and human TRAV12; are human TRBV20 and human TRAV13; are human TRBV20 and human TRAV19; are human TRBV20 and human TRAV21; are human TRBV20 and human TRAV30; are human TRBV28 and human TRAV12; are human TRBV28 and human TRAV13; are human TRBV28 and human TRAV19; are human TRBV28 and human TRAV21; or are human TRBV28 and human TRAV30.

[0839] In some embodiments, the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

[0840] In some embodiments, the first target molecule and the second target molecule:

[0841] These are human TRBV5 and human TRAV12-2; these are human TRBV5 and human TRAV13-1; these are human TRBV5 and human TRAV19; these are human TRBV5 and human TRAV21; these are human TRBV5 and human TRAV30; these are human TRBV6 and human TRAV12-2; these are human TRBV6 and human TRAV13-1; these are human TRBV6 and human TRAV19; these are human TRBV6 and human TRAV21. These are human TRBV6 and human TRAV30; these are human TRBV10 and human TRAV12-2; these are human TRBV10 and human TRAV13-1; these are human TRBV10 and human TRAV19; these are human TRBV10 and human TRAV21; these are human TRBV10 and human TRAV30; these are human TRBV7 and human TRAV12-2; these are human TRBV7 and human TRAV13-1; these are human TRBV7 and human TRAV12-2; these are human TRBV7 and human TRAV13-1; these are human TRBV7 and human TRAV12-2. RAV19; These are human TRBV7 and human TRAV21; These are human TRBV7 and human TRAV30; These are human TRBV19 and human TRAV12-2; These are human TRBV19 and human TRAV13-1; These are human TRBV19 and human TRAV19; These are human TRBV19 and human TRAV21; These are human TRBV19 and human TRAV30; These are human TRBV20 and human TRAV12-2; These are human TRBV 20 and human TRAV13-1; human TRBV20 and human TRAV19; human TRBV20 and human TRAV21; human TRBV20 and human TRAV30; human TRBV28 and human TRAV12-2; human TRBV28 and human TRAV13-1; human TRBV28 and human TRAV19; human TRBV28 and human TRAV21; or human TRBV28 and human TRAV30.

[0842] In some embodiments, the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30.

[0843] In some embodiments, the first target molecule and the second target molecule:

[0844] These are human TRBV5-1 and human TRAV12; these are human TRBV5-1 and human TRAV13; these are human TRBV5-1 and human TRAV19; these are human TRBV5-1 and human TRAV21; these are human TRBV5-1 and human TRAV30; these are human TRBV6-5 and human TRAV12; these are human TRBV6-5 and human TRAV13; these are human TRBV6-5 and human TRAV19; these are human TRBV6-5 and human TRAV21; these are human TRBV6-5 and human TRAV30; these are human TRBV10-1 and human TRAV12; these are human TRBV10-1 and human TRAV13; these are human T RBV10-1 and human TRAV19; respectively human TRBV10-1 and human TRAV21; respectively human TRBV10-1 and human TRAV30; respectively human TRBV10-2 and human TRAV12; respectively human TRBV10-2 and human TRAV13; respectively human TRBV10-2 and human TRAV19; respectively human TRBV10-2 and human TRAV21; respectively human TRBV10-2 and human TRAV30; respectively human TRBV10-3 and human TRAV12; respectively human TRBV10-3 and human TRAV13; respectively human TRBV10-3 and human TRAV19; respectively human TRBV10-3 and human TRAV21; divided They are human TRBV10-3 and human TRAV30; they are human TRBV7-2 and human TRAV12; they are human TRBV7-2 and human TRAV13; they are human TRBV7-2 and human TRAV19; they are human TRBV7-2 and human TRAV21; they are human TRBV7-2 and human TRAV30; they are human TRBV7-3 and human TRAV12; they are human TRBV7-3 and human TRAV13; they are human TRBV7-3 and human TRAV19; they are human TRBV7-3 and human TRAV21; they are human TRBV7-3 and human TRAV30; they are human TRBV19 and human TRAV12; they are human TRBV1 9 and TRAV13; TRBV19 and TRAV19; TRBV19 and TRAV21; TRBV19 and TRAV30; TRBV20-1 and TRAV12; TRBV20-1 and TRAV13; TRBV20-1 and TRAV19; TRBV20-1 and TRAV21; TRBV20-1 and TRAV30; TRBV28 and TRAV12; TRBV28 and TRAV13; TRBV28 and TRAV19; TRBV28 and TRAV21.Or they may be human TRBV28 and human TRAV30, respectively.

[0845] In some embodiments, the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30.

[0846] In some embodiments, the first target molecule and the second target molecule:

[0847] These are human TRBV5-1 and human TRAV12-2; these are human TRBV5-1 and human TRAV13-1; these are human TRBV5-1 and human TRAV19; these are human TRBV5-1 and human TRAV21; these are human TRBV5-1 and human TRAV30; these are human TRBV6-5 and human TRAV12-2; these are human TRBV6-5 and human TRAV13-1; these are human TRBV6-5 and human TRAV19; these are human TRBV6-5 and human TRAV21; these are human TRBV6-5 and human TRAV30; these are human TRBV10-1 and human TRAV12-2; these are human TRBV10-1 and human TRAV12-2. V13-1; These are human TRBV10-1 and human TRAV19; These are human TRBV10-1 and human TRAV21; These are human TRBV10-1 and human TRAV30; These are human TRBV10-2 and human TRAV12-2; These are human TRBV10-2 and human TRAV13-1; These are human TRBV10-2 and human TRAV19; These are human TRBV10-2 and human TRAV21; These are human TRBV10-2 and human TRAV30; These are human TRBV10-3 and human TRAV12-2; These are human TRBV10-3 and human TRAV13-1; These are human TRBV10-3 and human TRAV19; These are... Human TRBV10-3 and human TRAV21; respectively human TRBV10-3 and human TRAV30; respectively human TRBV7-2 and human TRAV12-2; respectively human TRBV7-2 and human TRAV13-1; respectively human TRBV7-2 and human TRAV19; respectively human TRBV7-2 and human TRAV21; respectively human TRBV7-2 and human TRAV30; respectively human TRBV7-3 and human TRAV12-2; respectively human TRBV7-3 and human TRAV13-1; respectively human TRBV7-3 and human TRAV19; respectively human TRBV7-3 and human TRAV21; respectively human TRBV7-3 and human TRAV30; They are human TRBV19 and human TRAV12-2; they are human TRBV19 and human TRAV13-1; they are human TRBV19 and human TRAV19; they are human TRBV19 and human TRAV21; they are human TRBV19 and human TRAV30; they are human TRBV20-1 and human TRAV12-2; they are human TRBV20-1 and human TRAV13-1; they are human TRBV20-1 and human TRAV19; they are human TRBV20-1 and human TRAV21; they are human TRBV20-1 and human TRAV30; they are human TRBV28 and human TRAV12-2; they are human TRBV28 and human TRAV13-1.These are human TRBV28 and human TRAV19; these are human TRBV28 and human TRAV21; or these are human TRBV28 and human TRAV30.

[0848] In some embodiments, the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20, or human TRBV28.

[0849] In some embodiments, the first target molecule and the second target molecule:

[0850] These are human TRAV12 and human TRBV5; these are human TRAV12 and human TRBV6; these are human TRAV12 and human TRBV10; these are human TRAV12 and human TRBV7; these are human TRAV12 and human TRBV19; these are human TRAV12 and human TRBV20; these are human TRAV12 and human TRBV28; these are human TRAV13 and human TRBV5; these are human TRAV13 and human TRBV6; these are human TRAV13 and human TRBV10; these are human TRAV13 and human TRBV7; these are human TRAV13 and human TRBV19; these are human TRAV13 and human TRBV20; these are human TRAV13 and human TRBV28; these are human TRAV19 and human TRBV5; these are human TRAV19 and human TRBV6; these are human TRAV19 and human TRBV10; these are human TRAV19 And human TRBV7; respectively human TRAV19 and human TRBV19; respectively human TRAV19 and human TRBV20; respectively human TRAV19 and human TRBV28; respectively human TRAV21 and human TRBV5; respectively human TRAV21 and human TRBV6; respectively human TRAV21 and human TRBV10; respectively human TRAV21 and human TRBV7; respectively human TRAV21 and human TRBV19; respectively human TRAV21 and human TRBV20; respectively human TRAV21 and human TRBV28; respectively human TRAV30 and human TRBV5; respectively human TRAV30 and human TRBV6; respectively human TRAV30 and human TRBV10; respectively human TRAV30 and human TRBV7; respectively human TRAV30 and human TRBV19; respectively human TRAV30 and human TRBV20; or respectively human TRAV30 and human TRBV28.

[0851] In some embodiments, the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20, or human TRBV28.

[0852] In some embodiments, the first target molecule and the second target molecule:

[0853] These are human TRAV12-2 and human TRBV5; these are human TRAV12-2 and human TRBV6; these are human TRAV12-2 and human TRBV10; these are human TRAV12-2 and human TRBV7; these are human TRAV12-2 and human TRBV19; these are human TRAV12-2 and human TRBV20; these are human TRAV12-2 and human TRBV28; these are human TRAV13-1 and human TRBV5; these are human T... RAV13-1 and human TRBV6; respectively human TRAV13-1 and human TRBV10; respectively human TRAV13-1 and human TRBV7; respectively human TRAV13-1 and human TRBV19; respectively human TRAV13-1 and human TRBV20; respectively human TRAV13-1 and human TRBV28; respectively human TRAV19 and human TRBV5; respectively human TRAV19 and human TRBV6; respectively human TRAV19 and human TRBV6 V10; refers to human TRAV19 and human TRBV7; refers to human TRAV19 and human TRBV19; refers to human TRAV19 and human TRBV20; refers to human TRAV19 and human TRBV28; refers to human TRAV21 and human TRBV5; refers to human TRAV21 and human TRBV6; refers to human TRAV21 and human TRBV10; refers to human TRAV21 and human TRBV7; refers to human TRAV21 and human TRBV19 ; are human TRAV21 and human TRBV20 respectively; are human TRAV21 and human TRBV28 respectively; are human TRAV30 and human TRBV5 respectively; are human TRAV30 and human TRBV6 respectively; are human TRAV30 and human TRBV10 respectively; are human TRAV30 and human TRBV7 respectively; are human TRAV30 and human TRBV19 respectively; are human TRAV30 and human TRBV20 respectively; or are human TRAV30 and human TRBV28 respectively.

[0854] In some embodiments, the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28.

[0855] In some embodiments, the first target molecule and the second target molecule:

[0856] These are human TRAV12 and human TRBV5-1; these are human TRAV12 and human TRBV6-5; these are human TRAV12 and human TRBV10-1; these are human TRAV12 and human TRBV10-2; these are human TRAV12 and human TRBV10-3; these are human TRAV12 and human TRBV7-2; these are human TRAV12 and human TRBV7-3; these are human TRAV12 and human TRBV19; these are human TRAV12 and human TRBV20-1; these are human TRAV12 and human TRBV28; these are human TRAV13 and human TRBV5-1; these are human TRAV13 and human TRBV6-5; these are human T RAV13 and human TRBV10-1; respectively human TRAV13 and human TRBV10-2; respectively human TRAV13 and human TRBV10-3; respectively human TRAV13 and human TRBV7-2; respectively human TRAV13 and human TRBV7-3; respectively human TRAV13 and human TRBV19; respectively human TRAV13 and human TRBV20-1; respectively human TRAV13 and human TRBV28; respectively human TRAV19 and human TRBV5-1; respectively human TRAV19 and human TRBV6-5; respectively human TRAV19 and human TRBV10-1; respectively human TRAV19 and human TRBV10-2; respectively human TRAV1 9 and human TRBV10-3; respectively human TRAV19 and human TRBV7-2; respectively human TRAV19 and human TRBV7-3; respectively human TRAV19 and human TRBV19; respectively human TRAV19 and human TRBV20-1; respectively human TRAV19 and human TRBV28; respectively human TRAV21 and human TRBV5-1; respectively human TRAV21 and human TRBV6-5; respectively human TRAV21 and human TRBV10-1; respectively human TRAV21 and human TRBV10-2; respectively human TRAV21 and human TRBV10-3; respectively human TRAV21 and human TRBV7-2; respectively human TRAV21 and human TR BV7-3; These are human TRAV21 and human TRBV19; These are human TRAV21 and human TRBV20-1; These are human TRAV21 and human TRBV28; These are human TRAV30 and human TRBV5-1; These are human TRAV30 and human TRBV6-5; These are human TRAV30 and human TRBV10-1; These are human TRAV30 and human TRBV10-2; These are human TRAV30 and human TRBV10-3; These are human TRAV30 and human TRBV7-2; These are human TRAV30 and human TRBV7-3; These are human TRAV30 and human TRBV19; These are human TRAV30 and human TRBV20-1;Or they may be human TRAV30 and human TRBV28, respectively.

[0857] In some embodiments, the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21, or human TRAV30, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28.

[0858] In some embodiments, the first target molecule and the second target molecule:

[0859] These are human TRAV12-2 and human TRBV5-1; these are human TRAV12-2 and human TRBV6-5; these are human TRAV12-2 and human TRBV10-1; these are human TRAV12-2 and human TRBV10-2; these are human TRAV12-2 and human TRBV10-3; these are human TRAV12-2 and human TRBV7-2; these are human TRAV12-2 and human TRBV7-3; these are human TRAV12-2 and human TRBV19; these are human TRAV12-2 and human TRBV20-1; these are human TRAV12-2 and human TRBV28; these are human TRAV13-1 and human TRBV5-1; these are... Human TRAV13-1 and human TRBV6-5; respectively human TRAV13-1 and human TRBV10-1; respectively human TRAV13-1 and human TRBV10-2; respectively human TRAV13-1 and human TRBV10-3; respectively human TRAV13-1 and human TRBV7-2; respectively human TRAV13-1 and human TRBV7-3; respectively human TRAV13-1 and human TRBV19; respectively human TRAV13-1 and human TRBV20-1; respectively human TRAV13-1 and human TRBV28; respectively human TRAV19 and human TRBV5-1; respectively human TRAV19 and human TRBV6-5; respectively human TRAV19 and... Human TRBV10-1; Human TRAV19 and Human TRBV10-2; Human TRAV19 and Human TRBV10-3; Human TRAV19 and Human TRBV7-2; Human TRAV19 and Human TRBV7-3; Human TRAV19 and Human TRBV19; Human TRAV19 and Human TRBV20-1; Human TRAV19 and Human TRBV28; Human TRAV21 and Human TRBV5-1; Human TRAV21 and Human TRBV6-5; Human TRAV21 and Human TRBV10-1; Human TRAV21 and Human TRBV10-2; Human TRAV21 and Human TRBV10-2 V10-3; These are human TRAV21 and human TRBV7-2; These are human TRAV21 and human TRBV7-3; These are human TRAV21 and human TRBV19; These are human TRAV21 and human TRBV20-1; These are human TRAV21 and human TRBV28; These are human TRAV30 and human TRBV5-1; These are human TRAV30 and human TRBV6-5; These are human TRAV30 and human TRBV10-1; These are human TRAV30 and human TRBV10-2; These are human TRAV30 and human TRBV10-3; These are human TRAV30 and human TRBV7-2; These are human TRAV30 and human TRBV7-3;These are human TRAV30 and human TRBV19; these are human TRAV30 and human TRBV20-1; or these are human TRAV30 and human TRBV28.

[0860] In some embodiments, the first conjugate comprises a whole antibody or its antigen-binding fragment, a bivalent antibody, a bispecific antibody, or a biparatopic antibody.

[0861] In some embodiments, the second conjugate comprises a whole antibody or its antigen-binding fragment, a bivalent antibody, a bispecific antibody, or a biparatopic antibody.

[0862] In some embodiments, the antigen-binding fragment is Fab, F(ab')2, Fv, single-chain Fv (scFv), single-domain antibody, double antibody (dAb), single-domain antibody, or camel antibody.

[0863] In some embodiments, the first conjugate includes a heavy chain variable region (VH), the VH including a heavy chain complementarity determination region 3 (HC CDR3), the HC CDR3 including a sequence of SEQ ID NO: 3343, SEQ ID NO: 3323, SEQ ID NO: 3353, SEQ ID NO: 1187, SEQ ID NO: 3373, SEQ ID NO: 3383, SEQ ID NO: 3393, SEQ ID NO: 3403 or SEQ ID NO: 3413.

[0864] In some embodiments, the first conjugate comprises a VH, the VH comprising a heavy chain complementarity determination region 1 (HCCDR1), the HCCDR1 comprising a sequence of SEQ ID NO: 3341, SEQ ID NO: 3321, SEQ ID NO: 3351, SEQ ID NO: 1190, SEQ ID NO: 3371, SEQ ID NO: 3381, SEQ ID NO: 3391, SEQ ID NO: 3401, SEQ ID NO: 3411, SEQ ID NO: 3421 or SEQ ID NO: 3702.

[0865] In some embodiments, the first conjugate comprises a VH, the VH comprising a heavy chain complementarity determination region 2 (HCCDR2), the HCCDR2 comprising a sequence of SEQ ID NO: 3342, SEQ ID NO: 3322, SEQ ID NO: 3352, SEQ ID NO: 1186, SEQ ID NO: 3372, SEQ ID NO: 3382, SEQ ID NO: 3392, SEQ ID NO: 3402, or SEQ ID NO: 3412.

[0866] In some embodiments, the first combination comprises VH, the VH comprising:

[0867] (i) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3341, HC CDR2 contains the sequence of SEQ ID NO: 3342 and HC CDR3 contains the sequence of SEQ ID NO: 3343;

[0868] (ii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3321, HC CDR2 contains the sequence of SEQ ID NO: 3322 and HC CDR3 contains the sequence of SEQ ID NO: 3323;

[0869] (iii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3351, HC CDR2 contains the sequence of SEQ ID NO: 3352 and HC CDR3 contains the sequence of SEQ ID NO: 3353;

[0870] (iv) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 1190, HC CDR2 contains the sequence of SEQ ID NO: 1186 and HC CDR3 contains the sequence of SEQ ID NO: 1187;

[0871] (v) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3371, HC CDR2 contains the sequence of SEQ ID NO: 3372 and HC CDR3 contains the sequence of SEQ ID NO: 3373;

[0872] (vi) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3381, HC CDR2 contains the sequence of SEQ ID NO: 3382 and HC CDR3 contains the sequence of SEQ ID NO: 3383;

[0873] (vii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3391, HC CDR2 contains the sequence of SEQ ID NO: 3392 and HC CDR3 contains the sequence of SEQ ID NO: 3393;

[0874] (viii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3401, HC CDR2 contains the sequence of SEQ ID NO: 3402 and HC CDR3 contains the sequence of SEQ ID NO: 3403;

[0875] (ix) HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; or

[0876] (x) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3411, HC CDR2 contains the sequence of SEQ ID NO: 3412 and HC CDR3 contains the sequence of SEQ ID NO: 3413.

[0877] In some embodiments, the first conjugate includes a light chain variable region (VL), the VL including a light chain complementarity determination region 3 (LC CDR3), the LC CDR3 including a sequence of SEQ ID NO: 3346, SEQ ID NO: 3326, SEQ ID NO: 3356, SEQ ID NO: 1193, SEQ ID NO: 3376, SEQ ID NO: 3386, SEQ ID NO: 3396, SEQ ID NO: 3406 or SEQ ID NO: 3416.

[0878] In some embodiments, the first conjugate comprises a VL, the VL comprising a light chain complementarity determination region 1 (LCCDR1), the LCCDR1 comprising a sequence of SEQ ID NO: 3344, SEQ ID NO: 3324, SEQ ID NO: 3354, SEQ ID NO: 1191, SEQ ID NO: 3374, SEQ ID NO: 3384, SEQ ID NO: 3394, SEQ ID NO: 3404, or SEQ ID NO: 3414.

[0879] In some embodiments, the first conjugate comprises a VL, the VL comprising a light chain complementarity determination region 2 (LCCDR2), the LCCDR2 comprising a sequence of SEQ ID NO: 3345, SEQ ID NO: 3325, SEQ ID NO: 3355, SEQ ID NO: 1192, SEQ ID NO: 3375, SEQ ID NO: 3395, SEQ ID NO: 3405, SEQ ID NO: 3415 or SEQ ID NO: 3443.

[0880] In some embodiments, the first combination comprises VL, the VL comprising:

[0881] (i) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3344, LC CDR2 contains the sequence of SEQ ID NO: 3345 and LC CDR3 contains the sequence of SEQ ID NO: 3346;

[0882] (ii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3324, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3326;

[0883] (iii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3355, and LC CDR3 contains the sequence of SEQ ID NO: 3356;

[0884] (iv) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 1191, LC CDR2 contains the sequence of SEQ ID NO: 1192 and LC CDR3 contains the sequence of SEQ ID NO: 1193;

[0885] (v) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3374, LC CDR2 contains the sequence of SEQ ID NO: 3375, and LC CDR3 contains the sequence of SEQ ID NO: 3376;

[0886] (vi) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3384, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3386;

[0887] (vii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3394, LC CDR2 contains the sequence of SEQ ID NO: 3395 and LC CDR3 contains the sequence of SEQ ID NO: 3396;

[0888] (viii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3404, LC CDR2 contains the sequence of SEQ ID NO: 3405 and LC CDR3 contains the sequence of SEQ ID NO: 3406;

[0889] (ix) LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3414, LC CDR2 contains the sequence of SEQ ID NO: 3415, and LC CDR3 contains the sequence of SEQ ID NO: 3416; or

[0890] (x) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3443 and LC CDR3 contains the sequence of SEQ ID NO: 3356.

[0891] In some embodiments, the first combination comprises:

[0892] (i) VH, which comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3341, HC CDR2 comprises the sequence of SEQ ID NO: 3342, and HC CDR3 comprises the sequence of SEQ ID NO: 3343; and VL, which comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3344, LC CDR2 comprises the sequence of SEQ ID NO: 3345, and LC CDR3 comprises the sequence of SEQ ID NO: 3346;

[0893] (ii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3321, HC CDR2 comprises the sequence of SEQ ID NO: 3322, and HC CDR3 comprises the sequence of SEQ ID NO: 3323; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3324, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3326;

[0894] (iii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, LC CDR2 comprises the sequence of SEQ ID NO: 3355, and LC CDR3 comprises the sequence of SEQ ID NO: 3356;

[0895] (iv) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 1190, HC CDR2 comprises the sequence of SEQ ID NO: 1186, and HC CDR3 comprises the sequence of SEQ ID NO: 1187; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 1191, LC CDR2 comprises the sequence of SEQ ID NO: 1192, and LC CDR3 comprises the sequence of SEQ ID NO: 1193;

[0896] (v) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3371, HC CDR2 comprises the sequence of SEQ ID NO: 3372, and HC CDR3 comprises the sequence of SEQ ID NO: 3373; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3374, LC CDR2 comprises the sequence of SEQ ID NO: 3375, and LC CDR3 comprises the sequence of SEQ ID NO: 3376;

[0897] (vi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3381, HC CDR2 comprises the sequence of SEQ ID NO:3382, and HC CDR3 comprises the sequence of SEQ ID NO:3383; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3384, LC CDR2 comprises the sequence of SEQ ID NO:3325, and LC CDR3 comprises the sequence of SEQ ID NO:3386;

[0898] (vi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3391, HC CDR2 comprises the sequence of SEQ ID NO:3392, and HC CDR3 comprises the sequence of SEQ ID NO:3393; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3394, LC CDR2 comprises the sequence of SEQ ID NO:3395, and LC CDR3 comprises the sequence of SEQ ID NO:3396;

[0899] (vii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3401, HC CDR2 comprises the sequence of SEQ ID NO:3402, and HC CDR3 comprises the sequence of SEQ ID NO:3403; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3404, LC CDR2 comprises the sequence of SEQ ID NO:3405, and LC CDR3 comprises the sequence of SEQ ID NO:3406;

[0900] (viii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3411, HC CDR2 comprises the sequence of SEQ ID NO: 3412, and HC CDR3 comprises the sequence of SEQ ID NO: 3413; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3414, LC CDR2 comprises the sequence of SEQ ID NO: 3415, and LC CDR3 comprises the sequence of SEQ ID NO: 3416;

[0901] (ix) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises the sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, wherein LC CDR2 comprises the sequence of SEQ ID NO: 3355, and wherein LC CDR3 comprises the sequence of SEQ ID NO: 3356; or

[0902] (x) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises a sequence of SEQ ID NO: 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3443, and wherein LC CDR3 comprises a sequence of SEQ ID NO: 3356.

[0903] In some embodiments, the first combination comprises a VH, the VH comprising a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

[0904] In some embodiments, the first combination comprises VH, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

[0905] In some embodiments, the first combination comprises a VL, the VL comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

[0906] In some embodiments, the first combination comprises a VL, the VL comprising any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

[0907] In some embodiments, the first combination comprises:

[0908] (i) VH, wherein VH comprises a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and

[0909] (ii) VL, which comprises sequences having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

[0910] In some embodiments, the first combination comprises:

[0911] (i) VH, wherein VH comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and

[0912] (ii) VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

[0913] In some embodiments, the first combination comprises:

[0914] (i) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3445, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3446;

[0915] (ii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3448, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3449;

[0916] (iii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3450, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3451;

[0917] (iv) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1349;

[0918] (v) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1196, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1195;

[0919] (v) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3455, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3456;

[0920] (vi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3457, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3458;

[0921] (vii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3463, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3464;

[0922] (viii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3465, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3466;

[0923] (ix) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3470, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3471;

[0924] (x) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3475; or

[0925] (xi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3476.

[0926] In some embodiments, the first combination comprises:

[0927] (i) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3445 and VL contains the sequence of SEQ ID NO: 3446;

[0928] (ii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3448 and VL comprises the sequence of SEQ ID NO: 3449;

[0929] (iii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3450 and VL comprises the sequence of SEQ ID NO: 3451;

[0930] (iv) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346 and VL comprises the sequence of SEQ ID NO: 1349;

[0931] (v) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1196 and VL contains the sequence of SEQ ID NO: 1195;

[0932] (vi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3455 and VL comprises the sequence of SEQ ID NO: 3456;

[0933] (vii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3457 and VL contains the sequence of SEQ ID NO: 3458;

[0934] (viii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3463 and VL comprises the sequence of SEQ ID NO: 3464;

[0935] (ix) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3465 and VL contains the sequence of SEQ ID NO: 3466;

[0936] (x) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3470 and VL contains the sequence of SEQ ID NO: 3471;

[0937] (xi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346, and VL comprises the sequence of SEQ ID NO: 3475; or

[0938] (xii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1346 and VL contains the sequence of SEQ ID NO: 3476.

[0939] In some embodiments, the second conjugate includes a heavy chain variable region (VH), the VH including a heavy chain complementarity determination region 3 (HC CDR3), the HC CDR3 including the sequence of SEQ ID NO: 3343, SEQ ID NO: 3323, SEQ ID NO: 3353, SEQ ID NO: 1187, SEQ ID NO: 3373, SEQ ID NO: 3383, SEQ ID NO: 3393, SEQ ID NO: 3403 or SEQ ID NO: 3413.

[0940] In some embodiments, the second conjugate comprises a VH, the VH comprising a heavy chain complementarity-determining region 1 (HCCDR1), the HCCDR1 comprising a sequence of SEQ ID NO: 3341, SEQ ID NO: 3321, SEQ ID NO: 3351, SEQ ID NO: 1190, SEQ ID NO: 3371, SEQ ID NO: 3381, SEQ ID NO: 3391, SEQ ID NO: 3401, SEQ ID NO: 3411, SEQ ID NO: 3421, or SEQ ID NO: 3702.

[0941] In some embodiments, the second conjugate comprises a VH, the VH comprising a heavy chain complementarity determination region 2 (HCCDR2), the HCCDR2 comprising a sequence of SEQ ID NO: 3342, SEQ ID NO: 3322, SEQ ID NO: 3352, SEQ ID NO: 1186, SEQ ID NO: 3372, SEQ ID NO: 3382, SEQ ID NO: 3392, SEQ ID NO: 3402, or SEQ ID NO: 3412.

[0942] In some embodiments, the second combination comprises VH, the VH comprising:

[0943] (i) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3341, HC CDR2 contains the sequence of SEQ ID NO: 3342 and HC CDR3 contains the sequence of SEQ ID NO: 3343;

[0944] (ii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3321, HC CDR2 contains the sequence of SEQ ID NO: 3322 and HC CDR3 contains the sequence of SEQ ID NO: 3323;

[0945] (iii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3351, HC CDR2 contains the sequence of SEQ ID NO: 3352 and HC CDR3 contains the sequence of SEQ ID NO: 3353;

[0946] (iv) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 1190, HC CDR2 contains the sequence of SEQ ID NO: 1186 and HC CDR3 contains the sequence of SEQ ID NO: 1187;

[0947] (v) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3371, HC CDR2 contains the sequence of SEQ ID NO: 3372 and HC CDR3 contains the sequence of SEQ ID NO: 3373;

[0948] (vi) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3381, HC CDR2 contains the sequence of SEQ ID NO: 3382 and HC CDR3 contains the sequence of SEQ ID NO: 3383;

[0949] (vii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3391, HC CDR2 contains the sequence of SEQ ID NO: 3392 and HC CDR3 contains the sequence of SEQ ID NO: 3393;

[0950] (viii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3401, HC CDR2 contains the sequence of SEQ ID NO: 3402 and HC CDR3 contains the sequence of SEQ ID NO: 3403;

[0951] (ix) HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; or

[0952] (x) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3411, HC CDR2 contains the sequence of SEQ ID NO: 3412 and HC CDR3 contains the sequence of SEQ ID NO: 3413.

[0953] In some embodiments, the second conjugate includes a light chain variable region (VL), the VL including a light chain complementarity determination region 3 (LC CDR3), the LC CDR3 including a sequence of SEQ ID NO: 3346, SEQ ID NO: 3326, SEQ ID NO: 3356, SEQ ID NO: 1193, SEQ ID NO: 3376, SEQ ID NO: 3386, SEQ ID NO: 3396, SEQ ID NO: 3406 or SEQ ID NO: 3416.

[0954] In some embodiments, the second conjugate comprises a VL, the VL comprising a light chain complementarity determination region 1 (LCCDR1), the LCCDR1 comprising a sequence of SEQ ID NO: 3344, SEQ ID NO: 3324, SEQ ID NO: 3354, SEQ ID NO: 1191, SEQ ID NO: 3374, SEQ ID NO: 3384, SEQ ID NO: 3394, SEQ ID NO: 3404, or SEQ ID NO: 3414.

[0955] In some embodiments, the second conjugate comprises a VL, the VL comprising a light chain complementarity determination region 2 (LCCDR2), the LCCDR2 comprising a sequence of SEQ ID NO: 3345, SEQ ID NO: 3325, SEQ ID NO: 3355, SEQ ID NO: 1192, SEQ ID NO: 3375, SEQ ID NO: 3395, SEQ ID NO: 3405, SEQ ID NO: 3415 or SEQ ID NO: 3443.

[0956] In some embodiments, the second combination comprises VL, the VL comprising:

[0957] (i) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3344, LC CDR2 contains the sequence of SEQ ID NO: 3345 and LC CDR3 contains the sequence of SEQ ID NO: 3346;

[0958] (ii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3324, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3326;

[0959] (iii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3355, and LC CDR3 contains the sequence of SEQ ID NO: 3356;

[0960] (iv) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 1191, LC CDR2 contains the sequence of SEQ ID NO: 1192 and LC CDR3 contains the sequence of SEQ ID NO: 1193;

[0961] (v) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3374, LC CDR2 contains the sequence of SEQ ID NO: 3375, and LC CDR3 contains the sequence of SEQ ID NO: 3376;

[0962] (vi) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3384, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3386;

[0963] (vii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3394, LC CDR2 contains the sequence of SEQ ID NO: 3395 and LC CDR3 contains the sequence of SEQ ID NO: 3396;

[0964] (viii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3404, LC CDR2 contains the sequence of SEQ ID NO: 3405 and LC CDR3 contains the sequence of SEQ ID NO: 3406;

[0965] (ix) LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3414, LC CDR2 contains the sequence of SEQ ID NO: 3415, and LC CDR3 contains the sequence of SEQ ID NO: 3416; or

[0966] (x) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3443 and LC CDR3 contains the sequence of SEQ ID NO: 3356.

[0967] In some embodiments, the second combination comprises:

[0968] (i) VH, which comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3341, HC CDR2 comprises the sequence of SEQ ID NO: 3342, and HC CDR3 comprises the sequence of SEQ ID NO: 3343; and VL, which comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3344, LC CDR2 comprises the sequence of SEQ ID NO: 3345, and LC CDR3 comprises the sequence of SEQ ID NO: 3346;

[0969] (ii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3321, HC CDR2 comprises the sequence of SEQ ID NO: 3322, and HC CDR3 comprises the sequence of SEQ ID NO: 3323; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3324, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3326;

[0970] (iii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, LC CDR2 comprises the sequence of SEQ ID NO: 3355, and LC CDR3 comprises the sequence of SEQ ID NO: 3356;

[0971] (iv) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 1190, HC CDR2 comprises the sequence of SEQ ID NO: 1186, and HC CDR3 comprises the sequence of SEQ ID NO: 1187; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 1191, LC CDR2 comprises the sequence of SEQ ID NO: 1192, and LC CDR3 comprises the sequence of SEQ ID NO: 1193;

[0972] (v) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3371, HC CDR2 comprises the sequence of SEQ ID NO: 3372, and HC CDR3 comprises the sequence of SEQ ID NO: 3373; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3374, LC CDR2 comprises the sequence of SEQ ID NO: 3375, and LC CDR3 comprises the sequence of SEQ ID NO: 3376;

[0973] (vi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3381, HC CDR2 comprises the sequence of SEQ ID NO:3382, and HC CDR3 comprises the sequence of SEQ ID NO:3383; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3384, LC CDR2 comprises the sequence of SEQ ID NO:3325, and LC CDR3 comprises the sequence of SEQ ID NO:3386;

[0974] (vii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3391, HC CDR2 comprises the sequence of SEQ ID NO:3392, and HC CDR3 comprises the sequence of SEQ ID NO:3393; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3394, LC CDR2 comprises the sequence of SEQ ID NO:3395, and LC CDR3 comprises the sequence of SEQ ID NO:3396;

[0975] (viii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO:3401, HC CDR2 comprises the sequence of SEQ ID NO:3402, and HC CDR3 comprises the sequence of SEQ ID NO:3403; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO:3404, LC CDR2 comprises the sequence of SEQ ID NO:3405, and LC CDR3 comprises the sequence of SEQ ID NO:3406;

[0976] (ix) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3411, HC CDR2 comprises the sequence of SEQ ID NO: 3412, and HC CDR3 comprises the sequence of SEQ ID NO: 3413; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3414, LC CDR2 comprises the sequence of SEQ ID NO: 3415, and LC CDR3 comprises the sequence of SEQ ID NO: 3416;

[0977] (x) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises the sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, wherein LC CDR2 comprises the sequence of SEQ ID NO: 3355, and wherein LC CDR3 comprises the sequence of SEQ ID NO: 3356; or

[0978] (xi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises a sequence of 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3443, and wherein LC CDR3 comprises a sequence of SEQ ID NO: 3356.

[0979] In some embodiments, the second combination comprises a VH, the VH comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

[0980] In some embodiments, the second combination comprises VH, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

[0981] In some embodiments, the second combination comprises a VL, the VL comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

[0982] In some embodiments, the second combination comprises VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

[0983] In some embodiments, the second combination comprises:

[0984] (i) VH, wherein VH comprises a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and

[0985] (ii) VL, which comprises sequences having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

[0986] In some embodiments, the second combination comprises:

[0987] (i) VH, wherein VH comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and

[0988] (ii) VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

[0989] In some embodiments, the second combination comprises:

[0990] (i) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3445, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3446;

[0991] (ii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3448, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3449;

[0992] (iii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3450, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3451;

[0993] (iv) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1349;

[0994] (v) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1196, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1195;

[0995] (vi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3455, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3456;

[0996] (vii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3457, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3458;

[0997] (viii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3463, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3464;

[0998] (ix) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3465, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3466;

[0999] (x) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3470, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3471;

[1000] (xi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3475; or

[1001] (xii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3476.

[1002] In some embodiments, the second combination comprises:

[1003] (i) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3445 and VL contains the sequence of SEQ ID NO: 3446;

[1004] (ii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3448 and VL comprises the sequence of SEQ ID NO: 3449;

[1005] (iii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3450 and VL comprises the sequence of SEQ ID NO: 3451;

[1006] (iv) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346 and VL comprises the sequence of SEQ ID NO: 1349;

[1007] (v) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1196 and VL contains the sequence of SEQ ID NO: 1195;

[1008] (vi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3455 and VL comprises the sequence of SEQ ID NO: 3456;

[1009] (vii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3457 and VL contains the sequence of SEQ ID NO: 3458;

[1010] (viii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3463 and VL comprises the sequence of SEQ ID NO: 3464;

[1011] (ix) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3465 and VL contains the sequence of SEQ ID NO: 3466;

[1012] (x) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3470 and VL contains the sequence of SEQ ID NO: 3471;

[1013] (xi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346, and VL comprises the sequence of SEQ ID NO: 3475; or

[1014] (xii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1346 and VL contains the sequence of SEQ ID NO: 3476.

[1015] In some embodiments, the first and second conjugates bind to different TCRβV regions.

[1016] In some embodiments, the first and second conjugates bind to different TCRβVs belonging to different subfamilies.

[1017] In some embodiments, the first and second conjugates bind to different members of the same TCRβV subfamily.

[1018] In some embodiments, the first conjugate comprises one or more heavy chain constant regions selected from the group consisting of: IgG1 heavy chain constant region or fragments thereof, IgG2 heavy chain constant region or fragments thereof, IgG3 heavy chain constant region or fragments thereof, IgGA1 heavy chain constant region or fragments thereof, IgGA2 heavy chain constant region or fragments thereof, IgG4 heavy chain constant region or fragments thereof, IgJ heavy chain constant region or fragments thereof, IgM heavy chain constant region or fragments thereof, IgD heavy chain constant region or fragments thereof, and IgE heavy chain constant region or fragments thereof.

[1019] In some embodiments, the first combination comprises a κ light chain constant region or a fragment thereof, a λ light chain constant region or a fragment thereof, or a combination thereof.

[1020] In some embodiments, the second conjugate comprises one or more heavy chain constant regions selected from the group consisting of: IgG1 heavy chain constant region or fragment thereof, IgG2 heavy chain constant region or fragment thereof, IgG3 heavy chain constant region or fragment thereof, IgGA1 heavy chain constant region or fragment thereof, IgGA2 heavy chain constant region or fragment thereof, IgG4 heavy chain constant region or fragment thereof, IgJ heavy chain constant region or fragment thereof, IgM heavy chain constant region or fragment thereof, IgD heavy chain constant region or fragment thereof, and IgE heavy chain constant region or fragment thereof.

[1021] In some embodiments, the second combination comprises a κ light chain constant region or a fragment thereof, a λ light chain constant region or a fragment thereof, or a combination thereof.

[1022] In some embodiments, the first agent is a multifunctional molecule.

[1023] In some embodiments, the first agent is a multispecific molecule.

[1024] In some embodiments, the second agent is a multifunctional molecule.

[1025] In some embodiments, the second agent is a multispecific molecule.

[1026] In some embodiments, the first agent, the second agent, or a combination thereof comprises at least two discontinuous polypeptide chains;

[1027] The first polypeptide chain of the at least two discontinuous polypeptide chains contains a first Fc region, and the second polypeptide chain of the at least two discontinuous polypeptide chains contains a second Fc region; and

[1028] The first Fc region and the second Fc region contain the Fc interface with the pestle and mortar.

[1029] In some embodiments, the first Fc region, the second Fc region, or a combination thereof may contain the Asn297Ala mutation, the Leu234Ala / Leu235Ala mutation, or a combination thereof.

[1030] In some embodiments, the first agent is a multispecific molecule, which further comprises one or more of a tumor-targeting portion, a cytokine molecule, a matrix-modifying portion, or an immune cell conjugate.

[1031] In some embodiments, the second agent is a multispecific molecule, which further comprises one or more of a tumor-targeting portion, a cytokine molecule, a matrix-modifying portion, or an immune cell conjugate.

[1032] In some embodiments, the first agent comprises the following configuration:

[1033] A-, B-[dimerization module]-C, -D,

[1034] in:

[1035] (a) The dimerization module includes a first immunoglobulin chain constant region and a second immunoglobulin chain constant region;

[1036] (b) A and C are connected to the first immunoglobulin chain constant region; and B and D are connected to the second immunoglobulin chain constant region;

[1037] (c) A, B, C, and D independently (i) are absent; (ii) are the first conjugate; (iii) are the tumor-targeting portion; (iv) are the cytokine molecule; (v) are the matrix-modifying portion; or (vi) are the immune cell conjugate; and

[1038] At least one, two, or three of A, B, C, and D contain the first combination.

[1039] In some embodiments, the second agent comprises the following configuration:

[1040] A-, B-[dimerization module]-C, -D,

[1041] in:

[1042] (a) The dimerization module includes a first immunoglobulin chain constant region and a second immunoglobulin chain constant region;

[1043] (b) A and C are connected to the first immunoglobulin chain constant region; and B and D are connected to the second immunoglobulin chain constant region;

[1044] (c) A, B, C, and D independently (i) are absent; (ii) are the second conjugate; (iii) are the tumor-targeting portion; (iv) are the cytokine molecule; (v) are the matrix-modifying portion; or (vi) are the immune cell conjugate; and

[1045] At least one, two, or three of A, B, C, and D contain the second combination.

[1046] In some embodiments, the first immunoglobulin chain constant region includes a first fragment crystallizable region (Fc region), and the second first immunoglobulin chain constant region includes a second fragment crystallizable region (Fc region).

[1047] In some embodiments, dimerization of the first Fc region and the second Fc region is enhanced by providing an Fc interface between the first Fc region and the second Fc region and one or more of the paired cavity protrusions, electrostatic interactions, or chain exchanges, such that the ratio of heteropolymers to homopolymers formed is greater relative to the unengineered interface.

[1048] In some embodiments, the immune cell conjugate is selected from the group consisting of: T cell conjugate, NK cell conjugate, B cell conjugate, dendritic cell conjugate, macrophage conjugate, and any combination thereof.

[1049] In some embodiments, the cytokine molecules are selected from the group consisting of: interleukin-2 (IL-2) or a functional variant thereof, interleukin-7 (IL-7) or a functional variant thereof, interleukin-12 (IL-12) or a functional variant thereof, interleukin-15 (IL-15) or a functional variant thereof, interleukin-18 (IL-18) or a functional variant thereof, interleukin-21 (IL-21) or a functional variant thereof, interferon-γ or a functional variant thereof, and any combination thereof.

[1050] In some embodiments, the cytokine molecule comprises interleukin-2 (IL-2) or a functional variant thereof.

[1051] In some embodiments, the interleukin-2 (IL-2) or a functional variant thereof comprises the sequence of SEQ ID NO: 2270 or SEQ ID NO: 2191.

[1052] In some embodiments, the cytokine molecule comprises interleukin-15 (IL-15) or a functional variant thereof.

[1053] In some embodiments, the interleukin-15 (IL-15) or a functional variant thereof comprises the sequence of SEQ ID NO: 2170.

[1054] In some embodiments, the cytokine molecule further comprises an IL15Rα dimerization domain covalently linked to interleukin-15 (IL-15) or a functional variant thereof.

[1055] In some embodiments, the IL15Rα dimerization domain comprises the IL-15 receptor α sushi domain or a functional variant thereof.

[1056] In some embodiments, the IL15Rα dimerization domain comprises the sequence of SEQ ID NO: 3472.

[1057] In some embodiments, the interleukin-15 (IL-15) or a functional variant thereof is covalently linked to the IL15Rα dimerization domain via a connector.

[1058] In some embodiments, the interleukin-15 (IL-15) or a functional variant thereof is covalently linked to the IL15Rα dimerization domain via a connector comprising the sequence of SEQ ID NO: 3473.

[1059] In some embodiments, the cytokine molecule comprises the sequence of SEQ ID NO: 3474.

[1060] In some embodiments, the matrix modification portion is selected from the group consisting of hyaluronidase, collagenase, chondroitinase, and matrix metalloproteinase.

[1061] In some embodiments, the tumor-targeting portion binds to a cancer antigen.

[1062] In some embodiments, the tumor-targeting portion binds to a cancer antigen.

[1063] In some embodiments, the cancer antigen is present on hematologic malignancies, solid tumors, metastatic cancers, soft tissue tumors, metastatic lesions, or combinations thereof.

[1064] In some embodiments, the cancer antigen is a tumor antigen, matrix antigen, or blood antigen.

[1065] In some embodiments, the cancer antigen is selected from the group consisting of: BCMA, CD19, CD20, CD22, FcRH5, PDL1, CD47, ganglioside 2 (GD2), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron kinase, c-Met, immature laminin receptor, TAG-72, BING-4, calcium-activated chloride channel 2, cyclin-B1, 9D7, Ep-CAM, EphA3, Her2 / neu, telomerase, SAP-1, susceptin, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, Gp100 / pmel17, tyrosinase, MC1R, β-catenin, BRCA1 / 2 CDK4, CML66, fibronectin, p53, Ras, TGF-β receptor, AFP, ETA, MAGE, CA-125, BAGE, GAGE, CDC27, α-actin-4, TRP1 / gp75, TRP2, gangliosides, WT1, epidermal growth factor receptor (EGFR), MART-2, MUC1, MUC2, MUM1, MUM2, MUM3, NA88-1, NPM, OA1, OGT, RCC, RU11, RU12, SAGE, TRG, TSTA, folate receptor α, L1-CAM, CAIX, gpA33, GD3, GM2, VEGFR, integrin, carbohydrates, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, TGF-β, hyaluronic acid, collagen, tendinin C and tendinin W.

[1066] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1067] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3445, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1068] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1069] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3446, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1070] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1071] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3448, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1072] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1073] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3449, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1074] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1075] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1076] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1077] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1078] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1079] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1080] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1081] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1082] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1083] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[1084] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1085] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1086] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1087] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1196, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1088] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1089] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1195, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1090] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1091] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3455, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1092] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1093] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3456, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1094] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1095] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3457, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460.

[1096] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[1097] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3458, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[1098] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1099] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3463, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460.

[1100] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[1101] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3464, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[1102] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1103] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3465, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3467, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3468.

[1104] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3469, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[1105] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3466, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[1106] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1107] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3470, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1108] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1109] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3471, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1110] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1111] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[1112] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[1113] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1114] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1115] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[1116] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[1117] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3475, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1118] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1119] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[1120] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[1121] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3476, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1122] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1123] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3445, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1124] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1125] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3446, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1126] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1127] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3448, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1128] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1129] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3449, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1130] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1131] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1132] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1133] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1134] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1135] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1136] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1137] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1138] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1139] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[1140] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1141] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1142] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1143] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1196, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1144] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1145] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1195, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1146] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1147] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3455, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1148] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1149] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3456, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1150] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1151] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3457, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460.

[1152] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[1153] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3458, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[1154] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1155] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3463, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460.

[1156] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[1157] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3464, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[1158] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1159] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3465, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3467, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3468.

[1160] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3469, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and

[1161] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3466, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

[1162] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1163] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3470, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447.

[1164] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and

[1165] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3471, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1166] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1167] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[1168] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[1169] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1170] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1171] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[1172] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[1173] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3475, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1174] In some embodiments, the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1175] (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505.

[1176] (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and...

[1177] (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3476, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

[1178] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1179] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3338;

[1180] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[1181] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3339.

[1182] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1183] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3318;

[1184] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[1185] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3319.

[1186] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1187] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328;

[1188] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[1189] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

[1190] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1191] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328;

[1192] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3350 or the sequence of SEQ ID NO: 3500; and

[1193] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

[1194] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1195] (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502;

[1196] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[1197] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3349.

[1198] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1199] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3358;

[1200] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[1201] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3359.

[1202] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1203] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3368;

[1204] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and

[1205] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3369.

[1206] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein:

[1207] (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3378;

[1208] (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3380; and

[1209] (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3379.

[1210] In some embodiments, the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second po...

Claims

1. A method of treating a disease or condition in a subject in need, the method comprising administering to the subject a first agent comprising a first conjugate binding to a first target molecule, and administering to the subject a second agent comprising a second conjugate binding to a second target molecule, thereby treating the subject's disease or condition; The second drug is applied after the first drug is applied. The first target molecule and the second target molecule are independently selected from the group consisting of the T cell receptor α variable region (TCRαV) and the T cell receptor β variable region (TCRβV); and The first target molecule and the second target molecule are different.

2. The method of claim 1, wherein the first agent and the second agent are not administered to the subject simultaneously.

3. The method according to claim 1 or 2, wherein administering the first agent comprises administering a therapeutically effective amount of the first agent to the subject.

4. The method according to any one of claims 1 to 3, wherein administering the second agent comprises administering a therapeutically effective amount of the second agent to the subject.

5. The method according to any one of claims 1 to 4, wherein the method is more effective in treating the subject’s disease or condition than in administering the first agent to the subject but not the second agent.

6. The method according to any one of claims 1 to 5, wherein the method is more effective in treating the subject’s disease or condition than in administering the second agent to the subject without administering the first agent.

7. The method according to any one of claims 1 to 6, wherein the method is more effective in treating the disease or condition of the subject than a method of administering the first agent to the subject in a first administration and subsequently administering the first agent to the subject in a second administration.

8. The method according to any one of claims 1 to 7, wherein the method is more effective in treating the subject’s disease or condition than a method of administering the second agent to the subject in a first administration and subsequently administering the second agent to the subject in a second administration.

9. The method according to any one of claims 1 to 8, wherein the method is more effective in treating the subject’s disease or condition than a method of administering the second agent to the subject in a first administration and subsequently administering the first agent to the subject in a second administration.

10. The method according to any one of claims 1 to 9, wherein the administration of the first agent comprises one or more doses.

11. The method according to any one of claims 1 to 10, wherein the administration of the first agent comprises two or more doses.

12. The method according to any one of claims 1 to 11, wherein the administration of the first agent comprises a dose once per week.

13. The method according to any one of claims 1 to 11, wherein the administration of the first agent comprises two or more doses per week.

14. The method according to any one of claims 1 to 11, wherein the first agent is administered to the subject once every two weeks.

15. The method according to any one of claims 1 to 11, wherein the first agent is administered to the subject once every three weeks.

16. The method according to any one of claims 1 to 12, wherein the first agent is administered to the subject once a week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

17. The method according to any one of claims 1 to 11 and 13, wherein the administration of the first agent comprises two or more doses per week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

18. The method according to any one of claims 1 to 11 and 14, wherein the first agent is administered to the subject once every two weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

19. The method according to any one of claims 1 to 11 and 15, wherein the first agent is administered to the subject once every three weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

20. The method according to any one of claims 1 to 19, wherein the administration of the second agent comprises one or more doses.

21. The method according to any one of claims 1 to 20, wherein the administration of the second agent comprises two or more doses.

22. The method according to any one of claims 1 to 21, wherein the administration of the second agent comprises a dose once per week.

23. The method according to any one of claims 1 to 21, wherein the administration of the second agent comprises two or more doses per week.

24. The method according to any one of claims 1 to 21, wherein the second agent is administered to the subject once every two weeks.

25. The method according to any one of claims 1 to 21, wherein the second agent is administered to the subject once every three weeks.

26. The method according to any one of claims 1 to 22, wherein the second agent is administered to the subject once a week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

27. The method according to any one of claims 1 to 21 and 23, wherein the administration of the second agent comprises two or more doses per week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

28. The method according to any one of claims 1 to 21 and 24, wherein the second agent is administered to the subject once every two weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

29. The method according to any one of claims 1 to 21 and 25, wherein the second agent is administered to the subject once every three weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

30. The method according to any one of claims 1 to 29, wherein the application of the first agent and the application of the second agent are spaced one week apart.

31. The method according to any one of claims 1 to 29, wherein the application of the first agent and the application of the second agent are spaced two weeks or more apart.

32. The method according to any one of claims 1 to 29, wherein the interval between the application of the first agent and the application of the second agent is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months.

33. The method according to any one of claims 1 to 32, wherein the application of the first agent and the second agent is repeated two or more times.

34. The method according to any one of claims 1 to 12, 16, 20 to 23, 26, 30, 32 and 33, wherein the first agent and the second agent are administered to the subject according to a dosing regimen, wherein the dosing regimen comprises administering the first agent once weekly for two weeks, followed by administering the second agent once weekly for two weeks, wherein the second agent is administered to the subject one week after the last administration of the first agent.

35. The method of claim 34, wherein the dosing regimen is repeated two or more times.

36. The method of claim 34 or 35, wherein the dosing regimen is repeated at weekly intervals.

37. The method according to any one of claims 34 to 36, wherein the dosing regimen is repeated at intervals of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.

38. The method according to any one of claims 1 to 37, wherein the first agent and the second agent are administered to the subject in the same amount.

39. The method according to any one of claims 1 to 37, wherein the first agent and the second agent are administered to the subject in different amounts.

40. The method according to any one of claims 1 to 39, wherein the application of the first agent comprises two or more doses, and each dose comprises the same amount of the first agent.

41. The method according to any one of claims 1 to 39, wherein the administration of the first agent comprises two or more doses, and each dose comprises a different amount of the first agent.

42. The method according to any one of claims 1 to 41, wherein the administration of the second agent comprises two or more doses, and each dose comprises the same amount of the second agent.

43. The method according to any one of claims 1 to 41, wherein the administration of the second agent comprises two or more doses, and each dose comprises a different amount of the second agent.

44. The method according to any one of claims 1 to 43, wherein the first agent is administered to the subject at a dose of about 0.001 mg / kg to about 10 mg / kg.

45. The method according to any one of claims 1 to 44, wherein the second agent is administered to the subject at a dose of about 0.001 mg / kg to about 10 mg / kg.

46. ​​The method according to any one of claims 1 to 45, wherein the first agent is administered to the subject at a dose of about 0.3 mg / kg or about 1 mg / kg.

47. The method according to any one of claims 1 to 46, wherein the second agent is administered to the subject at a dose of about 0.3 mg / kg or about 1 mg / kg.

48. The method according to any one of claims 1 to 47, wherein the first target molecule is a first TCRβV and the second target molecule is a second TCRβV, wherein the first TCRβV and the second TCRβV are different.

49. The method according to any one of claims 1 to 45, wherein the first target molecule is a first TCRαV and the second target molecule is a second TCRαV, wherein the first TCRαV and the second TCRαV are different.

50. The method according to any one of claims 1 to 45, wherein the first target molecule is TCRβV and the second target molecule is TCRαV.

51. The method according to any one of claims 1 to 45, wherein the first target molecule is TCRαV and the second target molecule is TCRβV.

52. The method according to any one of claims 1 to 48 and 50, wherein the first target molecule is human TCRβV6.

53. The method according to any one of claims 1 to 48 and 50, wherein the first target molecule is human TCRβV10.

54. The method according to any one of claims 1 to 48 and 51, wherein the second target molecule is human TCRβV15.

55. The method according to any one of claims 1 to 48 and 51, wherein the second target molecule is human TCRβV27.

56. The method according to any one of claims 1 to 48 and 51, wherein the second target molecule is human TCRβV5.

57. The method according to any one of claims 1 to 48, 52 and 56, wherein the first target molecule is human TCRβV6 and the second target molecule is human TCRβV5.

58. The method according to any one of claims 1 to 48, 52 and 56, wherein the first target molecule is human TCRβV6 and the second target molecule is human TCRβV15.

59. The method according to any one of claims 1 to 48, 52 and 56, wherein the first target molecule is human TCRβV6 and the second target molecule is human TCRβV27.

60. The method according to any one of claims 1 to 48, 53 and 56, wherein the first target molecule is human TCRβV10 and the second target molecule is human TCRβV5.

61. The method according to any one of claims 1 to 48, 53 and 56, wherein the first target molecule is human TCRβV10 and the second target molecule is human TCRβV15.

62. The method according to any one of claims 1 to 48, 53 and 56, wherein the first target molecule is human TCRβV10 and the second target molecule is human TCRβV27.

63. The method according to any one of claims 1 to 48 and 50, wherein the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28.

64. The method according to any one of claims 1 to 48, 50 and 63, wherein the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28.

65. The method according to any one of claims 1 to 45, 49 and 51, wherein the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

66. The method according to any one of claims 1 to 45, 49, 51 and 65, wherein the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

67. The method according to any one of claims 1 to 48 and 51, wherein the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV15, human TRBV27, human TRBV19, human TRBV20 or human TRBV28.

68. The method according to any one of claims 1 to 48, 51 and 67, wherein the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV15, human TRBV27, human TRBV19, human TRBV20-1 or human TRBV28.

69. The method according to any one of claims 1 to 45, 49 and 50, wherein the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

70. The method according to any one of claims 1 to 45, 49, 50 and 69, wherein the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

71. The method according to any one of claims 1 to 48, 63, 64, 67 and 68, wherein the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV15, human TRBV27, human TRBV19, human TRBV20 or human TRBV28, wherein the first target molecule and the second target molecule are different.

72. The method according to any one of claims 1 to 48, 63, 64, 67, 68 and 71, wherein the first target molecule and the second target molecule: These are human TRBV5 and human TRBV5, respectively. These are human TRBV5 and human TRBV6, respectively. These are human TRBV5 and human TRBV10, respectively. These are human TRBV5 and human TRBV7, respectively. These are human TRBV5 and human TRBV19, respectively. These are human TRBV5 and human TRBV20, respectively. These are human TRBV5 and human TRBV28, respectively. These are human TRBV6 and human TRBV5, respectively. These are human TRBV6 and human TRBV6, respectively. These are human TRBV6 and human TRBV10, respectively. They are human TRBV6 and human TRBV7, respectively. These are human TRBV6 and human TRBV15, respectively. These are human TRBV6 and human TRBV27, respectively. These are human TRBV6 and human TRBV19, respectively. These are human TRBV6 and human TRBV20, respectively. These are human TRBV6 and human TRBV28, respectively. These are human TRBV10 and human TRBV5, respectively. These are human TRBV10 and human TRBV10, respectively. These are human TRBV10 and human TRBV6, respectively. These are human TRBV10 and human TRBV7, respectively. These are human TRBV10 and human TRBV15, respectively. These are human TRBV10 and human TRBV27, respectively. These are human TRBV10 and human TRBV19, respectively. These are human TRBV10 and human TRBV20, respectively. These are human TRBV10 and human TRBV28, respectively. These are human TRBV7 and human TRBV5, respectively. They are human TRBV7 and human TRBV6, respectively. These are human TRBV7 and human TRBV10, respectively. They are human TRBV7 and human TRBV7, respectively. These are human TRBV7 and human TRBV19, respectively. These are human TRBV7 and human TRBV20, respectively. These are human TRBV7 and human TRBV28, respectively. These are human TRBV19 and human TRBV5, respectively. These are human TRBV19 and human TRBV6, respectively. They are human TRBV19 and human TRBV10, respectively. These are human TRBV19 and human TRBV7, respectively. These are human TRBV19 and human TRBV19, respectively. These are human TRBV19 and human TRBV20, respectively. These are human TRBV19 and human TRBV28, respectively. These are human TRBV20 and human TRBV5, respectively. These are human TRBV20 and human TRBV6, respectively. These are human TRBV20 and human TRBV10, respectively. These are human TRBV20 and human TRBV7, respectively. These are human TRBV20 and human TRBV19, respectively. These are human TRBV20 and human TRBV20, respectively. These are human TRBV20 and human TRBV28, respectively. These are human TRBV28 and human TRBV5, respectively. These are human TRBV28 and human TRBV6, respectively. These are human TRBV28 and human TRBV10, respectively. These are human TRBV28 and human TRBV7, respectively. These are human TRBV28 and human TRBV19, respectively. These are human TRBV28 and human TRBV20, respectively; or They are human TRBV28 and human TRBV28, respectively.

73. The method according to any one of claims 1 to 48, 63, 64, 67 and 68, wherein the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV15, human TRBV27, human TRBV19, human TRBV20-1 or human TRBV28, wherein the first target molecule and the second target molecule are different.

74. The method according to any one of claims 1 to 48, 63, 64, 67, 68 and 73, wherein the first target molecule and the second target molecule: These are human TRBV5-1 and human TRBV6-5, respectively. These are human TRBV5-1 and human TRBV10-1, respectively. These are human TRBV5-1 and human TRBV10-2, respectively. These are human TRBV5-1 and human TRBV10-3, respectively. These are human TRBV5-1 and human TRBV7-2, respectively. They are human TRBV5-1 and human TRBV7-3, respectively. These are human TRBV5-1 and human TRBV19, respectively. These are human TRBV5-1 and human TRBV20-1, respectively. These are human TRBV5-1 and human TRBV28, respectively. These are human TRBV6-5 and human TRBV5-1, respectively. These are human TRBV6-5 and human TRBV7-2, respectively. These are human TRBV6-5 and human TRBV7-3, respectively. These are human TRBV6-5 and human TRBV15, respectively. These are human TRBV6-5 and human TRBV27, respectively. These are human TRBV6-5 and human TRBV19, respectively. These are human TRBV6-5 and human TRBV20-1, respectively. These are human TRBV6-5 and human TRBV28, respectively. These are human TRBV10-1 and human TRBV5-1, respectively. These are human TRBV10-1 and human TRBV7-2, respectively. These are human TRBV10-1 and human TRBV7-3, respectively. These are human TRBV10-1 and human TRBV15, respectively. These are human TRBV10-1 and human TRBV27, respectively. These are human TRBV10-1 and human TRBV19, respectively. These are human TRBV10-1 and human TRBV20-1, respectively. These are human TRBV10-1 and human TRBV28, respectively. These are human TRBV10-2 and human TRBV5-1, respectively. These are human TRBV10-2 and human TRBV7-2, respectively. These are human TRBV10-2 and human TRBV7-3, respectively. These are human TRBV10-2 and human TRBV15, respectively. These are human TRBV10-2 and human TRBV27, respectively. These are human TRBV10-2 and human TRBV19, respectively. These are human TRBV10-2 and human TRBV20-1, respectively. These are human TRBV10-2 and human TRBV28, respectively. These are human TRBV10-3 and human TRBV5-1, respectively. These are human TRBV10-3 and human TRBV7-2, respectively. They are human TRBV10-3 and human TRBV7-3, respectively. These are human TRBV10-3 and human TRBV15, respectively. These are human TRBV10-3 and human TRBV27, respectively. These are human TRBV10-3 and human TRBV19, respectively. These are human TRBV10-3 and human TRBV20-1, respectively. These are human TRBV10-3 and human TRBV28, respectively. These are human TRBV7-2 and human TRBV5-1, respectively. These are human TRBV7-2 and human TRBV6-5, respectively. These are human TRBV7-2 and human TRBV10-1, respectively. These are human TRBV7-2 and human TRBV10-2, respectively. These are human TRBV7-2 and human TRBV10-3, respectively. They are human TRBV7-2 and human TRBV7-3, respectively. These are human TRBV7-2 and human TRBV19, respectively. These are human TRBV7-2 and human TRBV20-1, respectively. These are human TRBV7-2 and human TRBV28, respectively. These are human TRBV7-3 and human TRBV5-1, respectively. They are human TRBV7-3 and human TRBV6-5, respectively. These are human TRBV7-3 and human TRBV10-1, respectively. These are human TRBV7-3 and human TRBV10-2, respectively. They are human TRBV7-3 and human TRBV10-3, respectively. They are human TRBV7-3 and human TRBV7-2, respectively. These are human TRBV7-3 and human TRBV19, respectively. These are human TRBV7-3 and human TRBV20-1, respectively. These are human TRBV7-3 and human TRBV28, respectively. These are human TRBV19 and human TRBV5-1, respectively. These are human TRBV19 and human TRBV6-5, respectively. These are human TRBV19 and human TRBV10-1, respectively. These are human TRBV19 and human TRBV10-2, respectively. These are human TRBV19 and human TRBV10-3, respectively. These are human TRBV19 and human TRBV7-2, respectively. These are human TRBV19 and human TRBV7-3, respectively. These are human TRBV19 and human TRBV20-1, respectively. These are human TRBV19 and human TRBV28, respectively. These are human TRBV20-1 and human TRBV5-1, respectively. These are human TRBV20-1 and human TRBV6-5, respectively. These are human TRBV20-1 and human TRBV10-1, respectively. They are human TRBV20-1 and human TRBV10-2, respectively. These are human TRBV20-1 and human TRBV10-3, respectively. These are human TRBV20-1 and human TRBV7-2, respectively. These are human TRBV20-1 and human TRBV7-3, respectively. These are human TRBV20-1 and human TRBV19, respectively. These are human TRBV20-1 and human TRBV28, respectively. These are human TRBV28 and human TRBV5-1, respectively. These are human TRBV28 and human TRBV6-5, respectively. These are human TRBV28 and human TRBV10-1, respectively. These are human TRBV28 and human TRBV10-2, respectively. These are human TRBV28 and human TRBV10-3, respectively. These are human TRBV28 and human TRBV7-2, respectively. These are human TRBV28 and human TRBV7-3, respectively. These are human TRBV28 and human TRBV19, respectively; or They are human TRBV28 and human TRBV20-1, respectively.

75. The method according to any one of claims 1 to 45, 49, 65, 66, 69 and 70, wherein the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30, wherein the first target molecule and the second target molecule are different.

76. The method according to any one of claims 1 to 45, 49, 65, 66, 69, 70, and 75, wherein the first target molecule and the second target molecule: They are human TRAV12 and human TRAV12, respectively. They are human TRAV12 and human TRAV13, respectively. They are human TRAV12 and human TRAV19, respectively. They are human TRAV12 and human TRAV21, respectively. These are human TRAV12 and human TRAV30, respectively. They are human TRAV13 and human TRAV12, respectively. They are human TRAV13 and human TRAV13, respectively. They are human TRAV13 and human TRAV19, respectively. They are human TRAV13 and human TRAV21, respectively. They are TRAV13 and TRAV30, respectively. They are human TRAV19 and human TRAV12, respectively. They are human TRAV19 and human TRAV13, respectively. They are human TRAV19 and human TRAV19, respectively. They are human TRAV19 and human TRAV21, respectively. They are human TRAV19 and human TRAV30, respectively. They are human TRAV21 and human TRAV12, respectively. They are human TRAV21 and human TRAV13, respectively. They are human TRAV21 and human TRAV19, respectively. They are human TRAV21 and human TRAV21, respectively. They are human TRAV21 and human TRAV30, respectively. These are TRAV30 and TRAV12 for humans, respectively. They are TRAV30 and TRAV13 for humans, respectively. These are TRAV30 and TRAV19 for humans, respectively. These are TRAV30 and TRAV21 for humans, respectively; or They are TRAV30 and TRAV30 respectively.

77. The method according to any one of claims 1 to 45, 49, 65, 66, 69 and 70, wherein the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30, wherein the first target molecule and the second target molecule are different.

78. The method according to any one of claims 1 to 45, 49, 65, 66, 69, 70, and 77, wherein the first target molecule and the second target molecule: These are human TRAV12-2 and human TRAV13-1, respectively. These are human TRAV12-2 and human TRAV19, respectively. These are human TRAV12-2 and human TRAV21, respectively. These are human TRAV12-2 and human TRAV30, respectively. They are human TRAV13-1 and human TRAV12-2, respectively. These are human TRAV13-1 and human TRAV19, respectively. These are human TRAV13-1 and human TRAV21, respectively. These are human TRAV13-1 and human TRAV30, respectively. They are human TRAV19 and human TRAV12-2, respectively. They are human TRAV19 and human TRAV13-1, respectively. They are human TRAV19 and human TRAV21, respectively. They are human TRAV19 and human TRAV30, respectively. These are human TRAV21 and human TRAV12-2, respectively. These are human TRAV21 and human TRAV13-1, respectively. They are human TRAV21 and human TRAV19, respectively. They are human TRAV21 and human TRAV30, respectively. These are human TRAV30 and human TRAV12-2, respectively. These are human TRAV30 and human TRAV13-1, respectively. These are TRAV30 and TRAV19 for individuals, respectively; or They are TRAV30 and TRAV21, respectively.

79. The method according to any one of claims 1 to 45, 50, 63, 64, 69 and 70, wherein the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

80. The method according to any one of claims 1 to 45, 50, 63, 64, 69, 70, and 79, wherein the first target molecule and the second target molecule: These are human TRBV5 and human TRAV12, respectively. These are human TRBV5 and human TRAV13, respectively. These are human TRBV5 and human TRAV19, respectively. These are human TRBV5 and human TRAV21, respectively. These are human TRBV5 and human TRAV30, respectively. These are human TRBV6 and human TRAV12, respectively. These are human TRBV6 and human TRAV13, respectively. These are human TRBV6 and human TRAV19, respectively. These are human TRBV6 and human TRAV21, respectively. These are human TRBV6 and human TRAV30, respectively. These are human TRBV10 and human TRAV12, respectively. These are human TRBV10 and human TRAV13, respectively. These are human TRBV10 and human TRAV19, respectively. These are human TRBV10 and human TRAV21, respectively. These are human TRBV10 and human TRAV30, respectively. These are human TRBV7 and human TRAV12, respectively. These are human TRBV7 and human TRAV13, respectively. These are human TRBV7 and human TRAV19, respectively. These are human TRBV7 and human TRAV21, respectively. These are human TRBV7 and human TRAV30, respectively. These are human TRBV19 and human TRAV12, respectively. These are human TRBV19 and human TRAV13, respectively. These are human TRBV19 and human TRAV19, respectively. These are human TRBV19 and human TRAV21, respectively. These are human TRBV19 and human TRAV30, respectively. These are human TRBV20 and human TRAV12, respectively. These are human TRBV20 and human TRAV13, respectively. These are human TRBV20 and human TRAV19, respectively. These are human TRBV20 and human TRAV21, respectively. These are human TRBV20 and human TRAV30, respectively. These are human TRBV28 and human TRAV12, respectively. These are human TRBV28 and human TRAV13, respectively. These are human TRBV28 and human TRAV19, respectively. These are human TRBV28 and human TRAV21, respectively; or They are human TRBV28 and human TRAV30, respectively.

81. The method according to any one of claims 1 to 45, 50, 63, 64, 69 and 70, wherein the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

82. The method according to any one of claims 1 to 45, 50, 63, 64, 69, 70 and 81, wherein the first target molecule and the second target molecule: These are human TRBV5 and human TRAV12-2, respectively. These are human TRBV5 and human TRAV13-1, respectively. These are human TRBV5 and human TRAV19, respectively. These are human TRBV5 and human TRAV21, respectively. These are human TRBV5 and human TRAV30, respectively. These are human TRBV6 and human TRAV12-2, respectively. These are human TRBV6 and human TRAV13-1, respectively. These are human TRBV6 and human TRAV19, respectively. These are human TRBV6 and human TRAV21, respectively. These are human TRBV6 and human TRAV30, respectively. These are human TRBV10 and human TRAV12-2, respectively. These are human TRBV10 and human TRAV13-1, respectively. These are human TRBV10 and human TRAV19, respectively. These are human TRBV10 and human TRAV21, respectively. These are human TRBV10 and human TRAV30, respectively. These are human TRBV7 and human TRAV12-2, respectively. These are human TRBV7 and human TRAV13-1, respectively. These are human TRBV7 and human TRAV19, respectively. These are human TRBV7 and human TRAV21, respectively. These are human TRBV7 and human TRAV30, respectively. These are human TRBV19 and human TRAV12-2, respectively. These are human TRBV19 and human TRAV13-1, respectively. These are human TRBV19 and human TRAV19, respectively. These are human TRBV19 and human TRAV21, respectively. These are human TRBV19 and human TRAV30, respectively. These are human TRBV20 and human TRAV12-2, respectively. These are human TRBV20 and human TRAV13-1, respectively. These are human TRBV20 and human TRAV19, respectively. These are human TRBV20 and human TRAV21, respectively. These are human TRBV20 and human TRAV30, respectively. These are human TRBV28 and human TRAV12-2, respectively. These are human TRBV28 and human TRAV13-1, respectively. These are human TRBV28 and human TRAV19, respectively. These are human TRBV28 and human TRAV21, respectively; or They are human TRBV28 and human TRAV30, respectively.

83. The method according to any one of claims 1 to 45, 50, 63, 64, 69 and 70, wherein the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

84. The method according to any one of claims 1 to 45, 50, 63, 64, 69, 70 and 83, wherein the first target molecule and the second target molecule: These are human TRBV5-1 and human TRAV12, respectively. These are human TRBV5-1 and human TRAV13, respectively. These are human TRBV5-1 and human TRAV19, respectively. These are human TRBV5-1 and human TRAV21, respectively. These are human TRBV5-1 and human TRAV30, respectively. These are human TRBV6-5 and human TRAV12, respectively. These are human TRBV6-5 and human TRAV13, respectively. These are human TRBV6-5 and human TRAV19, respectively. These are human TRBV6-5 and human TRAV21, respectively. These are human TRBV6-5 and human TRAV30, respectively. These are human TRBV10-1 and human TRAV12, respectively. These are human TRBV10-1 and human TRAV13, respectively. These are human TRBV10-1 and human TRAV19, respectively. These are human TRBV10-1 and human TRAV21, respectively. These are human TRBV10-1 and human TRAV30, respectively. These are human TRBV10-2 and human TRAV12, respectively. These are human TRBV10-2 and human TRAV13, respectively. These are human TRBV10-2 and human TRAV19, respectively. These are human TRBV10-2 and human TRAV21, respectively. These are human TRBV10-2 and human TRAV30, respectively. These are human TRBV10-3 and human TRAV12, respectively. These are human TRBV10-3 and human TRAV13, respectively. These are human TRBV10-3 and human TRAV19, respectively. These are human TRBV10-3 and human TRAV21, respectively. These are human TRBV10-3 and human TRAV30, respectively. These are human TRBV7-2 and human TRAV12, respectively. These are human TRBV7-2 and human TRAV13, respectively. These are human TRBV7-2 and human TRAV19, respectively. These are human TRBV7-2 and human TRAV21, respectively. These are human TRBV7-2 and human TRAV30, respectively. These are human TRBV7-3 and human TRAV12, respectively. These are human TRBV7-3 and human TRAV13, respectively. These are human TRBV7-3 and human TRAV19, respectively. These are human TRBV7-3 and human TRAV21, respectively. These are human TRBV7-3 and human TRAV30, respectively. These are human TRBV19 and human TRAV12, respectively. These are human TRBV19 and human TRAV13, respectively. These are human TRBV19 and human TRAV19, respectively. These are human TRBV19 and human TRAV21, respectively. These are human TRBV19 and human TRAV30, respectively. These are human TRBV20-1 and human TRAV12, respectively. These are human TRBV20-1 and human TRAV13, respectively. These are human TRBV20-1 and human TRAV19, respectively. These are human TRBV20-1 and human TRAV21, respectively. These are human TRBV20-1 and human TRAV30, respectively. These are human TRBV28 and human TRAV12, respectively. These are human TRBV28 and human TRAV13, respectively. These are human TRBV28 and human TRAV19, respectively. These are human TRBV28 and human TRAV21, respectively; or They are human TRBV28 and human TRAV30, respectively.

85. The method according to any one of claims 1 to 45, 50, 63, 64, 69 and 70, wherein the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

86. The method according to any one of claims 1 to 45, 50, 63, 64, 69, 70 and 85, wherein the first target molecule and the second target molecule: These are human TRBV5-1 and human TRAV12-2, respectively. These are human TRBV5-1 and human TRAV13-1, respectively. These are human TRBV5-1 and human TRAV19, respectively. These are human TRBV5-1 and human TRAV21, respectively. These are human TRBV5-1 and human TRAV30, respectively. These are human TRBV6-5 and human TRAV12-2, respectively. These are human TRBV6-5 and human TRAV13-1, respectively. These are human TRBV6-5 and human TRAV19, respectively. These are human TRBV6-5 and human TRAV21, respectively. These are human TRBV6-5 and human TRAV30, respectively. These are human TRBV10-1 and human TRAV12-2, respectively. These are human TRBV10-1 and human TRAV13-1, respectively. These are human TRBV10-1 and human TRAV19, respectively. These are human TRBV10-1 and human TRAV21, respectively. These are human TRBV10-1 and human TRAV30, respectively. These are human TRBV10-2 and human TRAV12-2, respectively. These are human TRBV10-2 and human TRAV13-1, respectively. These are human TRBV10-2 and human TRAV19, respectively. These are human TRBV10-2 and human TRAV21, respectively. These are human TRBV10-2 and human TRAV30, respectively. These are human TRBV10-3 and human TRAV12-2, respectively. These are human TRBV10-3 and human TRAV13-1, respectively. These are human TRBV10-3 and human TRAV19, respectively. These are human TRBV10-3 and human TRAV21, respectively. These are human TRBV10-3 and human TRAV30, respectively. These are human TRBV7-2 and human TRAV12-2, respectively. These are human TRBV7-2 and human TRAV13-1, respectively. These are human TRBV7-2 and human TRAV19, respectively. These are human TRBV7-2 and human TRAV21, respectively. These are human TRBV7-2 and human TRAV30, respectively. These are human TRBV7-3 and human TRAV12-2, respectively. These are human TRBV7-3 and human TRAV13-1, respectively. These are human TRBV7-3 and human TRAV19, respectively. These are human TRBV7-3 and human TRAV21, respectively. These are human TRBV7-3 and human TRAV30, respectively. These are human TRBV19 and human TRAV12-2, respectively. These are human TRBV19 and human TRAV13-1, respectively. These are human TRBV19 and human TRAV19, respectively. These are human TRBV19 and human TRAV21, respectively. These are human TRBV19 and human TRAV30, respectively. These are human TRBV20-1 and human TRAV12-2, respectively. These are human TRBV20-1 and human TRAV13-1, respectively. These are human TRBV20-1 and human TRAV19, respectively. These are human TRBV20-1 and human TRAV21, respectively. These are human TRBV20-1 and human TRAV30, respectively. These are human TRBV28 and human TRAV12-2, respectively. These are human TRBV28 and human TRAV13-1, respectively. These are human TRBV28 and human TRAV19, respectively. These are human TRBV28 and human TRAV21, respectively; or They are human TRBV28 and human TRAV30, respectively.

87. The method according to any one of claims 1 to 45, 51 and 65 to 68, wherein the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28.

88. The method according to any one of claims 1 to 45, 51, 65 to 68 and 87, wherein the first target molecule and the second target molecule: These are human TRAV12 and human TRBV5, respectively. These are human TRAV12 and human TRBV6, respectively. These are human TRAV12 and human TRBV10, respectively. These are human TRAV12 and human TRBV7, respectively. These are human TRAV12 and human TRBV19, respectively. These are human TRAV12 and human TRBV20, respectively. These are human TRAV12 and human TRBV28, respectively. These are human TRAV13 and human TRBV5, respectively. These are human TRAV13 and human TRBV6, respectively. These are human TRAV13 and human TRBV10, respectively. These are human TRAV13 and human TRBV7, respectively. These are human TRAV13 and human TRBV19, respectively. These are human TRAV13 and human TRBV20, respectively. These are human TRAV13 and human TRBV28, respectively. These are human TRAV19 and human TRBV5, respectively. These are human TRAV19 and human TRBV6, respectively. These are human TRAV19 and human TRBV10, respectively. These are human TRAV19 and human TRBV7, respectively. These are human TRAV19 and human TRBV19, respectively. These are human TRAV19 and human TRBV20, respectively. These are human TRAV19 and human TRBV28, respectively. These are human TRAV21 and human TRBV5, respectively. These are human TRAV21 and human TRBV6, respectively. These are human TRAV21 and human TRBV10, respectively. These are human TRAV21 and human TRBV7, respectively. These are human TRAV21 and human TRBV19, respectively. These are human TRAV21 and human TRBV20, respectively. These are human TRAV21 and human TRBV28, respectively. These are human TRAV30 and human TRBV5, respectively. These are human TRAV30 and human TRBV6, respectively. These are human TRAV30 and human TRBV10, respectively. These are human TRAV30 and human TRBV7, respectively. These are human TRAV30 and human TRBV19, respectively. These are human TRAV30 and human TRBV20, respectively; or They are human TRAV30 and human TRBV28, respectively.

89. The method according to any one of claims 1 to 45, 51, 65 and 66 to 68, wherein the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28.

90. The method according to any one of claims 1 to 45, 51, 65, 66 to 68 and 89, wherein the first target molecule and the second target molecule: These are human TRAV12-2 and human TRBV5, respectively. These are human TRAV12-2 and human TRBV6, respectively. These are human TRAV12-2 and human TRBV10, respectively. These are human TRAV12-2 and human TRBV7, respectively. These are human TRAV12-2 and human TRBV19, respectively. These are human TRAV12-2 and human TRBV20, respectively. These are human TRAV12-2 and human TRBV28, respectively. These are human TRAV13-1 and human TRBV5, respectively. These are human TRAV13-1 and human TRBV6, respectively. These are human TRAV13-1 and human TRBV10, respectively. These are human TRAV13-1 and human TRBV7, respectively. These are human TRAV13-1 and human TRBV19, respectively. These are human TRAV13-1 and human TRBV20, respectively. These are human TRAV13-1 and human TRBV28, respectively. These are human TRAV19 and human TRBV5, respectively. These are human TRAV19 and human TRBV6, respectively. These are human TRAV19 and human TRBV10, respectively. These are human TRAV19 and human TRBV7, respectively. These are human TRAV19 and human TRBV19, respectively. These are human TRAV19 and human TRBV20, respectively. These are human TRAV19 and human TRBV28, respectively. These are human TRAV21 and human TRBV5, respectively. These are human TRAV21 and human TRBV6, respectively. These are human TRAV21 and human TRBV10, respectively. These are human TRAV21 and human TRBV7, respectively. These are human TRAV21 and human TRBV19, respectively. These are human TRAV21 and human TRBV20, respectively. These are human TRAV21 and human TRBV28, respectively. These are human TRAV30 and human TRBV5, respectively. These are human TRAV30 and human TRBV6, respectively. These are human TRAV30 and human TRBV10, respectively. These are human TRAV30 and human TRBV7, respectively. These are human TRAV30 and human TRBV19, respectively. These are human TRAV30 and human TRBV20, respectively; or They are human TRAV30 and human TRBV28, respectively.

91. The method according to any one of claims 1 to 45, 51 and 65 to 68, wherein the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28.

92. The method according to any one of claims 1 to 45, 51, 65 to 68 and 91, wherein the first target molecule and the second target molecule: These are human TRAV12 and human TRBV5-1, respectively. These are human TRAV12 and human TRBV6-5, respectively. These are human TRAV12 and human TRBV10-1, respectively. These are human TRAV12 and human TRBV10-2, respectively. These are human TRAV12 and human TRBV10-3, respectively. These are human TRAV12 and human TRBV7-2, respectively. These are human TRAV12 and human TRBV7-3, respectively. These are human TRAV12 and human TRBV19, respectively. These are human TRAV12 and human TRBV20-1, respectively. These are human TRAV12 and human TRBV28, respectively. These are human TRAV13 and human TRBV5-1, respectively. These are human TRAV13 and human TRBV6-5, respectively. These are human TRAV13 and human TRBV10-1, respectively. These are human TRAV13 and human TRBV10-2, respectively. These are human TRAV13 and human TRBV10-3, respectively. These are human TRAV13 and human TRBV7-2, respectively. These are human TRAV13 and human TRBV7-3, respectively. These are human TRAV13 and human TRBV19, respectively. These are human TRAV13 and human TRBV20-1, respectively. These are human TRAV13 and human TRBV28, respectively. These are human TRAV19 and human TRBV5-1, respectively. These are human TRAV19 and human TRBV6-5, respectively. These are human TRAV19 and human TRBV10-1, respectively. These are human TRAV19 and human TRBV10-2, respectively. These are human TRAV19 and human TRBV10-3, respectively. These are human TRAV19 and human TRBV7-2, respectively. These are human TRAV19 and human TRBV7-3, respectively. These are human TRAV19 and human TRBV19, respectively. These are human TRAV19 and human TRBV20-1, respectively. These are human TRAV19 and human TRBV28, respectively. These are human TRAV21 and human TRBV5-1, respectively. These are human TRAV21 and human TRBV6-5, respectively. These are human TRAV21 and human TRBV10-1, respectively. These are human TRAV21 and human TRBV10-2, respectively. These are human TRAV21 and human TRBV10-3, respectively. These are human TRAV21 and human TRBV7-2, respectively. These are human TRAV21 and human TRBV7-3, respectively. These are human TRAV21 and human TRBV19, respectively. These are human TRAV21 and human TRBV20-1, respectively. These are human TRAV21 and human TRBV28, respectively. These are human TRAV30 and human TRBV5-1, respectively. These are human TRAV30 and human TRBV6-5, respectively. These are human TRAV30 and human TRBV10-1, respectively. These are human TRAV30 and human TRBV10-2, respectively. These are human TRAV30 and human TRBV10-3, respectively. These are human TRAV30 and human TRBV7-2, respectively. These are human TRAV30 and human TRBV7-3, respectively. These are human TRAV30 and human TRBV19, respectively. These are human TRAV30 and human TRBV20-1, respectively; or They are human TRAV30 and human TRBV28, respectively.

93. The method according to any one of claims 1 to 45, 51 and 65 to 68, wherein the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV 10-1, human TRBV 10-2, human TRBV 10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28.

94. The method according to any one of claims 1 to 45, 51, 65 to 68 and 93, wherein the first target molecule and the second target molecule: These are human TRAV12-2 and human TRBV5-1, respectively. These are human TRAV12-2 and human TRBV6-5, respectively. These are human TRAV12-2 and human TRBV10-1, respectively. These are human TRAV12-2 and human TRBV10-2, respectively. These are human TRAV12-2 and human TRBV10-3, respectively. These are human TRAV12-2 and human TRBV7-2, respectively. These are human TRAV12-2 and human TRBV7-3, respectively. These are human TRAV12-2 and human TRBV19, respectively. These are human TRAV12-2 and human TRBV20-1, respectively. These are human TRAV12-2 and human TRBV28, respectively. These are human TRAV13-1 and human TRBV5-1, respectively. These are human TRAV13-1 and human TRBV6-5, respectively. These are human TRAV13-1 and human TRBV10-1, respectively. These are human TRAV13-1 and human TRBV10-2, respectively. These are human TRAV13-1 and human TRBV10-3, respectively. These are human TRAV13-1 and human TRBV7-2, respectively. These are human TRAV13-1 and human TRBV7-3, respectively. These are human TRAV13-1 and human TRBV19, respectively. These are human TRAV13-1 and human TRBV20-1, respectively. These are human TRAV13-1 and human TRBV28, respectively. These are human TRAV19 and human TRBV5-1, respectively. These are human TRAV19 and human TRBV6-5, respectively. These are human TRAV19 and human TRBV10-1, respectively. These are human TRAV19 and human TRBV10-2, respectively. These are human TRAV19 and human TRBV10-3, respectively. These are human TRAV19 and human TRBV7-2, respectively. These are human TRAV19 and human TRBV7-3, respectively. These are human TRAV19 and human TRBV19, respectively. These are human TRAV19 and human TRBV20-1, respectively. These are human TRAV19 and human TRBV28, respectively. These are human TRAV21 and human TRBV5-1, respectively. These are human TRAV21 and human TRBV6-5, respectively. These are human TRAV21 and human TRBV10-1, respectively. These are human TRAV21 and human TRBV10-2, respectively. These are human TRAV21 and human TRBV10-3, respectively. These are human TRAV21 and human TRBV7-2, respectively. These are human TRAV21 and human TRBV7-3, respectively. These are human TRAV21 and human TRBV19, respectively. These are human TRAV21 and human TRBV20-1, respectively. These are human TRAV21 and human TRBV28, respectively. These are human TRAV30 and human TRBV5-1, respectively. These are human TRAV30 and human TRBV6-5, respectively. These are human TRAV30 and human TRBV10-1, respectively. These are human TRAV30 and human TRBV10-2, respectively. These are human TRAV30 and human TRBV10-3, respectively. These are human TRAV30 and human TRBV7-2, respectively. These are human TRAV30 and human TRBV7-3, respectively. These are human TRAV30 and human TRBV19, respectively. These are human TRAV30 and human TRBV20-1, respectively; or They are human TRAV30 and human TRBV28, respectively.

95. The method according to any one of claims 1 to 94, wherein the first conjugate comprises a whole antibody or its antigen-binding fragment, a bivalent antibody, a bispecific antibody, or a biparatopic antibody.

96. The method according to any one of claims 1 to 95, wherein the second conjugate comprises a whole antibody or its antigen-binding fragment, a bivalent antibody, a bispecific antibody, or a biparatopic antibody.

97. The method according to claim 95 or 96, wherein the antigen-binding fragment is Fab, F(ab')2, Fv, single-chain Fv (scFv), single-domain antibody, double antibody, single-domain antibody, or camel antibody.

98. The method according to any one of claims 1 to 97, wherein the first conjugate comprises a heavy chain variable region (VH), the VH comprising a heavy chain complementarity determination region 3 (HC CDR3), the HC CDR3 comprising a sequence of SEQ ID NO: 3343, SEQ ID NO: 3323, SEQ ID NO: 3353, SEQ ID NO: 1187, SEQ ID NO: 3373, SEQ ID NO: 3383, SEQ ID NO: 3393, SEQ ID NO: 3403 or SEQ ID NO: 3413.

99. The method according to any one of claims 1 to 98, wherein the first conjugate comprises VH, the VH comprising heavy chain complementarity determination region 1 (HC CDR1), the HC CDR1 comprising the sequence of SEQ ID NO: 3341, SEQ ID NO: 3321, SEQ ID NO: 3351, SEQ ID NO: 1190, SEQ ID NO: 3371, SEQ ID NO: 3381, SEQ ID NO: 3391, SEQ ID NO: 3401, SEQ ID NO: 3411, SEQ ID NO: 3421 or SEQ ID NO: 3702.

100. The method according to any one of claims 1 to 99, wherein the first conjugate comprises VH, the VH comprising heavy chain complementarity determination region 2 (HC CDR2), the HC CDR2 comprising the sequence of SEQ ID NO: 3342, SEQ ID NO: 3322, SEQ ID NO: 3352, SEQ ID NO: 1186, SEQ ID NO: 3372, SEQ ID NO: 3382, SEQ ID NO: 3392, SEQ ID NO: 3402 or SEQ ID NO: 3412.

101. The method according to any one of claims 1 to 100, wherein the first combination comprises VH, the VH comprising: (i) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3341, HC CDR2 contains the sequence of SEQ ID NO: 3342 and HC CDR3 contains the sequence of SEQ ID NO: 3343; (ii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3321, HC CDR2 contains the sequence of SEQ ID NO: 3322 and HC CDR3 contains the sequence of SEQ ID NO: 3323; (iii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3351, HC CDR2 contains the sequence of SEQ ID NO: 3352 and HC CDR3 contains the sequence of SEQ ID NO: 3353; (iv) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 1190, HC CDR2 contains the sequence of SEQ ID NO: 1186 and HC CDR3 contains the sequence of SEQ ID NO: 1187; (v) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3371, HC CDR2 contains the sequence of SEQ ID NO: 3372 and HC CDR3 contains the sequence of SEQ ID NO: 3373; (vi) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3381, HC CDR2 contains the sequence of SEQ ID NO: 3382 and HC CDR3 contains the sequence of SEQ ID NO: 3383; (vii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3391, HC CDR2 contains the sequence of SEQ ID NO: 3392 and HC CDR3 contains the sequence of SEQ ID NO: 3393; (viii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3401, HC CDR2 contains the sequence of SEQ ID NO: 3402 and HC CDR3 contains the sequence of SEQ ID NO: 3403; (ix) HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; or (x) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3411, HC CDR2 contains the sequence of SEQ ID NO: 3412 and HC CDR3 contains the sequence of SEQ ID NO: 3413.

102. The method according to any one of claims 1 to 101, wherein the first conjugate comprises a light chain variable region (VL), the VL comprises a light chain complementarity determination region 3 (LC CDR3), and the LC CDR3 comprises a sequence of SEQ ID NO: 3346, SEQ ID NO: 3326, SEQ ID NO: 3356, SEQ ID NO: 1193, SEQ ID NO: 3376, SEQ ID NO: 3386, SEQ ID NO: 3396, SEQ ID NO: 3406 or SEQ ID NO: 3416.

103. The method according to any one of claims 1 to 102, wherein the first conjugate comprises a VL, the VL comprising a light chain complementarity determination region 1 (LC CDR1), the LC CDR1 comprising a sequence of SEQ ID NO: 3344, SEQ ID NO: 3324, SEQ ID NO: 3354, SEQ ID NO: 1191, SEQ ID NO: 3374, SEQ ID NO: 3384, SEQ ID NO: 3394, SEQ ID NO: 3404 or SEQ ID NO: 3414.

104. The method according to any one of claims 1 to 103, wherein the first conjugate comprises VL, the VL comprising a light chain complementarity determination region 2 (LC CDR2), the LC CDR2 comprising a sequence of SEQ ID NO: 3345, SEQ ID NO: 3325, SEQ ID NO: 3355, SEQ ID NO: 1192, SEQ ID NO: 3375, SEQ ID NO: 3395, SEQ ID NO: 3405, SEQ ID NO: 3415 or SEQ ID NO: 3443.

105. The method according to any one of claims 1 to 104, wherein the first combination comprises VL, the VL comprising: (i) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3344, LC CDR2 contains the sequence of SEQ ID NO: 3345 and LC CDR3 contains the sequence of SEQ ID NO: 3346; (ii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3324, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3326; (iii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3355, and LC CDR3 contains the sequence of SEQ ID NO: 3356; (iv) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 1191, LC CDR2 contains the sequence of SEQ ID NO: 1192 and LC CDR3 contains the sequence of SEQ ID NO: 1193; (v) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3374, LC CDR2 contains the sequence of SEQ ID NO: 3375, and LC CDR3 contains the sequence of SEQ ID NO: 3376; (vi) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3384, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3386; (vii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3394, LC CDR2 contains the sequence of SEQ ID NO: 3395, and LC CDR3 contains the sequence of SEQ ID NO: 3396; (viii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3404, LC CDR2 contains the sequence of SEQ ID NO: 3405 and LC CDR3 contains the sequence of SEQ ID NO: 3406; (ix) LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3414, LC CDR2 contains the sequence of SEQ ID NO: 3415, and LC CDR3 contains the sequence of SEQ ID NO: 3416; or (x) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3443 and LC CDR3 contains the sequence of SEQ ID NO: 3356.

106. The method according to any one of claims 1 to 105, wherein the first combination comprises: (i) VH, which comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3341, HC CDR2 comprises the sequence of SEQ ID NO: 3342, and HC CDR3 comprises the sequence of SEQ ID NO: 3343; and VL, which comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3344, LC CDR2 comprises the sequence of SEQ ID NO: 3345, and LC CDR3 comprises the sequence of SEQ ID NO: 3346; (ii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3321, HC CDR2 comprises the sequence of SEQ ID NO: 3322, and HC CDR3 comprises the sequence of SEQ ID NO: 3323; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3324, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3326; (iii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, LC CDR2 comprises the sequence of SEQ ID NO: 3355, and LC CDR3 comprises the sequence of SEQ ID NO: 3356; (iv) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 1190, HC CDR2 comprises the sequence of SEQ ID NO: 1186, and HC CDR3 comprises the sequence of SEQ ID NO: 1187; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 1191, LC CDR2 comprises the sequence of SEQ ID NO: 1192, and LC CDR3 comprises the sequence of SEQ ID NO: 1193; (v) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3371, HC CDR2 comprises the sequence of SEQ ID NO: 3372, and HC CDR3 comprises the sequence of SEQ ID NO: 3373; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3374, LC CDR2 comprises the sequence of SEQ ID NO: 3375, and LC CDR3 comprises the sequence of SEQ ID NO: 3376; (vi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3381, HC CDR2 comprises the sequence of SEQ ID NO: 3382, and HC CDR3 comprises the sequence of SEQ ID NO: 3383; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3384, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3386; (vii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3391, HC CDR2 comprises the sequence of SEQ ID NO: 3392, and HC CDR3 comprises the sequence of SEQ ID NO: 3393; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3394, LC CDR2 comprises the sequence of SEQ ID NO: 3395, and LC CDR3 comprises the sequence of SEQ ID NO: 3396; (viii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3401, HC CDR2 comprises the sequence of SEQ ID NO: 3402, and HC CDR3 comprises the sequence of SEQ ID NO: 3403; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3404, LC CDR2 comprises the sequence of SEQ ID NO: 3405, and LC CDR3 comprises the sequence of SEQ ID NO: 3406; (ix) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3411, HC CDR2 comprises the sequence of SEQ ID NO: 3412, and HC CDR3 comprises the sequence of SEQ ID NO: 3413; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3414, LC CDR2 comprises the sequence of SEQ ID NO: 3415, and LC CDR3 comprises the sequence of SEQ ID NO: 3416; (x) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LCCDR3, wherein LC CDR1 comprises a sequence of SEQ ID NO: 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3355, and wherein LC CDR3 comprises a sequence of SEQ ID NO: 3356; or (xi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LCCDR3, wherein LC CDR1 comprises a sequence of 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3443, and wherein LCCDR3 comprises a sequence of SEQ ID NO: 3356.

107. The method according to any one of claims 1 to 106, wherein the first conjugate comprises VH, the VH comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

108. The method according to any one of claims 1 to 107, wherein the first combination comprises VH, the VH comprising any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470.

109. The method according to any one of claims 1 to 108, wherein the first combination comprises a VL, the VL comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

110. The method according to any one of claims 1 to 109, wherein the first combination comprises VL, the VL comprising any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

111. The method according to any one of claims 1 to 110, wherein the first combination comprises: (i) VH, wherein VH comprises a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and (ii) VL, which comprises sequences having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

112. The method according to any one of claims 1 to 111, wherein the first combination comprises: (i) VH, wherein VH comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and (ii) VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

113. The method according to any one of claims 1 to 112, wherein the first combination comprises: (i) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3445, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3446; (ii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3448, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3449; (iii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3450, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3451; (iv) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1349; (v) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1196, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1195; (vi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3455, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3456; (vii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3457, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3458; (viii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3463, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3464; (ix) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3465, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3466; (x) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3470, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3471; (xi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3475; or (xii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3476.

114. The method according to any one of claims 1 to 113, wherein the first combination comprises: (i) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3445 and VL contains the sequence of SEQ ID NO: 3446; (ii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3448 and VL comprises the sequence of SEQ ID NO: 3449; (iii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3450 and VL comprises the sequence of SEQ ID NO: 3451; (iv) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346 and VL comprises the sequence of SEQ ID NO: 1349; (v) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1196 and VL contains the sequence of SEQ ID NO: 1195; (vi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3455 and VL comprises the sequence of SEQ ID NO: 3456; (vii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3457 and VL contains the sequence of SEQ ID NO: 3458; (viii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3463 and VL comprises the sequence of SEQ ID NO: 3464; (ix) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3465 and VL contains the sequence of SEQ ID NO: 3466; (x) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3470 and VL contains the sequence of SEQ ID NO: 3471; (xi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346, and VL comprises the sequence of SEQ ID NO: 3475; or (xii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1346 and VL contains the sequence of SEQ ID NO: 3476.

115. The method according to any one of claims 1 to 114, wherein the second conjugate comprises a heavy chain variable region (VH), the VH comprising a heavy chain complementarity determination region 3 (HC CDR3), the HC CDR3 comprising a sequence of SEQ ID NO: 3343, SEQ ID NO: 3323, SEQ ID NO: 3353, SEQ ID NO: 1187, SEQ ID NO: 3373, SEQ ID NO: 3383, SEQ ID NO: 3393, SEQ ID NO: 3403 or SEQ ID NO: 3413.

116. The method according to any one of claims 1 to 115, wherein the second conjugate comprises VH, the VH comprising heavy chain complementarity determination region 1 (HC CDR1), the HC CDR1 comprising the sequence of SEQ ID NO: 3341, SEQ ID NO: 3321, SEQ ID NO: 3351, SEQ ID NO: 1190, SEQ ID NO: 3371, SEQ ID NO: 3381, SEQ ID NO: 3391, SEQ ID NO: 3401, SEQ ID NO: 3411, SEQ ID NO: 3421 or SEQ ID NO: 3702.

117. The method according to any one of claims 1 to 116, wherein the second conjugate comprises VH, the VH comprising heavy chain complementarity determination region 2 (HC CDR2), the HC CDR2 comprising the sequence of SEQ ID NO: 3342, SEQ ID NO: 3322, SEQ ID NO: 3352, SEQ ID NO: 1186, SEQ ID NO: 3372, SEQ ID NO: 3382, SEQ ID NO: 3392, SEQ ID NO: 3402 or SEQ ID NO: 3412.

118. The method according to any one of claims 1 to 117, wherein the second combination comprises VH, the VH comprising: (i) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3341, HC CDR2 contains the sequence of SEQ ID NO: 3342 and HC CDR3 contains the sequence of SEQ ID NO: 3343; (ii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3321, HC CDR2 contains the sequence of SEQ ID NO: 3322 and HC CDR3 contains the sequence of SEQ ID NO: 3323; (iii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3351, HC CDR2 contains the sequence of SEQ ID NO: 3352 and HC CDR3 contains the sequence of SEQ ID NO: 3353; (iv) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 1190, HC CDR2 contains the sequence of SEQ ID NO: 1186 and HC CDR3 contains the sequence of SEQ ID NO: 1187; (v) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3371, HC CDR2 contains the sequence of SEQ ID NO: 3372 and HC CDR3 contains the sequence of SEQ ID NO: 3373; (vi) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3381, HC CDR2 contains the sequence of SEQ ID NO: 3382 and HC CDR3 contains the sequence of SEQ ID NO: 3383; (vii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3391, HC CDR2 contains the sequence of SEQ ID NO: 3392 and HC CDR3 contains the sequence of SEQ ID NO: 3393; (viii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3401, HC CDR2 contains the sequence of SEQ ID NO: 3402 and HC CDR3 contains the sequence of SEQ ID NO: 3403; (ix) HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; or (x) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3411, HC CDR2 contains the sequence of SEQ ID NO: 3412 and HC CDR3 contains the sequence of SEQ ID NO: 3413.

119. The method according to any one of claims 1 to 118, wherein the second conjugate comprises a light chain variable region (VL), the VL comprising a light chain complementarity determination region 3 (LC CDR3), the LC CDR3 comprising a sequence of SEQ ID NO: 3346, SEQ ID NO: 3326, SEQ ID NO: 3356, SEQ ID NO: 1193, SEQ ID NO: 3376, SEQ ID NO: 3386, SEQ ID NO: 3396, SEQ ID NO: 3406 or SEQ ID NO: 3416.

120. The method according to any one of claims 1 to 119, wherein the second conjugate comprises a VL, the VL comprising a light chain complementarity determination region 1 (LC CDR1), the LC CDR1 comprising a sequence of SEQ ID NO: 3344, SEQ ID NO: 3324, SEQ ID NO: 3354, SEQ ID NO: 1191, SEQ ID NO: 3374, SEQ ID NO: 3384, SEQ ID NO: 3394, SEQ ID NO: 3404 or SEQ ID NO: 3414.

121. The method according to any one of claims 1 to 120, wherein the second conjugate comprises a VL, the VL comprising a light chain complementarity determination region 2 (LC CDR2), the LC CDR2 comprising a sequence of SEQ ID NO: 3345, SEQ ID NO: 3325, SEQ ID NO: 3355, SEQ ID NO: 1192, SEQ ID NO: 3375, SEQ ID NO: 3395, SEQ ID NO: 3405, SEQ ID NO: 3415 or SEQ ID NO: 3443.

122. The method according to any one of claims 1 to 121, wherein the second combination comprises VL, the VL comprising: (i) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3344, LC CDR2 contains the sequence of SEQ ID NO: 3345 and LC CDR3 contains the sequence of SEQ ID NO: 3346; (ii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3324, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3326; (iii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3355, and LC CDR3 contains the sequence of SEQ ID NO: 3356; (iv) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 1191, LC CDR2 contains the sequence of SEQ ID NO: 1192 and LC CDR3 contains the sequence of SEQ ID NO: 1193; (v) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3374, LC CDR2 contains the sequence of SEQ ID NO: 3375, and LC CDR3 contains the sequence of SEQ ID NO: 3376; (vi) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3384, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3386; (vii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3394, LC CDR2 contains the sequence of SEQ ID NO: 3395, and LC CDR3 contains the sequence of SEQ ID NO: 3396; (viii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3404, LC CDR2 contains the sequence of SEQ ID NO: 3405 and LC CDR3 contains the sequence of SEQ ID NO: 3406; (ix) LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3414, LC CDR2 contains the sequence of SEQ ID NO: 3415, and LC CDR3 contains the sequence of SEQ ID NO: 3416; or (x) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3443 and LC CDR3 contains the sequence of SEQ ID NO: 3356.

123. The method according to any one of claims 1 to 122, wherein the second combination comprises: (i) VH, which comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3341, HC CDR2 comprises the sequence of SEQ ID NO: 3342, and HC CDR3 comprises the sequence of SEQ ID NO: 3343; and VL, which comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3344, LC CDR2 comprises the sequence of SEQ ID NO: 3345, and LC CDR3 comprises the sequence of SEQ ID NO: 3346; (ii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3321, HC CDR2 comprises the sequence of SEQ ID NO: 3322, and HC CDR3 comprises the sequence of SEQ ID NO: 3323; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3324, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3326; (iii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, LC CDR2 comprises the sequence of SEQ ID NO: 3355, and LC CDR3 comprises the sequence of SEQ ID NO: 3356; (iv) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 1190, HC CDR2 comprises the sequence of SEQ ID NO: 1186, and HC CDR3 comprises the sequence of SEQ ID NO: 1187; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 1191, LC CDR2 comprises the sequence of SEQ ID NO: 1192, and LC CDR3 comprises the sequence of SEQ ID NO: 1193; (v) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3371, HC CDR2 comprises the sequence of SEQ ID NO: 3372, and HC CDR3 comprises the sequence of SEQ ID NO: 3373; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3374, LC CDR2 comprises the sequence of SEQ ID NO: 3375, and LC CDR3 comprises the sequence of SEQ ID NO: 3376; (vi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3381, HC CDR2 comprises the sequence of SEQ ID NO: 3382, and HC CDR3 comprises the sequence of SEQ ID NO: 3383; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3384, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3386; (vii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3391, HC CDR2 comprises the sequence of SEQ ID NO: 3392, and HC CDR3 comprises the sequence of SEQ ID NO: 3393; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3394, LC CDR2 comprises the sequence of SEQ ID NO: 3395, and LC CDR3 comprises the sequence of SEQ ID NO: 3396; (viii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3401, HC CDR2 comprises the sequence of SEQ ID NO: 3402, and HC CDR3 comprises the sequence of SEQ ID NO: 3403; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3404, LC CDR2 comprises the sequence of SEQ ID NO: 3405, and LC CDR3 comprises the sequence of SEQ ID NO: 3406; (ix) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3411, HC CDR2 comprises the sequence of SEQ ID NO: 3412, and HC CDR3 comprises the sequence of SEQ ID NO: 3413; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3414, LC CDR2 comprises the sequence of SEQ ID NO: 3415, and LC CDR3 comprises the sequence of SEQ ID NO: 3416; (x) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LCCDR3, wherein LC CDR1 comprises a sequence of SEQ ID NO: 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3355, and wherein LC CDR3 comprises a sequence of SEQ ID NO: 3356; or (xi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LCCDR3, wherein LC CDR1 comprises a sequence of 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3443, and wherein LCCDR3 comprises a sequence of SEQ ID NO: 3356.

124. The method according to any one of claims 1 to 123, wherein the second combination comprises VH, said VH comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

125. The method according to any one of claims 1 to 124, wherein the second combination comprises VH, the VH comprising any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

126. The method according to any one of claims 1 to 125, wherein the second combination comprises a VL, the VL comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

127. The method according to any one of claims 1 to 126, wherein the second combination comprises VL, the VL comprising any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

128. The method according to any one of claims 1 to 127, wherein the second combination comprises: (i) VH, wherein VH comprises a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and (ii) VL, which comprises sequences having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

129. The method according to any one of claims 1 to 128, wherein the second combination comprises: (i) VH, wherein VH comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and (ii) VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

130. The method according to any one of claims 1 to 129, wherein the second combination comprises: (i) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3445, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3446; (ii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3448, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3449; (iii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3450, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3451; (iv) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1349; (v) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1196, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1195; (vi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3455, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3456; (vii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3457, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3458; (viii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3463, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3464; (ix) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3465, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3466; (x) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3470, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3471; (xi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3475; or (xii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3476.

131. The method according to any one of claims 1 to 130, wherein the second combination comprises: (i) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3445 and VL contains the sequence of SEQ ID NO: 3446; (ii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3448 and VL comprises the sequence of SEQ ID NO: 3449; (iii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3450 and VL comprises the sequence of SEQ ID NO: 3451; (iv) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346 and VL comprises the sequence of SEQ ID NO: 1349; (v) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1196 and VL contains the sequence of SEQ ID NO: 1195; (vi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3455 and VL comprises the sequence of SEQ ID NO: 3456; (vii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3457 and VL contains the sequence of SEQ ID NO: 3458; (viii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3463 and VL comprises the sequence of SEQ ID NO: 3464; (ix) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3465 and VL contains the sequence of SEQ ID NO: 3466; (x) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3470 and VL contains the sequence of SEQ ID NO: 3471; (xi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346, and VL comprises the sequence of SEQ ID NO: 3475; or (xii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1346 and VL contains the sequence of SEQ ID NO: 3476.

132. The method according to any one of claims 1 to 131, wherein the first binder and the second binder bind to different TCRβV regions.

133. The method according to any one of claims 1 to 131, wherein the first conjugate and the second conjugate bind to different TCRβV belonging to different subfamilies.

134. The method according to any one of claims 1 to 131, wherein the first binder and the second binder bind to different members of the same TCRβV subfamily.

135. The method according to any one of claims 1 to 134, wherein the first conjugate comprises one or more heavy chain constant regions selected from the group consisting of: IgG1 heavy chain constant region or fragment thereof, IgG2 heavy chain constant region or fragment thereof, IgG3 heavy chain constant region or fragment thereof, IgGA1 heavy chain constant region or fragment thereof, IgGA2 heavy chain constant region or fragment thereof, IgG4 heavy chain constant region or fragment thereof, IgJ heavy chain constant region or fragment thereof, IgM heavy chain constant region or fragment thereof, IgD heavy chain constant region or fragment thereof, and IgE heavy chain constant region or fragment thereof.

136. The method according to any one of claims 1 to 135, wherein the first conjugate comprises a κ light chain constant region or a fragment thereof, a λ light chain constant region or a fragment thereof, or a combination thereof.

137. The method according to any one of claims 1 to 136, wherein the second conjugate comprises one or more heavy chain constant regions selected from the group consisting of: IgG1 heavy chain constant region or fragment thereof, IgG2 heavy chain constant region or fragment thereof, IgG3 heavy chain constant region or fragment thereof, IgGA1 heavy chain constant region or fragment thereof, IgGA2 heavy chain constant region or fragment thereof, IgG4 heavy chain constant region or fragment thereof, IgJ heavy chain constant region or fragment thereof, IgM heavy chain constant region or fragment thereof, IgD heavy chain constant region or fragment thereof, and IgE heavy chain constant region or fragment thereof.

138. The method according to any one of claims 1 to 137, wherein the second combination comprises a κ light chain constant region or a fragment thereof, a λ light chain constant region or a fragment thereof, or a combination thereof.

139. The method according to any one of claims 1 to 138, wherein the first agent is a multifunctional molecule.

140. The method according to any one of claims 1 to 139, wherein the first agent is a multispecific molecule.

141. The method according to any one of claims 1 to 140, wherein the second agent is a multifunctional molecule.

142. The method according to any one of claims 1 to 141, wherein the second agent is a multispecific molecule.

143. The method according to any one of claims 1 to 142, wherein the first agent, the second agent, or a combination thereof comprises at least two discontinuous polypeptide chains; The first polypeptide chain of the at least two discontinuous polypeptide chains contains a first Fc region, and the second polypeptide chain of the at least two discontinuous polypeptide chains contains a second Fc region; and The first Fc region and the second Fc region contain the Fc interface with the pestle and mortar.

144. The method of claim 143, wherein the first Fc region, the second Fc region, or a combination thereof comprises the Asn297Ala mutation, the Leu234Ala / Leu235Ala mutation, or a combination thereof.

145. The method according to any one of claims 139 to 144, wherein the first agent is a multispecific molecule, the multispecific molecule further comprising one or more of a tumor-targeting portion, a cytokine molecule, a matrix-modifying portion, or an immune cell conjugate.

146. The method according to any one of claims 141 to 145, wherein the second agent is a multispecific molecule, the multispecific molecule further comprising one or more of a tumor-targeting portion, a cytokine molecule, a matrix-modifying portion, or an immune cell conjugate.

147. The method according to any one of claims 139 to 146, wherein the first agent comprises the following configuration: A-, B-[dimerization module]-C, -D, in: (a) The dimerization module includes a first immunoglobulin chain constant region and a second immunoglobulin chain constant region; (b) A and C are connected to the first immunoglobulin chain constant region; and B and D are connected to the second immunoglobulin chain constant region; (c) A, B, C, and D independently (i) are absent; (ii) are the first conjugate; (iii) are the tumor-targeting portion; (iv) are the cytokine molecule; (v) are the matrix-modifying portion; or (vi) are the immune cell conjugate; and At least one, two, or three of A, B, C, and D contain the first combination.

148. The method according to any one of claims 141 to 147, wherein the second agent comprises the following configuration: A-, B-[dimerization module]-C, -D, in: (a) The dimerization module includes a first immunoglobulin chain constant region and a second immunoglobulin chain constant region; (b) A and C are connected to the first immunoglobulin chain constant region; and B and D are connected to the second immunoglobulin chain constant region; (c) A, B, C, and D independently (i) are absent; (ii) are the second conjugate; (iii) are the tumor-targeting portion; (iv) are the cytokine molecule; (v) are the matrix-modifying portion; or (vi) are the immune cell conjugate; and At least one, two, or three of A, B, C, and D contain the second combination.

149. The method of claim 147 or 148, wherein the first immunoglobulin chain constant region comprises a first fragment crystallizable region (Fc region), and the second first immunoglobulin chain constant region comprises a second fragment crystallizable region (Fc region).

150. The method of claim 149, wherein the dimerization of the first Fc region and the second Fc region is enhanced by providing an Fc interface between the first Fc region and the second Fc region and one or more of a paired cavity protrusion, electrostatic interaction, or chain exchange, such that the ratio of heteropolymer to homopolymer formed is greater relative to the unengineered interface.

151. The method according to any one of claims 145 to 150, wherein the immune cell conjugate is selected from the group consisting of: T cell conjugate, NK cell conjugate, B cell conjugate, dendritic cell conjugate, macrophage conjugate, and any combination thereof.

152. The method according to any one of claims 145 to 151, wherein the cytokine molecule is selected from the group consisting of: interleukin-2 (IL-2) or a functional variant thereof, interleukin-7 (IL-7) or a functional variant thereof, interleukin-12 (IL-12) or a functional variant thereof, interleukin-15 (IL-15) or a functional variant thereof, interleukin-18 (IL-18) or a functional variant thereof, interleukin-21 (IL-21) or a functional variant thereof, interferon-γ or a functional variant thereof, and any combination thereof.

153. The method of claim 152, wherein the cytokine molecule comprises interleukin-2 (IL-2) or a functional variant thereof.

154. The method of claim 153, wherein the interleukin-2 (IL-2) or a functional variant thereof comprises the sequence of SEQ ID NO: 2270 or SEQ ID NO: 2191.

155. The method of claim 152, wherein the cytokine molecule comprises interleukin-15 (IL-15) or a functional variant thereof.

156. The method of claim 155, wherein the interleukin-15 (IL-15) or a functional variant thereof comprises the sequence of SEQ ID NO: 2170.

157. The method according to claim 155 or 156, wherein the cytokine molecule further comprises an IL15Rα dimerization domain covalently linked to the interleukin-15 (IL-15) or a functional variant thereof.

158. The method of claim 157, wherein the IL15Rα dimerization domain comprises the IL-15 receptor αsushi domain or a functional variant thereof.

159. The method according to claim 157 or 158, wherein the IL15Rα dimerizing domain comprises the sequence of SEQ ID NO: 3472.

160. The method according to any one of claims 157 to 159, wherein the interleukin-15 (IL-15) or a functional variant thereof is covalently linked to the IL15Rα dimerization domain via a connector.

161. The method of claim 160, wherein the interleukin-15 (IL-15) or a functional variant thereof is covalently linked to the IL15Rα dimerization domain via a connector comprising the sequence of SEQ ID NO: 3473.

162. The method according to any one of claims 155 to 161, wherein the cytokine molecule comprises the sequence of SEQ ID NO: 3474.

163. The method according to any one of claims 145 to 162, wherein the matrix modification portion is selected from the group consisting of hyaluronidase, collagenase, chondroitinase, and matrix metalloproteinase.

164. The method according to any one of claims 145 to 163, wherein the tumor-targeting portion binds to the cancer antigen.

165. The method of claim 164, wherein the tumor-targeting portion binds to the cancer antigen.

166. The method according to claim 164 or 165, wherein the cancer antigen is present on hematologic malignancies, solid tumors, metastatic cancers, soft tissue tumors, metastatic lesions, or combinations thereof.

167. The method according to any one of claims 164 to 166, wherein the cancer antigen is a tumor antigen, matrix antigen, or blood antigen.

168. The method according to any one of claims 164 to 167, wherein the cancer antigen is selected from the group consisting of: BCMA, CD19, CD20, CD22, FcRH5, PDL1, CD47, ganglioside 2 (GD2), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron kinase, c-Met, immature laminin receptor, TAG-72, BING-4, calcium-activated chloride channel 2, cyclin-B1, 9D7, Ep-CAM, EphA3, Her2 / neu, telomerase, SAP-1, susceptin, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, Gp100 / pmel17, tyrosinase, MC1R, β-linked Cyclic proteins, BRCA1 / 2, CDK4, CML66, fibronectin, p53, Ras, TGF-β receptor, AFP, ETA, MAGE, CA-125, BAGE, GAGE, CDC27, α-actin-4, TRP1 / gp75, TRP2, gangliosides, WT1, epidermal growth factor receptor (EGFR), MART-2, MUC1, MUC2, MUM1, MUM2, MUM3, NA88-1, NPM, OA1, OGT, RCC, RU11, RU12, SAGE, TRG, TSTA, folate receptor α, L1-CAM, CAIX, gpA33, GD3, GM2, VEGFR, integrin, carbohydrates, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, TGF-β, hyaluronic acid, collagen, tendinin C and tendinin W.

169. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3445, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3446, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

170. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3448, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3449, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

171. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

172. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

173. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

174. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1196, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1195, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

175. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3455, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3456, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

176. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3457, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3458, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

177. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3463, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3464, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

178. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3465, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3467, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3468. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3469, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3466, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

179. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3470, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3471, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

180. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and... (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

181. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and... (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3475, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

182. The method according to any one of claims 1 to 168, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and... (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3476, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

183. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3445, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3446, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

184. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3448, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3449, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

185. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

186. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

187. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

188. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1196, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1195, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

189. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3455, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3456, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

190. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3457, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3458, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

191. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3463, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3464, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

192. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3465, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3467, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3468. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3469, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3466, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

193. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3470, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3471, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

194. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and... (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

195. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and... (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3475, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

196. The method according to any one of claims 1 to 182, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-15 or a functional variant thereof, wherein the IL-15 or a functional variant thereof comprises the sequence of SEQ ID NO: 2170, wherein the IL-15 or a functional variant thereof is covalently linked to an IL15Rα dimerization domain via a linker, the IL15Rα dimerization domain comprising the sequence of SEQ ID NO: 3472, the linker comprising the sequence of SEQ ID NO: 3473, and... (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3476, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

197. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3338; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3339.

198. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3318; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3319.

199. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

200. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3350 or the sequence of SEQ ID NO: 3500; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

201. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3349.

202. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3358; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3359.

203. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3368; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3369.

204. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3378; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3380; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3379.

205. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3388; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3390; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3389.

206. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3398; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3400; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3399.

207. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3408; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3409.

208. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3349.

209. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3428.

210. The method according to any one of claims 1 to 196, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3437.

211. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3338; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3339.

212. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3318; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3319.

213. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3328; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3329.

214. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3328; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3350 or the sequence of SEQ ID NO: 3500; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3329.

215. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3349.

216. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3358; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3359.

217. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3368; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3369.

218. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3378; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3380; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3379.

219. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3388; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3390; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3389.

220. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3398; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3400; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3399.

221. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3408; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3409.

222. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3349.

223. The method according to any one of claims 1 to 210, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3428.

224. The method according to any one of claims 1 to 210, wherein the first pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3437.

225. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3338; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3339.

226. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3318; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3319.

227. The method according to any one of claims 1 to 224, wherein the second pharmaceutical agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

228. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3328; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3350 or the sequence of SEQ ID NO: 3500; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3329.

229. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3349.

230. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3358; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3359.

231. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3368; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3369.

232. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3378; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3380; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3379.

233. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3388; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3390; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3389.

234. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3398; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3400; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3399.

235. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3408; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3409.

236. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3349.

237. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3428.

238. The method according to any one of claims 1 to 224, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains a sequence that has at least 75% sequence identity with the sequence of SEQ ID NO: 3437.

239. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3338; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3339.

240. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3318; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3319.

241. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3328; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3329.

242. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3328; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3350 or the sequence of SEQ ID NO: 3500; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3329.

243. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3349.

244. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3358; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3359.

245. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3368; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3369.

246. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3378; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3380; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3379.

247. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3388; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3390; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3389.

248. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3398; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3400; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3399.

249. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3408; (ii) The second polypeptide chain comprises the sequence of SEQ ID NO: 3340 or the sequence of SEQ ID NO: 3503; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3409.

250. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3349.

251. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3428.

252. The method according to any one of claims 1 to 238, wherein the second agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains the sequence of SEQ ID NO: 3348 or the sequence of SEQ ID NO: 3502; (ii) The second polypeptide chain contains the sequence of SEQ ID NO: 3420; and (iii) The third polypeptide chain contains the sequence of SEQ ID NO: 3437.

253. The method according to any one of claims 1 to 252, wherein the disease or symptom is cancer.

254. The method of claim 253, wherein the cancer is a solid tumor.

255. The method of claim 254, wherein the solid tumor is melanoma, pancreatic cancer, breast cancer, colorectal cancer, lung cancer, skin cancer, ovarian cancer, or liver cancer.

256. The method of claim 253 or 254, wherein the solid tumor is selected from the group consisting of: high mutation burden (TMB-H), microsatellite instability / DNA mismatch repair (MSI-H / dMMR), virus-associated tumors, metastatic triple-negative breast cancer (mTNBC), recurrent and refractory epithelial ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), K-Ras wild-type CRC, K-Ras mutant CRC, and primary stage IV or recurrent non-small cell lung cancer (NSCLC).

257. The method of claim 256, wherein the virus-associated tumor comprises Merkel cell carcinoma, cervical cancer, oropharyngeal cancer, anal cancer, penile cancer, vaginal cancer, or vulvar cancer.

258. The method of claim 253, wherein the cancer is a blood cancer.

259. The method of claim 258, wherein the hematologic malignancy is a B-cell or T-cell malignancy.

260. The method of claim 259, wherein the B-cell or T-cell malignancy is Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma, or acute lymphoblastic leukemia.

261. The method of claim 260, wherein the non-Hodgkin's lymphoma is B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, or hairy cell leukemia.

262. The method according to any one of claims 1 to 261, wherein the application comprises applying a first pharmaceutical composition comprising the first pharmaceutical agent and a second pharmaceutical composition comprising the second pharmaceutical agent, wherein the first pharmaceutical composition and the second pharmaceutical composition independently further comprise a pharmaceutically acceptable excipient, carrier, or diluent.

263. A combination therapy for treating a disease or symptom in a subject in need, the combination therapy comprising administering to the subject a first agent comprising a first conjugate binding to a first target molecule, and administering to the subject a second agent comprising a second conjugate binding to a second target molecule, thereby treating the subject's disease or symptom; The second drug is applied after the first drug is applied. The first target molecule and the second target molecule are independently selected from the group consisting of the T cell receptor α variable region (TCRαV) and the T cell receptor β variable region (TCRβV); and The first target molecule and the second target molecule are different.

264. The combination therapy of claim 263, wherein the first agent and the second agent are not administered to the subject simultaneously.

265. The combination therapy according to claim 263 or 264, wherein administering the first agent comprises administering a therapeutically effective amount of the first agent to the subject.

266. The combination therapy according to any one of claims 263 to 265, wherein administering the second agent comprises administering a therapeutically effective amount of the second agent to the subject.

267. The combination therapy according to any one of claims 263 to 266, wherein the combination therapy is more effective in treating the subject’s disease or condition than in administering the first agent to the subject without administering the second agent.

268. The combination therapy according to any one of claims 263 to 267, wherein the combination therapy is more effective in treating the subject’s disease or condition than in administering the second agent to the subject without administering the first agent.

269. The combination therapy according to any one of claims 263 to 268, wherein the combination therapy is more effective in treating the subject’s disease or condition than in a method of administering the first agent to the subject in a first administration and subsequently administering the first agent to the subject in a second administration.

270. The combination therapy according to any one of claims 263 to 269, wherein the combination therapy is more effective in treating the subject’s disease or condition than in a method of administering the second agent to the subject in a first administration and subsequently administering the second agent to the subject in a second administration.

271. The combination therapy according to any one of claims 263 to 270, wherein the combination therapy is more effective in treating the subject’s disease or condition than in a method of administering the second agent to the subject in a first administration and subsequently administering the second agent to the subject in a second administration.

272. The combination therapy according to any one of claims 263 to 271, wherein the administration of the first agent comprises one or more doses.

273. The combination therapy according to any one of claims 263 to 272, wherein the administration of the first agent comprises two or more doses.

274. The combination therapy according to any one of claims 263 to 273, wherein the administration of the first agent comprises a dose once per week.

275. The combination therapy according to any one of claims 263 to 273, wherein the administration of the first agent comprises two or more doses per week.

276. The combination therapy according to any one of claims 263 to 273, wherein the first agent is administered to the subject once every two weeks.

277. The combination therapy according to any one of claims 263 to 273, wherein the first agent is administered to the subject once every three weeks.

278. The combination therapy according to any one of claims 263 to 274, wherein the first agent is administered to the subject once a week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

279. The combination therapy according to any one of claims 263 to 273 and 275, wherein the administration of the first agent comprises two or more doses per week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

280. The combination therapy according to any one of claims 263 to 273 and 276, wherein the first agent is administered to the subject once every two weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

281. The combination therapy according to any one of claims 263 to 273 and 277, wherein the first agent is administered to the subject once every three weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

282. The combination therapy according to any one of claims 263 to 281, wherein the administration of the second agent comprises one or more doses.

283. The combination therapy according to any one of claims 263 to 282, wherein the administration of the second agent comprises two or more doses.

284. The combination therapy according to any one of claims 263 to 283, wherein the administration of the second agent comprises a dose once per week.

285. The combination therapy according to any one of claims 263 to 283, wherein the administration of the second agent comprises two or more doses per week.

286. The combination therapy according to any one of claims 263 to 283, wherein the second agent is administered to the subject once every two weeks.

287. The combination therapy according to any one of claims 263 to 283, wherein the second agent is administered to the subject once every three weeks.

288. The combination therapy according to any one of claims 263 to 282, wherein the second agent is administered to the subject once a week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

289. The combination therapy according to any one of claims 263 to 282 and 285, wherein the administration of the second agent comprises two or more doses per week for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

290. The combination therapy according to any one of claims 263 to 282 and 286, wherein the second agent is administered to the subject once every two weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

291. The combination therapy according to any one of claims 263 to 282 and 287, wherein the second agent is administered to the subject once every three weeks for at least 1 week, 2 weeks, 3 weeks or 4 weeks, at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months, or at least 1 year, 2 years or 3 years.

292. The combination therapy according to any one of claims 263 to 291, wherein the administration of the first agent and the administration of the second agent are spaced one week apart.

293. The combination therapy according to any one of claims 263 to 291, wherein the administration of the first agent and the administration of the second agent are spaced two weeks or more apart.

294. The combination therapy according to any one of claims 263 to 291, wherein the interval between the administration of the first agent and the administration of the second agent is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.

295. The combination therapy according to any one of claims 263 to 294, wherein the administration of the first agent and the second agent is repeated two or more times.

296. The combination therapy according to any one of the preceding claims, wherein the first agent and the second agent are administered to the subject according to a dosing regimen, wherein the dosing regimen comprises administering the first agent once weekly for two weeks, followed by administering the second agent once weekly for two weeks, wherein the second agent is administered to the subject one week after the last administration of the first agent.

297. The combination therapy of claim 296, wherein the dosing regimen is repeated two or more times.

298. The combination therapy according to claim 296 or 297, wherein the dosing regimen is repeated at weekly intervals.

299. The combination therapy according to any one of claims 296 to 298, wherein the dosing regimen is repeated at intervals of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.

300. The combination therapy according to any one of claims 263 to 299, wherein the first agent and the second agent are administered to the subject in the same amount.

301. The combination therapy according to any one of claims 263 to 299, wherein the first agent and the second agent are administered to the subject in different amounts.

302. The combination therapy according to any one of claims 263 to 301, wherein the administration of the first agent comprises two or more doses, and each dose comprises the same amount of the first agent.

303. The combination therapy according to any one of claims 263 to 301, wherein the administration of the first agent comprises two or more doses, and each dose comprises a different amount of the first agent.

304. The combination therapy according to any one of claims 263 to 303, wherein the administration of the second agent comprises two or more doses, and each dose comprises the same amount of the second agent.

305. The combination therapy according to any one of claims 263 to 303, wherein the administration of the second agent comprises two or more doses, and each dose comprises a different amount of the second agent.

306. The combination therapy according to any one of claims 263 to 305, wherein the first agent is administered to the subject at a dose of about 0.001 mg / kg to about 10 mg / kg.

307. The combination therapy according to any one of claims 263 to 306, wherein the second agent is administered to the subject at a dose of about 0.001 mg / kg to about 10 mg / kg.

308. The combination therapy according to any one of claims 263 to 307, wherein the first agent is administered to the subject at a dose of about 0.3 mg / kg or about 1 mg / kg.

309. The combination therapy according to any one of claims 263 to 308, wherein the second agent is administered to the subject at a dose of about 0.3 mg / kg or about 1 mg / kg.

310. The combination therapy according to any one of claims 263 to 309, wherein the first target molecule is a first TCRβV and the second target molecule is a second TCRβV, wherein the first TCRβV and the second TCRβV are different.

311. The combination therapy according to any one of claims 263 to 307, wherein the first target molecule is a first TCRαV and the second target molecule is a second TCRαV, wherein the first TCRαV and the second TCRαV are different.

312. The combination therapy according to any one of claims 263 to 307, wherein the first target molecule is TCRβV and the second target molecule is TCRαV.

313. The combination therapy according to any one of claims 263 to 307, wherein the first target molecule is TCRαV and the second target molecule is TCRβV.

314. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TCRβV6.

315. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TCRβV10.

316. The combination therapy according to any one of the preceding claims, wherein the second target molecule is human TCRβV15.

317. The combination therapy according to any one of the preceding claims, wherein the second target molecule is human TCRβV27.

318. The combination therapy according to any one of the preceding claims, wherein the second target molecule is human TCRβV5.

319. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TCRβV6 and the second target molecule is human TCRβV5.

320. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TCRβV6 and the second target molecule is human TCRβV15.

321. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TCRβV6 and the second target molecule is human TCRβV27.

322. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TCRβV10 and the second target molecule is human TCRβV5.

323. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TCRβV10 and the second target molecule is human TCRβV15.

324. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TCRβV10 and the second target molecule is human TCRβV27.

325. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28.

326. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1, or human TRBV28.

327. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

328. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

329. The combination therapy according to any one of the preceding claims, wherein the second target molecule is human TRBV5, human TRBV15, human TRBV27, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28.

330. The combination therapy according to any one of the preceding claims, wherein the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV15, human TRBV27, human TRBV19, human TRBV20-1, or human TRBV28.

331. The combination therapy according to any one of the preceding claims, wherein the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

332. The combination therapy according to any one of the preceding claims, wherein the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

333. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV15, human TRBV27, human TRBV19, human TRBV20 or human TRBV28, wherein the first target molecule and the second target molecule are different.

334. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRBV5 and human TRBV5, respectively. These are human TRBV5 and human TRBV6, respectively. These are human TRBV5 and human TRBV10, respectively. These are human TRBV5 and human TRBV7, respectively. These are human TRBV5 and human TRBV19, respectively. These are human TRBV5 and human TRBV20, respectively. These are human TRBV5 and human TRBV28, respectively. These are human TRBV6 and human TRBV5, respectively. These are human TRBV6 and human TRBV6, respectively. These are human TRBV6 and human TRBV10, respectively. They are human TRBV6 and human TRBV7, respectively. These are human TRBV6 and human TRBV15, respectively. These are human TRBV6 and human TRBV27, respectively. These are human TRBV6 and human TRBV19, respectively. These are human TRBV6 and human TRBV20, respectively. These are human TRBV6 and human TRBV28, respectively. These are human TRBV10 and human TRBV5, respectively. These are human TRBV10 and human TRBV6, respectively. These are human TRBV10 and human TRBV10, respectively. These are human TRBV10 and human TRBV7, respectively. These are human TRBV10 and human TRBV15, respectively. These are human TRBV10 and human TRBV27, respectively. These are human TRBV10 and human TRBV19, respectively. These are human TRBV10 and human TRBV20, respectively. These are human TRBV10 and human TRBV28, respectively. These are human TRBV7 and human TRBV5, respectively. They are human TRBV7 and human TRBV6, respectively. These are human TRBV7 and human TRBV10, respectively. They are human TRBV7 and human TRBV7, respectively. These are human TRBV7 and human TRBV19, respectively. These are human TRBV7 and human TRBV20, respectively. These are human TRBV7 and human TRBV28, respectively. These are human TRBV19 and human TRBV5, respectively. These are human TRBV19 and human TRBV6, respectively. They are human TRBV19 and human TRBV10, respectively. These are human TRBV19 and human TRBV7, respectively. These are human TRBV19 and human TRBV19, respectively. These are human TRBV19 and human TRBV20, respectively. These are human TRBV19 and human TRBV28, respectively. These are human TRBV20 and human TRBV5, respectively. These are human TRBV20 and human TRBV6, respectively. These are human TRBV20 and human TRBV10, respectively. These are human TRBV20 and human TRBV7, respectively. These are human TRBV20 and human TRBV19, respectively. These are human TRBV20 and human TRBV20, respectively. These are human TRBV20 and human TRBV28, respectively. These are human TRBV28 and human TRBV5, respectively. These are human TRBV28 and human TRBV6, respectively. These are human TRBV28 and human TRBV10, respectively. These are human TRBV28 and human TRBV7, respectively. These are human TRBV28 and human TRBV19, respectively. These are human TRBV28 and human TRBV20, respectively; or They are human TRBV28 and human TRBV28, respectively.

335. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV15, human TRBV27, human TRBV19, human TRBV20-1 or human TRBV28, wherein the first target molecule and the second target molecule are different.

336. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRBV5-1 and human TRBV6-5, respectively. These are human TRBV5-1 and human TRBV10-1, respectively. These are human TRBV5-1 and human TRBV10-2, respectively. These are human TRBV5-1 and human TRBV10-3, respectively. These are human TRBV5-1 and human TRBV7-2, respectively. They are human TRBV5-1 and human TRBV7-3, respectively. These are human TRBV5-1 and human TRBV19, respectively. These are human TRBV5-1 and human TRBV20-1, respectively. These are human TRBV5-1 and human TRBV28, respectively. These are human TRBV6-5 and human TRBV5-1, respectively. These are human TRBV6-5 and human TRBV7-2, respectively. These are human TRBV6-5 and human TRBV7-3, respectively. These are human TRBV6-5 and human TRBV15, respectively. These are human TRBV6-5 and human TRBV27, respectively. These are human TRBV6-5 and human TRBV19, respectively. These are human TRBV6-5 and human TRBV20-1, respectively. These are human TRBV6-5 and human TRBV28, respectively. These are human TRBV10-1 and human TRBV5-1, respectively. These are human TRBV10-1 and human TRBV7-2, respectively. These are human TRBV10-1 and human TRBV7-3, respectively. These are human TRBV10-1 and human TRBV15, respectively. These are human TRBV10-1 and human TRBV27, respectively. These are human TRBV10-1 and human TRBV19, respectively. These are human TRBV10-1 and human TRBV20-1, respectively. These are human TRBV10-1 and human TRBV28, respectively. These are human TRBV10-2 and human TRBV5-1, respectively. These are human TRBV10-2 and human TRBV7-2, respectively. These are human TRBV10-2 and human TRBV7-3, respectively. These are human TRBV10-2 and human TRBV15, respectively. These are human TRBV10-2 and human TRBV27, respectively. These are human TRBV10-2 and human TRBV19, respectively. These are human TRBV10-2 and human TRBV20-1, respectively. These are human TRBV10-2 and human TRBV28, respectively. These are human TRBV10-3 and human TRBV5-1, respectively. These are human TRBV10-3 and human TRBV7-2, respectively. They are human TRBV10-3 and human TRBV7-3, respectively. These are human TRBV10-3 and human TRBV15, respectively. These are human TRBV10-3 and human TRBV27, respectively. These are human TRBV10-3 and human TRBV19, respectively. These are human TRBV10-3 and human TRBV20-1, respectively. These are human TRBV10-3 and human TRBV28, respectively. These are human TRBV7-2 and human TRBV5-1, respectively. These are human TRBV7-2 and human TRBV6-5, respectively. These are human TRBV7-2 and human TRBV10-1, respectively. These are human TRBV7-2 and human TRBV10-2, respectively. These are human TRBV7-2 and human TRBV10-3, respectively. They are human TRBV7-2 and human TRBV7-3, respectively. These are human TRBV7-2 and human TRBV19, respectively. These are human TRBV7-2 and human TRBV20-1, respectively. These are human TRBV7-2 and human TRBV28, respectively. These are human TRBV7-3 and human TRBV5-1, respectively. They are human TRBV7-3 and human TRBV6-5, respectively. These are human TRBV7-3 and human TRBV10-1, respectively. These are human TRBV7-3 and human TRBV10-2, respectively. They are human TRBV7-3 and human TRBV10-3, respectively. They are human TRBV7-3 and human TRBV7-2, respectively. These are human TRBV7-3 and human TRBV19, respectively. These are human TRBV7-3 and human TRBV20-1, respectively. These are human TRBV7-3 and human TRBV28, respectively. These are human TRBV19 and human TRBV5-1, respectively. These are human TRBV19 and human TRBV6-5, respectively. These are human TRBV19 and human TRBV10-1, respectively. These are human TRBV19 and human TRBV10-2, respectively. These are human TRBV19 and human TRBV10-3, respectively. These are human TRBV19 and human TRBV7-2, respectively. These are human TRBV19 and human TRBV7-3, respectively. These are human TRBV19 and human TRBV20-1, respectively. These are human TRBV19 and human TRBV28, respectively. These are human TRBV20-1 and human TRBV5-1, respectively. These are human TRBV20-1 and human TRBV6-5, respectively. These are human TRBV20-1 and human TRBV10-1, respectively. They are human TRBV20-1 and human TRBV10-2, respectively. These are human TRBV20-1 and human TRBV10-3, respectively. These are human TRBV20-1 and human TRBV7-2, respectively. These are human TRBV20-1 and human TRBV7-3, respectively. These are human TRBV20-1 and human TRBV19, respectively. These are human TRBV20-1 and human TRBV28, respectively. These are human TRBV28 and human TRBV5-1, respectively. These are human TRBV28 and human TRBV6-5, respectively. These are human TRBV28 and human TRBV10-1, respectively. These are human TRBV28 and human TRBV10-2, respectively. These are human TRBV28 and human TRBV10-3, respectively. These are human TRBV28 and human TRBV7-2, respectively. These are human TRBV28 and human TRBV7-3, respectively. These are human TRBV28 and human TRBV19, respectively; or They are human TRBV28 and human TRBV20-1, respectively.

337. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30, wherein the first target molecule and the second target molecule are different.

338. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: They are human TRAV12 and human TRAV12, respectively. They are human TRAV12 and human TRAV13, respectively. They are human TRAV12 and human TRAV19, respectively. They are human TRAV12 and human TRAV21, respectively. These are human TRAV12 and human TRAV30, respectively. They are human TRAV13 and human TRAV12, respectively. They are human TRAV13 and human TRAV13, respectively. They are human TRAV13 and human TRAV19, respectively. They are human TRAV13 and human TRAV21, respectively. They are TRAV13 and TRAV30, respectively. They are human TRAV19 and human TRAV12, respectively. They are human TRAV19 and human TRAV13, respectively. They are human TRAV19 and human TRAV19, respectively. They are human TRAV19 and human TRAV21, respectively. They are human TRAV19 and human TRAV30, respectively. They are human TRAV21 and human TRAV12, respectively. They are human TRAV21 and human TRAV13, respectively. They are human TRAV21 and human TRAV19, respectively. They are human TRAV21 and human TRAV21, respectively. They are human TRAV21 and human TRAV30, respectively. These are TRAV30 and TRAV12 for humans, respectively. They are TRAV30 and TRAV13 for humans, respectively. These are TRAV30 and TRAV19 for humans, respectively. These are TRAV30 and TRAV21 for humans, respectively; or They are TRAV30 and TRAV30 respectively.

339. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30, wherein the first target molecule and the second target molecule are different.

340. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRAV12-2 and human TRAV13-1, respectively. These are human TRAV12-2 and human TRAV19, respectively. These are human TRAV12-2 and human TRAV21, respectively. These are human TRAV12-2 and human TRAV30, respectively. They are human TRAV13-1 and human TRAV12-2, respectively. These are human TRAV13-1 and human TRAV19, respectively. These are human TRAV13-1 and human TRAV21, respectively. These are human TRAV13-1 and human TRAV30, respectively. They are human TRAV19 and human TRAV12-2, respectively. They are human TRAV19 and human TRAV13-1, respectively. They are human TRAV19 and human TRAV21, respectively. They are human TRAV19 and human TRAV30, respectively. These are human TRAV21 and human TRAV12-2, respectively. These are human TRAV21 and human TRAV13-1, respectively. They are human TRAV21 and human TRAV19, respectively. They are human TRAV21 and human TRAV30, respectively. These are human TRAV30 and human TRAV12-2, respectively. These are human TRAV30 and human TRAV13-1, respectively. These are TRAV30 and TRAV19 for individuals, respectively; or They are TRAV30 and TRAV21, respectively.

341. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

342. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRBV5 and human TRAV12, respectively. These are human TRBV5 and human TRAV13, respectively. These are human TRBV5 and human TRAV19, respectively. These are human TRBV5 and human TRAV21, respectively. These are human TRBV5 and human TRAV30, respectively. These are human TRBV6 and human TRAV12, respectively. These are human TRBV6 and human TRAV13, respectively. These are human TRBV6 and human TRAV19, respectively. These are human TRBV6 and human TRAV21, respectively. These are human TRBV6 and human TRAV30, respectively. These are human TRBV10 and human TRAV12, respectively. These are human TRBV10 and human TRAV13, respectively. These are human TRBV10 and human TRAV19, respectively. These are human TRBV10 and human TRAV21, respectively. These are human TRBV10 and human TRAV30, respectively. These are human TRBV7 and human TRAV12, respectively. These are human TRBV7 and human TRAV13, respectively. These are human TRBV7 and human TRAV19, respectively. These are human TRBV7 and human TRAV21, respectively. These are human TRBV7 and human TRAV30, respectively. These are human TRBV19 and human TRAV12, respectively. These are human TRBV19 and human TRAV13, respectively. These are human TRBV19 and human TRAV19, respectively. These are human TRBV19 and human TRAV21, respectively. These are human TRBV19 and human TRAV30, respectively. These are human TRBV20 and human TRAV12, respectively. These are human TRBV20 and human TRAV13, respectively. These are human TRBV20 and human TRAV19, respectively. These are human TRBV20 and human TRAV21, respectively. These are human TRBV20 and human TRAV30, respectively. These are human TRBV28 and human TRAV12, respectively. These are human TRBV28 and human TRAV13, respectively. These are human TRBV28 and human TRAV19, respectively. These are human TRBV28 and human TRAV21, respectively; or They are human TRBV28 and human TRAV30, respectively.

343. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

344. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRBV5 and human TRAV12-2, respectively. These are human TRBV5 and human TRAV13-1, respectively. These are human TRBV5 and human TRAV19, respectively. These are human TRBV5 and human TRAV21, respectively. These are human TRBV5 and human TRAV30, respectively. These are human TRBV6 and human TRAV12-2, respectively. These are human TRBV6 and human TRAV13-1, respectively. These are human TRBV6 and human TRAV19, respectively. These are human TRBV6 and human TRAV21, respectively. These are human TRBV6 and human TRAV30, respectively. These are human TRBV10 and human TRAV12-2, respectively. These are human TRBV10 and human TRAV13-1, respectively. These are human TRBV10 and human TRAV19, respectively. These are human TRBV10 and human TRAV21, respectively. These are human TRBV10 and human TRAV30, respectively. These are human TRBV7 and human TRAV12-2, respectively. These are human TRBV7 and human TRAV13-1, respectively. These are human TRBV7 and human TRAV19, respectively. These are human TRBV7 and human TRAV21, respectively. These are human TRBV7 and human TRAV30, respectively. These are human TRBV19 and human TRAV12-2, respectively. These are human TRBV19 and human TRAV13-1, respectively. These are human TRBV19 and human TRAV19, respectively. These are human TRBV19 and human TRAV21, respectively. These are human TRBV19 and human TRAV30, respectively. These are human TRBV20 and human TRAV12-2, respectively. These are human TRBV20 and human TRAV13-1, respectively. These are human TRBV20 and human TRAV19, respectively. These are human TRBV20 and human TRAV21, respectively. These are human TRBV20 and human TRAV30, respectively. These are human TRBV28 and human TRAV12-2, respectively. These are human TRBV28 and human TRAV13-1, respectively. These are human TRBV28 and human TRAV19, respectively. These are human TRBV28 and human TRAV21, respectively; or They are human TRBV28 and human TRAV30, respectively.

345. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28, and the second target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30.

346. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRBV5-1 and human TRAV12, respectively. These are human TRBV5-1 and human TRAV13, respectively. These are human TRBV5-1 and human TRAV19, respectively. These are human TRBV5-1 and human TRAV21, respectively. These are human TRBV5-1 and human TRAV30, respectively. These are human TRBV6-5 and human TRAV12, respectively. These are human TRBV6-5 and human TRAV13, respectively. These are human TRBV6-5 and human TRAV19, respectively. These are human TRBV6-5 and human TRAV21, respectively. These are human TRBV6-5 and human TRAV30, respectively. These are human TRBV10-1 and human TRAV12, respectively. These are human TRBV10-1 and human TRAV13, respectively. These are human TRBV10-1 and human TRAV19, respectively. These are human TRBV10-1 and human TRAV21, respectively. These are human TRBV10-1 and human TRAV30, respectively. These are human TRBV10-2 and human TRAV12, respectively. These are human TRBV10-2 and human TRAV13, respectively. These are human TRBV10-2 and human TRAV19, respectively. These are human TRBV10-2 and human TRAV21, respectively. These are human TRBV10-2 and human TRAV30, respectively. These are human TRBV10-3 and human TRAV12, respectively. These are human TRBV10-3 and human TRAV13, respectively. These are human TRBV10-3 and human TRAV19, respectively. These are human TRBV10-3 and human TRAV21, respectively. These are human TRBV10-3 and human TRAV30, respectively. These are human TRBV7-2 and human TRAV12, respectively. These are human TRBV7-2 and human TRAV13, respectively. These are human TRBV7-2 and human TRAV19, respectively. These are human TRBV7-2 and human TRAV21, respectively. These are human TRBV7-2 and human TRAV30, respectively. These are human TRBV7-3 and human TRAV12, respectively. These are human TRBV7-3 and human TRAV13, respectively. These are human TRBV7-3 and human TRAV19, respectively. These are human TRBV7-3 and human TRAV21, respectively. These are human TRBV7-3 and human TRAV30, respectively. These are human TRBV19 and human TRAV12, respectively. These are human TRBV19 and human TRAV13, respectively. These are human TRBV19 and human TRAV19, respectively. These are human TRBV19 and human TRAV21, respectively. These are human TRBV19 and human TRAV30, respectively. These are human TRBV20-1 and human TRAV12, respectively. These are human TRBV20-1 and human TRAV13, respectively. These are human TRBV20-1 and human TRAV19, respectively. These are human TRBV20-1 and human TRAV21, respectively. These are human TRBV20-1 and human TRAV30, respectively. These are human TRBV28 and human TRAV12, respectively. These are human TRBV28 and human TRAV13, respectively. These are human TRBV28 and human TRAV19, respectively. These are human TRBV28 and human TRAV21, respectively; or They are human TRBV28 and human TRAV30, respectively.

347. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28, and the second target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30.

348. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRBV5-1 and human TRAV12-2, respectively. These are human TRBV5-1 and human TRAV13-1, respectively. These are human TRBV5-1 and human TRAV19, respectively. These are human TRBV5-1 and human TRAV21, respectively. These are human TRBV5-1 and human TRAV30, respectively. These are human TRBV6-5 and human TRAV12-2, respectively. These are human TRBV6-5 and human TRAV13-1, respectively. These are human TRBV6-5 and human TRAV19, respectively. These are human TRBV6-5 and human TRAV21, respectively. These are human TRBV6-5 and human TRAV30, respectively. These are human TRBV10-1 and human TRAV12-2, respectively. These are human TRBV10-1 and human TRAV13-1, respectively. These are human TRBV10-1 and human TRAV19, respectively. These are human TRBV10-1 and human TRAV21, respectively. These are human TRBV10-1 and human TRAV30, respectively. These are human TRBV10-2 and human TRAV12-2, respectively. These are human TRBV10-2 and human TRAV13-1, respectively. These are human TRBV10-2 and human TRAV19, respectively. These are human TRBV10-2 and human TRAV21, respectively. These are human TRBV10-2 and human TRAV30, respectively. These are human TRBV10-3 and human TRAV12-2, respectively. These are human TRBV10-3 and human TRAV13-1, respectively. These are human TRBV10-3 and human TRAV19, respectively. These are human TRBV10-3 and human TRAV21, respectively. These are human TRBV10-3 and human TRAV30, respectively. These are human TRBV7-2 and human TRAV12-2, respectively. These are human TRBV7-2 and human TRAV13-1, respectively. These are human TRBV7-2 and human TRAV19, respectively. These are human TRBV7-2 and human TRAV21, respectively. These are human TRBV7-2 and human TRAV30, respectively. These are human TRBV7-3 and human TRAV12-2, respectively. These are human TRBV7-3 and human TRAV13-1, respectively. These are human TRBV7-3 and human TRAV19, respectively. These are human TRBV7-3 and human TRAV21, respectively. These are human TRBV7-3 and human TRAV30, respectively. These are human TRBV19 and human TRAV12-2, respectively. These are human TRBV19 and human TRAV13-1, respectively. These are human TRBV19 and human TRAV19, respectively. These are human TRBV19 and human TRAV21, respectively. These are human TRBV19 and human TRAV30, respectively. These are human TRBV20-1 and human TRAV12-2, respectively. These are human TRBV20-1 and human TRAV13-1, respectively. These are human TRBV20-1 and human TRAV19, respectively. These are human TRBV20-1 and human TRAV21, respectively. These are human TRBV20-1 and human TRAV30, respectively. These are human TRBV28 and human TRAV12-2, respectively. These are human TRBV28 and human TRAV13-1, respectively. These are human TRBV28 and human TRAV19, respectively. These are human TRBV28 and human TRAV21, respectively; or They are human TRBV28 and human TRAV30, respectively.

349. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28.

350. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRAV12 and human TRBV5, respectively. These are human TRAV12 and human TRBV6, respectively. These are human TRAV12 and human TRBV10, respectively. These are human TRAV12 and human TRBV7, respectively. These are human TRAV12 and human TRBV19, respectively. These are human TRAV12 and human TRBV20, respectively. These are human TRAV12 and human TRBV28, respectively. These are human TRAV13 and human TRBV5, respectively. These are human TRAV13 and human TRBV6, respectively. These are human TRAV13 and human TRBV10, respectively. These are human TRAV13 and human TRBV7, respectively. These are human TRAV13 and human TRBV19, respectively. These are human TRAV13 and human TRBV20, respectively. These are human TRAV13 and human TRBV28, respectively. These are human TRAV19 and human TRBV5, respectively. These are human TRAV19 and human TRBV6, respectively. These are human TRAV19 and human TRBV10, respectively. These are human TRAV19 and human TRBV7, respectively. These are human TRAV19 and human TRBV19, respectively. These are human TRAV19 and human TRBV20, respectively. These are human TRAV19 and human TRBV28, respectively. These are human TRAV21 and human TRBV5, respectively. These are human TRAV21 and human TRBV6, respectively. These are human TRAV21 and human TRBV10, respectively. These are human TRAV21 and human TRBV7, respectively. These are human TRAV21 and human TRBV19, respectively. These are human TRAV21 and human TRBV20, respectively. These are human TRAV21 and human TRBV28, respectively. These are human TRAV30 and human TRBV5, respectively. These are human TRAV30 and human TRBV6, respectively. These are human TRAV30 and human TRBV10, respectively. These are human TRAV30 and human TRBV7, respectively. These are human TRAV30 and human TRBV19, respectively. These are human TRAV30 and human TRBV20, respectively; or They are human TRAV30 and human TRBV28, respectively.

351. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRBV5, human TRBV6, human TRBV10, human TRBV7, human TRBV19, human TRBV20 or human TRBV28.

352. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRAV12-2 and human TRBV5, respectively. These are human TRAV12-2 and human TRBV6, respectively. These are human TRAV12-2 and human TRBV10, respectively. These are human TRAV12-2 and human TRBV7, respectively. These are human TRAV12-2 and human TRBV19, respectively. These are human TRAV12-2 and human TRBV20, respectively. These are human TRAV12-2 and human TRBV28, respectively. These are human TRAV13-1 and human TRBV5, respectively. These are human TRAV13-1 and human TRBV6, respectively. These are human TRAV13-1 and human TRBV10, respectively. These are human TRAV13-1 and human TRBV7, respectively. These are human TRAV13-1 and human TRBV19, respectively. These are human TRAV13-1 and human TRBV20, respectively. These are human TRAV13-1 and human TRBV28, respectively. These are human TRAV19 and human TRBV5, respectively. These are human TRAV19 and human TRBV6, respectively. These are human TRAV19 and human TRBV10, respectively. These are human TRAV19 and human TRBV7, respectively. These are human TRAV19 and human TRBV19, respectively. These are human TRAV19 and human TRBV20, respectively. These are human TRAV19 and human TRBV28, respectively. These are human TRAV21 and human TRBV5, respectively. These are human TRAV21 and human TRBV6, respectively. These are human TRAV21 and human TRBV10, respectively. These are human TRAV21 and human TRBV7, respectively. These are human TRAV21 and human TRBV19, respectively. These are human TRAV21 and human TRBV20, respectively. These are human TRAV21 and human TRBV28, respectively. These are human TRAV30 and human TRBV5, respectively. These are human TRAV30 and human TRBV6, respectively. These are human TRAV30 and human TRBV10, respectively. These are human TRAV30 and human TRBV7, respectively. These are human TRAV30 and human TRBV19, respectively. These are human TRAV30 and human TRBV20, respectively; or They are human TRAV30 and human TRBV28, respectively.

353. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRAV12, human TRAV13, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV10-1, human TRBV10-2, human TRBV10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28.

354. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRAV12 and human TRBV5-1, respectively. These are human TRAV12 and human TRBV6-5, respectively. These are human TRAV12 and human TRBV10-1, respectively. These are human TRAV12 and human TRBV10-2, respectively. These are human TRAV12 and human TRBV10-3, respectively. These are human TRAV12 and human TRBV7-2, respectively. These are human TRAV12 and human TRBV7-3, respectively. These are human TRAV12 and human TRBV19, respectively. These are human TRAV12 and human TRBV20-1, respectively. These are human TRAV12 and human TRBV28, respectively. These are human TRAV13 and human TRBV5-1, respectively. These are human TRAV13 and human TRBV6-5, respectively. These are human TRAV13 and human TRBV10-1, respectively. These are human TRAV13 and human TRBV10-2, respectively. These are human TRAV13 and human TRBV10-3, respectively. These are human TRAV13 and human TRBV7-2, respectively. These are human TRAV13 and human TRBV7-3, respectively. These are human TRAV13 and human TRBV19, respectively. These are human TRAV13 and human TRBV20-1, respectively. These are human TRAV13 and human TRBV28, respectively. These are human TRAV19 and human TRBV5-1, respectively. These are human TRAV19 and human TRBV6-5, respectively. These are human TRAV19 and human TRBV10-1, respectively. These are human TRAV19 and human TRBV10-2, respectively. These are human TRAV19 and human TRBV10-3, respectively. These are human TRAV19 and human TRBV7-2, respectively. These are human TRAV19 and human TRBV7-3, respectively. These are human TRAV19 and human TRBV19, respectively. These are human TRAV19 and human TRBV20-1, respectively. These are human TRAV19 and human TRBV28, respectively. These are human TRAV21 and human TRBV5-1, respectively. These are human TRAV21 and human TRBV6-5, respectively. These are human TRAV21 and human TRBV10-1, respectively. These are human TRAV21 and human TRBV10-2, respectively. These are human TRAV21 and human TRBV10-3, respectively. These are human TRAV21 and human TRBV7-2, respectively. These are human TRAV21 and human TRBV7-3, respectively. These are human TRAV21 and human TRBV19, respectively. These are human TRAV21 and human TRBV20-1, respectively. These are human TRAV21 and human TRBV28, respectively. These are human TRAV30 and human TRBV5-1, respectively. These are human TRAV30 and human TRBV6-5, respectively. These are human TRAV30 and human TRBV10-1, respectively. These are human TRAV30 and human TRBV10-2, respectively. These are human TRAV30 and human TRBV10-3, respectively. These are human TRAV30 and human TRBV7-2, respectively. These are human TRAV30 and human TRBV7-3, respectively. These are human TRAV30 and human TRBV19, respectively. These are human TRAV30 and human TRBV20-1, respectively; or They are human TRAV30 and human TRBV28, respectively.

355. The combination therapy according to any one of the preceding claims, wherein the first target molecule is human TRAV12-2, human TRAV13-1, human TRAV19, human TRAV21 or human TRAV30, and the second target molecule is human TRBV5-1, human TRBV6-5, human TRBV 10-1, human TRBV 10-2, human TRBV 10-3, human TRBV7-2, human TRBV7-3, human TRBV19, human TRBV20-1 or human TRBV28.

356. The combination therapy according to any one of the preceding claims, wherein the first target molecule and the second target molecule: These are human TRAV12-2 and human TRBV5-1, respectively. These are human TRAV12-2 and human TRBV6-5, respectively. These are human TRAV12-2 and human TRBV10-1, respectively. These are human TRAV12-2 and human TRBV10-2, respectively. These are human TRAV12-2 and human TRBV10-3, respectively. These are human TRAV12-2 and human TRBV7-2, respectively. These are human TRAV12-2 and human TRBV7-3, respectively. These are human TRAV12-2 and human TRBV19, respectively. These are human TRAV12-2 and human TRBV20-1, respectively. These are human TRAV12-2 and human TRBV28, respectively. These are human TRAV13-1 and human TRBV5-1, respectively. These are human TRAV13-1 and human TRBV6-5, respectively. These are human TRAV13-1 and human TRBV10-1, respectively. These are human TRAV13-1 and human TRBV10-2, respectively. These are human TRAV13-1 and human TRBV10-3, respectively. These are human TRAV13-1 and human TRBV7-2, respectively. These are human TRAV13-1 and human TRBV7-3, respectively. These are human TRAV13-1 and human TRBV19, respectively. These are human TRAV13-1 and human TRBV20-1, respectively. These are human TRAV13-1 and human TRBV28, respectively. These are human TRAV19 and human TRBV5-1, respectively. These are human TRAV19 and human TRBV6-5, respectively. These are human TRAV19 and human TRBV10-1, respectively. These are human TRAV19 and human TRBV10-2, respectively. These are human TRAV19 and human TRBV10-3, respectively. These are human TRAV19 and human TRBV7-2, respectively. These are human TRAV19 and human TRBV7-3, respectively. These are human TRAV19 and human TRBV19, respectively. These are human TRAV19 and human TRBV20-1, respectively. These are human TRAV19 and human TRBV28, respectively. These are human TRAV21 and human TRBV5-1, respectively. These are human TRAV21 and human TRBV6-5, respectively. These are human TRAV21 and human TRBV10-1, respectively. These are human TRAV21 and human TRBV10-2, respectively. These are human TRAV21 and human TRBV10-3, respectively. These are human TRAV21 and human TRBV7-2, respectively. These are human TRAV21 and human TRBV7-3, respectively. These are human TRAV21 and human TRBV19, respectively. These are human TRAV21 and human TRBV20-1, respectively. These are human TRAV21 and human TRBV28, respectively. These are human TRAV30 and human TRBV5-1, respectively. These are human TRAV30 and human TRBV6-5, respectively. These are human TRAV30 and human TRBV10-1, respectively. These are human TRAV30 and human TRBV10-2, respectively. These are human TRAV30 and human TRBV10-3, respectively. These are human TRAV30 and human TRBV7-2, respectively. These are human TRAV30 and human TRBV7-3, respectively. These are human TRAV30 and human TRBV19, respectively. These are human TRAV30 and human TRBV20-1, respectively; or They are human TRAV30 and human TRBV28, respectively.

357. The combination therapy according to any one of claims 263 to 356, wherein the first conjugate comprises a whole antibody or an antigen-binding fragment thereof, a bivalent antibody, a bispecific antibody, or a biparatopic antibody.

358. The combination therapy according to any one of claims 263 to 357, wherein the second conjugate comprises a whole antibody or an antigen-binding fragment thereof, a bivalent antibody, a bispecific antibody, or a biparatopic antibody.

359. The combination therapy according to claim 357 or 358, wherein the antigen-binding fragment is Fab, F(ab')2, Fv, single-chain Fv (scFv), single-domain antibody, double antibody (dAb), single-domain antibody, or camel antibody.

360. The combination therapy according to any one of claims 263 to 359, wherein the first conjugate comprises a heavy chain variable region (VH), the VH comprising a heavy chain complementarity-determining region 3 (HC CDR3), the HC CDR3 comprising a sequence of SEQ ID NO: 3343, SEQ ID NO: 3323, SEQ ID NO: 3353, SEQ ID NO: 1187, SEQ ID NO: 3373, SEQ ID NO: 3383, SEQ ID NO: 3393, SEQ ID NO: 3403 or SEQ ID NO: 3413.

361. The combination therapy according to any one of claims 263 to 360, wherein the first conjugate comprises VH, the VH comprising heavy chain complementarity-determining region 1 (HC CDR1), the HC CDR1 comprising the sequence of SEQ ID NO: 3341, SEQ ID NO: 3321, SEQ ID NO: 3351, SEQ ID NO: 1190, SEQ ID NO: 3371, SEQ ID NO: 3381, SEQ ID NO: 3391, SEQ ID NO: 3401, SEQ ID NO: 3411, SEQ ID NO: 3421 or SEQ ID NO: 3702.

362. The combination therapy according to any one of claims 263 to 361, wherein the first conjugate comprises VH, the VH comprising heavy chain complementarity-determining region 2 (HC CDR2), the HC CDR2 comprising the sequence of SEQ ID NO: 3342, SEQ ID NO: 3322, SEQ ID NO: 3352, SEQ ID NO: 1186, SEQ ID NO: 3372, SEQ ID NO: 3382, SEQ ID NO: 3392, SEQ ID NO: 3402 or SEQ ID NO: 3412.

363. The combination therapy according to any one of claims 263 to 362, wherein the first combination comprises VH, the VH comprising: (i) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3341, HC CDR2 contains the sequence of SEQ ID NO: 3342 and HC CDR3 contains the sequence of SEQ ID NO: 3343; (ii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3321, HC CDR2 contains the sequence of SEQ ID NO: 3322 and HC CDR3 contains the sequence of SEQ ID NO: 3323; (iii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3351, HC CDR2 contains the sequence of SEQ ID NO: 3352 and HC CDR3 contains the sequence of SEQ ID NO: 3353; (iv) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 1190, HC CDR2 contains the sequence of SEQ ID NO: 1186 and HC CDR3 contains the sequence of SEQ ID NO: 1187; (v) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3371, HC CDR2 contains the sequence of SEQ ID NO: 3372 and HC CDR3 contains the sequence of SEQ ID NO: 3373; (vi) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3381, HC CDR2 contains the sequence of SEQ ID NO: 3382 and HC CDR3 contains the sequence of SEQ ID NO: 3383; (vii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3391, HC CDR2 contains the sequence of SEQ ID NO: 3392 and HC CDR3 contains the sequence of SEQ ID NO: 3393; (viii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3401, HC CDR2 contains the sequence of SEQ ID NO: 3402 and HC CDR3 contains the sequence of SEQ ID NO: 3403; (ix) HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; or (x) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3411, HC CDR2 contains the sequence of SEQ ID NO: 3412 and HC CDR3 contains the sequence of SEQ ID NO: 3413.

364. The combination therapy according to any one of claims 263 to 363, wherein the first conjugate comprises a light chain variable region (VL), the VL comprising a light chain complementarity-determining region 3 (LC CDR3), the LC CDR3 comprising a sequence of SEQ ID NO: 3346, SEQ ID NO: 3326, SEQ ID NO: 3356, SEQ ID NO: 1193, SEQ ID NO: 3376, SEQ ID NO: 3386, SEQ ID NO: 3396, SEQ ID NO: 3406 or SEQ ID NO: 3416.

365. The combination therapy according to any one of claims 263 to 364, wherein the first conjugate comprises a VL, the VL comprising a light chain complementarity-determining region 1 (LC CDR1), the LC CDR1 comprising a sequence of SEQ ID NO: 3344, SEQ ID NO: 3324, SEQ ID NO: 3354, SEQ ID NO: 1191, SEQ ID NO: 3374, SEQ ID NO: 3384, SEQ ID NO: 3394, SEQ ID NO: 3404 or SEQ ID NO: 3414.

366. The combination therapy according to any one of claims 263 to 365, wherein the first conjugate comprises a VL, the VL comprising a light chain complementarity-determining region 2 (LC CDR2), the LC CDR2 comprising a sequence of SEQ ID NO: 3345, SEQ ID NO: 3325, SEQ ID NO: 3355, SEQ ID NO: 1192, SEQ ID NO: 3375, SEQ ID NO: 3395, SEQ ID NO: 3405, SEQ ID NO: 3415 or SEQ ID NO: 3443.

367. The combination therapy according to any one of claims 263 to 366, wherein the first combination comprises VL, the VL comprising: (i) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3344, LC CDR2 contains the sequence of SEQ ID NO: 3345 and LC CDR3 contains the sequence of SEQ ID NO: 3346; (ii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3324, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3326; (iii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3355, and LC CDR3 contains the sequence of SEQ ID NO: 3356; (iv) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 1191, LC CDR2 contains the sequence of SEQ ID NO: 1192 and LC CDR3 contains the sequence of SEQ ID NO: 1193; (v) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3374, LC CDR2 contains the sequence of SEQ ID NO: 3375, and LC CDR3 contains the sequence of SEQ ID NO: 3376; (vi) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3384, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3386; (vii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3394, LC CDR2 contains the sequence of SEQ ID NO: 3395, and LC CDR3 contains the sequence of SEQ ID NO: 3396; (viii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3404, LC CDR2 contains the sequence of SEQ ID NO: 3405 and LC CDR3 contains the sequence of SEQ ID NO: 3406; (ix) LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3414, LC CDR2 contains the sequence of SEQ ID NO: 3415, and LC CDR3 contains the sequence of SEQ ID NO: 3416; or (x) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3443 and LC CDR3 contains the sequence of SEQ ID NO: 3356.

368. The combination therapy according to any one of claims 263 to 367, wherein the first combination comprises: (i) VH, which comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3341, HC CDR2 comprises the sequence of SEQ ID NO: 3342, and HC CDR3 comprises the sequence of SEQ ID NO: 3343; and VL, which comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3344, LC CDR2 comprises the sequence of SEQ ID NO: 3345, and LC CDR3 comprises the sequence of SEQ ID NO: 3346; (ii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3321, HC CDR2 comprises the sequence of SEQ ID NO: 3322, and HC CDR3 comprises the sequence of SEQ ID NO: 3323; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3324, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3326; (iii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, LC CDR2 comprises the sequence of SEQ ID NO: 3355, and LC CDR3 comprises the sequence of SEQ ID NO: 3356; (iv) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 1190, HC CDR2 comprises the sequence of SEQ ID NO: 1186, and HC CDR3 comprises the sequence of SEQ ID NO: 1187; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 1191, LC CDR2 comprises the sequence of SEQ ID NO: 1192, and LC CDR3 comprises the sequence of SEQ ID NO: 1193; (v) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3371, HC CDR2 comprises the sequence of SEQ ID NO: 3372, and HC CDR3 comprises the sequence of SEQ ID NO: 3373; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3374, LC CDR2 comprises the sequence of SEQ ID NO: 3375, and LC CDR3 comprises the sequence of SEQ ID NO: 3376; (vi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3381, HC CDR2 comprises the sequence of SEQ ID NO: 3382, and HC CDR3 comprises the sequence of SEQ ID NO: 3383; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3384, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3386; (vii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3391, HC CDR2 comprises the sequence of SEQ ID NO: 3392, and HC CDR3 comprises the sequence of SEQ ID NO: 3393; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3394, LC CDR2 comprises the sequence of SEQ ID NO: 3395, and LC CDR3 comprises the sequence of SEQ ID NO: 3396; (viii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3401, HC CDR2 comprises the sequence of SEQ ID NO: 3402, and HC CDR3 comprises the sequence of SEQ ID NO: 3403; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3404, LC CDR2 comprises the sequence of SEQ ID NO: 3405, and LC CDR3 comprises the sequence of SEQ ID NO: 3406; (ix) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3411, HC CDR2 comprises the sequence of SEQ ID NO: 3412, and HC CDR3 comprises the sequence of SEQ ID NO: 3413; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3414, LC CDR2 comprises the sequence of SEQ ID NO: 3415, and LC CDR3 comprises the sequence of SEQ ID NO: 3416; (x) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LCCDR3, wherein LC CDR1 comprises a sequence of SEQ ID NO: 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3355, and wherein LC CDR3 comprises a sequence of SEQ ID NO: 3356; or (xi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LCCDR3, wherein LC CDR1 comprises a sequence of 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3443, and wherein LCCDR3 comprises a sequence of SEQ ID NO: 3356.

369. The combination therapy according to any one of claims 263 to 368, wherein the first combination comprises a VH, the VH comprising a sequence having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

370. The combination therapy according to any one of claims 263 to 369, wherein the first combination comprises VH, the VH comprising any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470.

371. The combination therapy according to any one of claims 263 to 370, wherein the first combination comprises a VL, the VL comprising a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

372. The combination therapy according to any one of claims 263 to 371, wherein the first combination comprises VL, the VL comprising any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

373. The combination therapy according to any one of claims 263 to 372, wherein the first combination comprises: (i) VH, wherein VH comprises a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and (ii) VL, which comprises sequences having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

374. The combination therapy according to any one of claims 263 to 373, wherein the first combination comprises: (i) VH, wherein VH comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and (ii) VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

375. The combination therapy according to any one of claims 263 to 374, wherein the first combination comprises: (i) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3445, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3446; (ii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3448, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3449; (iii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3450, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3451; (iv) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1349; (v) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1196, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1195; (vi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3455, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3456; (vii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3457, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3458; (viii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3463, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3464; (ix) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3465, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3466; (x) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3470, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3471; (xi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3475; or (xii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3476.

376. The combination therapy according to any one of claims 263 to 375, wherein the first combination comprises: (i) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3445 and VL contains the sequence of SEQ ID NO: 3446; (ii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3448 and VL comprises the sequence of SEQ ID NO: 3449; (iii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3450 and VL comprises the sequence of SEQ ID NO: 3451; (iv) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346 and VL comprises the sequence of SEQ ID NO: 1349; (v) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1196 and VL contains the sequence of SEQ ID NO: 1195; (vi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3455 and VL comprises the sequence of SEQ ID NO: 3456; (vii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3457 and VL contains the sequence of SEQ ID NO: 3458; (viii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3463 and VL comprises the sequence of SEQ ID NO: 3464; (ix) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3465 and VL contains the sequence of SEQ ID NO: 3466; (x) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3470 and VL contains the sequence of SEQ ID NO: 3471; (xi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346, and VL comprises the sequence of SEQ ID NO: 3475; or (xii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1346 and VL contains the sequence of SEQ ID NO: 3476.

377. The combination therapy according to any one of claims 263 to 376, wherein the second conjugate comprises a heavy chain variable region (VH), the VH comprising a heavy chain complementarity-determining region 3 (HC CDR3), the HC CDR3 comprising a sequence of SEQ ID NO: 3343, SEQ ID NO: 3323, SEQ ID NO: 3353, SEQ ID NO: 1187, SEQ ID NO: 3373, SEQ ID NO: 3383, SEQ ID NO: 3393, SEQ ID NO: 3403 or SEQ ID NO: 3413.

378. The combination therapy according to any one of claims 263 to 377, wherein the second conjugate comprises VH, the VH comprising heavy chain complementarity-determining region 1 (HC CDR1), the HC CDR1 comprising the sequence of SEQ ID NO: 3341, SEQ ID NO: 3321, SEQ ID NO: 3351, SEQ ID NO: 1190, SEQ ID NO: 3371, SEQ ID NO: 3381, SEQ ID NO: 3391, SEQ ID NO: 3401, SEQ ID NO: 3411, SEQ ID NO: 3421 or SEQ ID NO: 3702.

379. The combination therapy according to any one of claims 263 to 378, wherein the second conjugate comprises VH, the VH comprising heavy chain complementarity-determining region 2 (HC CDR2), the HC CDR2 comprising the sequence of SEQ ID NO: 3342, SEQ ID NO: 3322, SEQ ID NO: 3352, SEQ ID NO: 1186, SEQ ID NO: 3372, SEQ ID NO: 3382, SEQ ID NO: 3392, SEQ ID NO: 3402 or SEQ ID NO: 3412.

380. The combination therapy according to any one of claims 263 to 379, wherein the second combination comprises VH, the VH comprising: (i) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3341, HC CDR2 contains the sequence of SEQ ID NO: 3342 and HC CDR3 contains the sequence of SEQ ID NO: 3343; (ii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3321, HC CDR2 contains the sequence of SEQ ID NO: 3322 and HC CDR3 contains the sequence of SEQ ID NO: 3323; (iii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3351, HC CDR2 contains the sequence of SEQ ID NO: 3352 and HC CDR3 contains the sequence of SEQ ID NO: 3353; (iv) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 1190, HC CDR2 contains the sequence of SEQ ID NO: 1186 and HC CDR3 contains the sequence of SEQ ID NO: 1187; (v) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3371, HC CDR2 contains the sequence of SEQ ID NO: 3372 and HC CDR3 contains the sequence of SEQ ID NO: 3373; (vi) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3381, HC CDR2 contains the sequence of SEQ ID NO: 3382 and HC CDR3 contains the sequence of SEQ ID NO: 3383; (vii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3391, HC CDR2 contains the sequence of SEQ ID NO: 3392 and HC CDR3 contains the sequence of SEQ ID NO: 3393; (viii) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3401, HC CDR2 contains the sequence of SEQ ID NO: 3402 and HC CDR3 contains the sequence of SEQ ID NO: 3403; (ix) HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; or (x) HC CDR1, HC CDR2 and HC CDR3, wherein HC CDR1 contains the sequence of SEQ ID NO: 3411, HC CDR2 contains the sequence of SEQ ID NO: 3412 and HC CDR3 contains the sequence of SEQ ID NO: 3413.

381. The combination therapy according to any one of claims 263 to 380, wherein the second conjugate comprises a light chain variable region (VL), the VL comprising a light chain complementarity-determining region 3 (LC CDR3), the LC CDR3 comprising a sequence of SEQ ID NO: 3346, SEQ ID NO: 3326, SEQ ID NO: 3356, SEQ ID NO: 1193, SEQ ID NO: 3376, SEQ ID NO: 3386, SEQ ID NO: 3396, SEQ ID NO: 3406 or SEQ ID NO: 3416.

382. The combination therapy according to any one of claims 263 to 381, wherein the second conjugate comprises VL, the VL comprising a light chain complementarity-determining region 1 (LC CDR1), the LC CDR1 comprising a sequence of SEQ ID NO: 3344, SEQ ID NO: 3324, SEQ ID NO: 3354, SEQ ID NO: 1191, SEQ ID NO: 3374, SEQ ID NO: 3384, SEQ ID NO: 3394, SEQ ID NO: 3404 or SEQ ID NO: 3414.

383. The combination therapy according to any one of claims 263 to 382, ​​wherein the second conjugate comprises VL, the VL comprising a light chain complementarity-determining region 2 (LC CDR2), the LC CDR2 comprising a sequence of SEQ ID NO: 3345, SEQ ID NO: 3325, SEQ ID NO: 3355, SEQ ID NO: 1192, SEQ ID NO: 3375, SEQ ID NO: 3395, SEQ ID NO: 3405, SEQ ID NO: 3415 or SEQ ID NO: 3443.

384. The combination therapy according to any one of claims 263 to 383, wherein the second combination comprises VL, the VL comprising: (i) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3344, LC CDR2 contains the sequence of SEQ ID NO: 3345 and LC CDR3 contains the sequence of SEQ ID NO: 3346; (ii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3324, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3326; (iii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3355, and LC CDR3 contains the sequence of SEQ ID NO: 3356; (iv) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 1191, LC CDR2 contains the sequence of SEQ ID NO: 1192 and LC CDR3 contains the sequence of SEQ ID NO: 1193; (v) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3374, LC CDR2 contains the sequence of SEQ ID NO: 3375, and LC CDR3 contains the sequence of SEQ ID NO: 3376; (vi) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3384, LC CDR2 contains the sequence of SEQ ID NO: 3325, and LC CDR3 contains the sequence of SEQ ID NO: 3386; (vii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3394, LC CDR2 contains the sequence of SEQ ID NO: 3395, and LC CDR3 contains the sequence of SEQ ID NO: 3396; (viii) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3404, LC CDR2 contains the sequence of SEQ ID NO: 3405 and LC CDR3 contains the sequence of SEQ ID NO: 3406; (ix) LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3414, LC CDR2 contains the sequence of SEQ ID NO: 3415, and LC CDR3 contains the sequence of SEQ ID NO: 3416; or (x) LC CDR1, LC CDR2 and LC CDR3, wherein LC CDR1 contains the sequence of SEQ ID NO: 3354, LC CDR2 contains the sequence of SEQ ID NO: 3443 and LC CDR3 contains the sequence of SEQ ID NO: 3356.

385. The combination therapy according to any one of claims 263 to 384, wherein the second combination comprises: (i) VH, which comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3341, HC CDR2 comprises the sequence of SEQ ID NO: 3342, and HC CDR3 comprises the sequence of SEQ ID NO: 3343; and VL, which comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3344, LC CDR2 comprises the sequence of SEQ ID NO: 3345, and LC CDR3 comprises the sequence of SEQ ID NO: 3346; (ii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3321, HC CDR2 comprises the sequence of SEQ ID NO: 3322, and HC CDR3 comprises the sequence of SEQ ID NO: 3323; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3324, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3326; (iii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3351, HC CDR2 comprises the sequence of SEQ ID NO: 3352, and HC CDR3 comprises the sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3354, LC CDR2 comprises the sequence of SEQ ID NO: 3355, and LC CDR3 comprises the sequence of SEQ ID NO: 3356; (iv) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 1190, HC CDR2 comprises the sequence of SEQ ID NO: 1186, and HC CDR3 comprises the sequence of SEQ ID NO: 1187; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 1191, LC CDR2 comprises the sequence of SEQ ID NO: 1192, and LC CDR3 comprises the sequence of SEQ ID NO: 1193; (v) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3371, HC CDR2 comprises the sequence of SEQ ID NO: 3372, and HC CDR3 comprises the sequence of SEQ ID NO: 3373; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3374, LC CDR2 comprises the sequence of SEQ ID NO: 3375, and LC CDR3 comprises the sequence of SEQ ID NO: 3376; (vi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3381, HC CDR2 comprises the sequence of SEQ ID NO: 3382, and HC CDR3 comprises the sequence of SEQ ID NO: 3383; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3384, LC CDR2 comprises the sequence of SEQ ID NO: 3325, and LC CDR3 comprises the sequence of SEQ ID NO: 3386; (vii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3391, HC CDR2 comprises the sequence of SEQ ID NO: 3392, and HC CDR3 comprises the sequence of SEQ ID NO: 3393; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3394, LC CDR2 comprises the sequence of SEQ ID NO: 3395, and LC CDR3 comprises the sequence of SEQ ID NO: 3396; (viii) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3401, HC CDR2 comprises the sequence of SEQ ID NO: 3402, and HC CDR3 comprises the sequence of SEQ ID NO: 3403; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3404, LC CDR2 comprises the sequence of SEQ ID NO: 3405, and LC CDR3 comprises the sequence of SEQ ID NO: 3406; (ix) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises the sequence of SEQ ID NO: 3411, HC CDR2 comprises the sequence of SEQ ID NO: 3412, and HC CDR3 comprises the sequence of SEQ ID NO: 3413; and VL, wherein VL comprises LC CDR1, LC CDR2, and LC CDR3, wherein LC CDR1 comprises the sequence of SEQ ID NO: 3414, LC CDR2 comprises the sequence of SEQ ID NO: 3415, and LC CDR3 comprises the sequence of SEQ ID NO: 3416; (x) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LCCDR3, wherein LC CDR1 comprises a sequence of SEQ ID NO: 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3355, and wherein LC CDR3 comprises a sequence of SEQ ID NO: 3356; or (xi) VH, wherein VH comprises HC CDR1, HC CDR2, and HC CDR3, wherein HC CDR1 comprises a sequence of SEQ ID NO: 3351, SEQ ID NO: 3421, or SEQ ID NO: 3702, wherein HC CDR2 comprises a sequence of SEQ ID NO: 3352, and wherein HC CDR3 comprises a sequence of SEQ ID NO: 3353; and VL, wherein VL comprises LC CDR1, LC CDR2, and LCCDR3, wherein LC CDR1 comprises a sequence of 3354, wherein LC CDR2 comprises a sequence of SEQ ID NO: 3443, and wherein LCCDR3 comprises a sequence of SEQ ID NO: 3356.

386. The combination therapy according to any one of claims 263 to 385, wherein the second combination comprises a VH, the VH comprising a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465, and SEQ ID NO: 3470.

387. The combination therapy according to any one of claims 263 to 386, wherein the second combination comprises VH, the VH comprising any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470.

388. The combination therapy according to any one of claims 263 to 387, wherein the second combination comprises a VL, the VL comprising a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475, and SEQ ID NO: 3476.

389. The combination therapy according to any one of claims 263 to 388, wherein the second combination comprises VL, the VL comprising any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

390. The combination therapy according to any one of claims 263 to 389, wherein the second combination comprises: (i) VH, wherein VH comprises a sequence having at least 75% sequence identity with any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and (ii) VL, which comprises sequences having at least 75% sequence identity with any one of the sequences selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

391. The combination therapy according to any one of claims 263 to 390, wherein the second combination comprises: (i) VH, wherein VH comprises any sequence selected from the group consisting of: SEQ ID NO: 3445, SEQ ID NO: 3448, SEQ ID NO: 3450, SEQ ID NO: 1346, SEQ ID NO: 1196, SEQ ID NO: 3455, SEQ ID NO: 3457, SEQ ID NO: 3463, SEQ ID NO: 3465 and SEQ ID NO: 3470; and (ii) VL, which comprises any sequence selected from the group consisting of: SEQ ID NO: 3446, SEQ ID NO: 3449, SEQ ID NO: 3451, SEQ ID NO: 1349, SEQ ID NO: 1195, SEQ ID NO: 3456, SEQ ID NO: 3458, SEQ ID NO: 3464, SEQ ID NO: 3466, SEQ ID NO: 3471, SEQ ID NO: 3475 and SEQ ID NO: 3476.

392. The combination therapy according to any one of claims 263 to 391, wherein the second combination comprises: (i) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3445, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3446; (ii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3448, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3449; (iii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3450, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3451; (iv) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1349; (v) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1196, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1195; (vi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3455, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3456; (vii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3457, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3458; (viii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3463, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3464; (ix) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3465, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3466; (x) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3470, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3471; (xi) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3475; or (xii) VH and VL, wherein VH comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 1346, and VL comprises a sequence having at least 75% sequence identity with the sequence of SEQ ID NO: 3476.

393. The combination therapy according to any one of claims 263 to 392, wherein the second combination comprises: (i) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3445 and VL contains the sequence of SEQ ID NO: 3446; (ii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3448 and VL comprises the sequence of SEQ ID NO: 3449; (iii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3450 and VL comprises the sequence of SEQ ID NO: 3451; (iv) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346 and VL comprises the sequence of SEQ ID NO: 1349; (v) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1196 and VL contains the sequence of SEQ ID NO: 1195; (vi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3455 and VL comprises the sequence of SEQ ID NO: 3456; (vii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3457 and VL contains the sequence of SEQ ID NO: 3458; (viii) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 3463 and VL comprises the sequence of SEQ ID NO: 3464; (ix) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3465 and VL contains the sequence of SEQ ID NO: 3466; (x) VH and VL, wherein VH contains the sequence of SEQ ID NO: 3470 and VL contains the sequence of SEQ ID NO: 3471; (xi) VH and VL, wherein VH comprises the sequence of SEQ ID NO: 1346, and VL comprises the sequence of SEQ ID NO: 3475; or (xii) VH and VL, wherein VH contains the sequence of SEQ ID NO: 1346 and VL contains the sequence of SEQ ID NO: 3476.

394. The combination therapy according to any one of claims 263 to 393, wherein the first binder and the second binder bind to different TCRβV regions.

395. The combination therapy according to any one of claims 263 to 393, wherein the first and second conjugates bind to different TCRβVs belonging to different subfamilies.

396. The combination therapy according to any one of claims 263 to 393, wherein the first and second binders bind to different members of the same TCRβV subfamily.

397. The combination therapy according to any one of claims 263 to 396, wherein the first conjugate comprises one or more heavy chain constant regions selected from the group consisting of: IgG1 heavy chain constant region or fragment thereof, IgG2 heavy chain constant region or fragment thereof, IgG3 heavy chain constant region or fragment thereof, IgGA1 heavy chain constant region or fragment thereof, IgGA2 heavy chain constant region or fragment thereof, IgG4 heavy chain constant region or fragment thereof, IgJ heavy chain constant region or fragment thereof, IgM heavy chain constant region or fragment thereof, IgD heavy chain constant region or fragment thereof, and IgE heavy chain constant region or fragment thereof.

398. The combination therapy according to any one of claims 263 to 397, wherein the first conjugate comprises a constant region of the κ light chain or a fragment thereof, a constant region of the λ light chain or a fragment thereof, or a combination thereof.

399. The combination therapy according to any one of claims 263 to 398, wherein the second conjugate comprises one or more heavy chain constant regions selected from the group consisting of: IgG1 heavy chain constant region or fragment thereof, IgG2 heavy chain constant region or fragment thereof, IgG3 heavy chain constant region or fragment thereof, IgGA1 heavy chain constant region or fragment thereof, IgGA2 heavy chain constant region or fragment thereof, IgG4 heavy chain constant region or fragment thereof, IgJ heavy chain constant region or fragment thereof, IgM heavy chain constant region or fragment thereof, IgD heavy chain constant region or fragment thereof, and IgE heavy chain constant region or fragment thereof.

400. The combination therapy according to any one of claims 263 to 399, wherein the second conjugate comprises a constant region of a κ light chain or a fragment thereof, a constant region of a λ light chain or a fragment thereof, or a combination thereof.

401. The combination therapy according to any one of claims 263 to 400, wherein the first agent is a multifunctional molecule.

402. The combination therapy according to any one of claims 263 to 401, wherein the first agent is a multispecific molecule.

403. The combination therapy according to any one of claims 263 to 402, wherein the second agent is a multifunctional molecule.

404. The combination therapy according to any one of claims 263 to 403, wherein the second agent is a multispecific molecule.

405. The combination therapy according to any one of claims 263 to 404, wherein the first agent, the second agent, or the combination thereof comprises at least two discontinuous polypeptide chains; The first polypeptide chain of the at least two discontinuous polypeptide chains contains a first Fc region, and the second polypeptide chain of the at least two discontinuous polypeptide chains contains a second Fc region; and The first Fc region and the second Fc region contain the Fc interface with the pestle and mortar.

406. The combination therapy of claim 405, wherein the first Fc region, the second Fc region, or the combination thereof comprises an Asn297Ala mutation, a Leu234Ala / Leu235Ala mutation, or a combination thereof.

407. The combination therapy according to any one of claims 401 to 406, wherein the first agent is a multispecific molecule, the multispecific molecule further comprising one or more of a tumor-targeting portion, a cytokine molecule, a matrix-modifying portion, or an immune cell conjugate.

408. The combination therapy according to any one of claims 403 to 407, wherein the second agent is a multispecific molecule, the multispecific molecule further comprising one or more of a tumor-targeting portion, a cytokine molecule, a matrix-modifying portion, or an immune cell conjugate.

409. The combination therapy according to any one of claims 401 to 408, wherein the first agent comprises the following configuration: A-, B-[dimerization module]-C, -D, in: (a) The dimerization module includes a first immunoglobulin chain constant region and a second immunoglobulin chain constant region; (b) A and C are connected to the first immunoglobulin chain constant region; and B and D are connected to the second immunoglobulin chain constant region; (c) A, B, C, and D independently (i) are absent; (ii) are the first conjugate; (iii) are the tumor-targeting portion; (iv) are the cytokine molecule; (v) are the matrix-modifying portion; or (vi) are the immune cell conjugate; and At least one, two, or three of A, B, C, and D contain the first combination.

410. The combination therapy according to any one of claims 403 to 409, wherein the second agent comprises the following configuration: A-, B-[dimerization module]-C, -D, in: (a) The dimerization module includes a first immunoglobulin chain constant region and a second immunoglobulin chain constant region; (b) A and C are connected to the first immunoglobulin chain constant region; and B and D are connected to the second immunoglobulin chain constant region; (c) A, B, C, and D independently (i) are absent; (ii) are the second conjugate; (iii) are the tumor-targeting portion; (iv) are the cytokine molecule; (v) are the matrix-modifying portion; or (vi) are the immune cell conjugate; and At least one, two, or three of A, B, C, and D contain the second combination.

411. The combination therapy according to claim 409 or 410, wherein the first immunoglobulin chain constant region comprises a first fragment crystallizable region (Fc region), and the second first immunoglobulin chain constant region comprises a second fragment crystallizable region (Fc region).

412. The combination therapy of claim 411, wherein the dimerization of the first Fc region and the second Fc region is enhanced by providing an Fc interface between the first Fc region and the second Fc region and one or more of a paired cavity protrusion, electrostatic interaction, or chain exchange, such that the ratio of heteropolymer to homopolymer formed is greater relative to the unengineered interface.

413. The combination therapy according to any one of claims 407 to 412, wherein the immune cell conjugate is selected from the group consisting of: T cell conjugates, NK cell conjugates, B cell conjugates, dendritic cell conjugates, macrophage conjugates, and any combination thereof.

414. The combination therapy according to any one of claims 407 to 413, wherein the cytokine molecule is selected from the group consisting of: interleukin-2 (IL-2) or a functional variant thereof, interleukin-7 (IL-7) or a functional variant thereof, interleukin-12 (IL-12) or a functional variant thereof, interleukin-15 (IL-15) or a functional variant thereof, interleukin-18 (IL-18) or a functional variant thereof, interleukin-21 (IL-21) or a functional variant thereof, interferon-γ or a functional variant thereof, and any combination thereof.

415. The combination therapy of claim 414, wherein the cytokine molecule comprises interleukin-2 (IL-2) or a functional variant thereof.

416. The combination therapy of claim 415, wherein the interleukin-2 (IL-2) or a functional variant thereof comprises the sequence of SEQ ID NO: 2270 or SEQ ID NO: 2191.

417. The combination therapy of claim 414, wherein the cytokine molecule comprises interleukin-15 (IL-15) or a functional variant thereof.

418. The combination therapy of claim 417, wherein the interleukin-15 (IL-15) or a functional variant thereof comprises the sequence of SEQ ID NO: 2170.

419. The combination therapy according to claim 414 or 418, wherein the cytokine molecule further comprises an IL15Rα dimerization domain covalently linked to interleukin-15 (IL-15) or a functional variant thereof.

420. The combination therapy of claim 419, wherein the IL15Rα dimerization domain comprises the IL-15 receptor α sushi domain or a functional variant thereof.

421. The combination therapy according to claim 419 or 420, wherein the IL15Rα dimerization domain comprises the sequence of SEQ ID NO: 3472.

422. The combination therapy according to any one of claims 419 to 421, wherein the interleukin-15 (IL-15) or a functional variant thereof is covalently linked to the IL15Rα dimerization domain via a connector.

423. The combination therapy of claim 422, wherein the interleukin-15 (IL-15) or a functional variant thereof is covalently linked to the IL15Rα dimerization domain via a connector comprising the sequence of SEQ ID NO: 3473.

424. The combination therapy according to any one of claims 417 to 423, wherein the cytokine molecule comprises the sequence of SEQ ID NO: 3474.

425. The combination therapy according to any one of claims 407 to 424, wherein the matrix modification portion is selected from the group consisting of hyaluronidase, collagenase, chondroitinase, and matrix metalloproteinase.

426. The combination therapy according to any one of claims 407 to 425, wherein the tumor-targeting portion binds to the cancer antigen.

427. The combination therapy of claim 426, wherein the tumor-targeting portion binds to the cancer antigen.

428. The combination therapy according to claim 426 or 427, wherein the cancer antigen is present on hematologic malignancies, solid tumors, metastatic cancers, soft tissue tumors, metastatic lesions, or combinations thereof.

429. The combination therapy according to any one of claims 426 to 428, wherein the cancer antigen is a tumor antigen, a matrix antigen, or a blood antigen.

430. The combination therapy according to any one of claims 426 to 429, wherein the cancer antigen is selected from the group consisting of: BCMA, CD19, CD20, CD22, FcRH5, PDL1, CD47, ganglioside 2 (GD2), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PMSA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron kinase, c-Met, immature laminin receptor, TAG-72, BING-4, calcium-activated chloride channel 2, cyclin-B1, 9D7, Ep-CAM, EphA3, Her2 / neu, telomerase, SAP-1, susceptin, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, Gp100 / pmel17, tyrosinase, MC1R, β- Catenin, BRCA1 / 2, CDK4, CML66, fibronectin, p53, Ras, TGF-β receptor, AFP, ETA, MAGE, CA-125, BAGE, GAGE, CDC27, α-actin-4, TRP1 / gp75, TRP2, gangliosides, WT1, epidermal growth factor receptor (EGFR), MART-2, MUC1, MUC2, MUM1, MUM2, MUM3, NA88-1, NPM, OA1, OGT, RCC, RU11, RU12, SAGE, TRG, TSTA, folate receptor α, L1-CAM, CAIX, gpA33, GD3, GM2, VEGFR, integrin, carbohydrates, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, TGF-β, hyaluronic acid, collagen, tendinin C and tendinin W.

431. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3445, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3446, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

432. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3448, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3449, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

433. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

434. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3450, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3451, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

435. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1346, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3452 or the sequence of SEQ ID NO: 3504, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3453 or the sequence of SEQ ID NO: 3505. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3454 or the sequence of SEQ ID NO: 3501, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1349, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

436. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 1196, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 1195, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

437. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3455, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3649, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3447. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3648, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2270, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3456, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3644.

438. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3457, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3458, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

439. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3463, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3459, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3460. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3462, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3464, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461.

440. The combination therapy according to any one of claims 263 to 430, wherein the first agent comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, the second polypeptide chain, and the third polypeptide chain are discontinuous, and wherein: (i) The first polypeptide chain contains a VH, the VH containing the sequence of SEQ ID NO: 3465, wherein the VH is connected to a heavy chain constant region, the heavy chain constant region containing the sequence of SEQ ID NO: 3467, wherein the heavy chain constant region contains the first Fc region, the first Fc region containing the sequence of SEQ ID NO: 3468. (ii) The second polypeptide chain comprises a cytokine molecule, wherein the cytokine molecule is linked to the second Fc region via a linker, the second Fc region comprising the sequence of SEQ ID NO: 3469, the linker comprising the sequence of SEQ ID NO: 3308, wherein the cytokine molecule comprises IL-2 or a functional variant thereof, the IL-2 or a functional variant thereof comprising the sequence of SEQ ID NO: 2191, and (iii) The third polypeptide chain comprises a VL containing the sequence of SEQ ID NO: 3466, wherein the VL is connected to a light chain constant region containing the sequence of SEQ ID NO: 3461. ...

Images